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NOVEL α-MSH PEPTIDE ANALOGS FOR MELANOMA TARGETING
By

Adam Michael Flook
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Ph.D; Biomedical Sciences, University of New Mexico, 2014

ABSTRACT
Skin cancer is the one of the most diagnosed cancers in the United States
with increasing incidence over the past two decades. There are three major
forms of skin cancer but melanoma is the deadliest. It is estimated that 76,690
new diagnoses of melanoma and 9,480 deaths will occur in 2013. Melanoma
accounts for approximately 1.6% of all cancer related deaths and is the 5th
leading diagnosed cancer in the United States. The mean survival rate of
patients diagnosed with metastatic melanoma is six months, with five year
survival rates of less than 5%. In this project, we describe the design and
characterization of novel melanoma-targeting peptide analogs for use in
diagnostic imaging of both primary and metastatic melanoma lesions.
Novel α-MSH peptide conjugates were designed to target the
melanocortin-1 receptor present and over-expressed on melanoma cells. These
peptides were synthesized and their in-vitro melanocortin-1 receptor binding
affinities were established in murine melanoma cells. Once binding affinities were
determined, the peptides were radiolabeled with
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99m

Tc utilizing a novel direct

radiolabeling technique developed in our laboratory. The peptides were purified
via reverse-phase high performance liquid chromatography and in-vivo
melanoma targeting and pharmacokinetic properties were determined in B16/F1
melanoma-bearing female C57BL/6 mice. Biodistribution and SPECT/CT imaging
studies were performed with the promising 99mTc-labeled peptide conjugates.
All α-MSH peptide conjugates tested showed low nanomolar binding
affinity for the melanocortin-1 receptor. All peptides were readily radiolabeld with
99m

Tc with greater than 95% radiochemical purity. All 99mTc-labeled peptides

displayed high specific in-vivo melanoma tumor uptake while maintaining low
normal organ accumulation, and were excreted through the urinary system in a
timely fashion. In addition, all tested

99m

Tc-labeld α-MSH peptides demonstrated

clear visualization of in-vivo tumor lesions with SPECT/CT. While all peptides
exhibited high melanoma uptake, extremely high non-specific renal uptake was
of concern. After synthesis of α-MSH peptide conjugates containing a different
amino acid linker, renal uptake was drastically reduced and a lead compound
had emerged, showing favorable in-vivo melanoma targeting and uptake
properties with limited amounts of non-specific renal accumulation.
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Chapter 1
Introduction
Carcinogenesis
Over the last half of a century, cancer research has spawned a vast and
complex body of knowledge into the underlying mechanisms of cancerous cell
development. The research to date reveals cancer to be a complex disease
involving dynamic alterations at both a genomic and proteomic level [1, 2].
These alterations allow for the process of carcinogenesis to take place.
Carcinogenesis is a highly complicated, multi-step mechanism of malignant
transformation by genomic mutations producing both oncogenic and tumor
suppressive genes capable of transforming normal cells into highly malignant
cells [1, 2]. The combination of oncogenic gene activation and tumor suppressive
capabilities allows for excessive, uncontrolled cellular proliferation and
development of clinically diagnosed tumors. These processes have been
reiteratively studied and classified utilizing transgenic mouse models and
cancerous cell lines (both human and animal) to determine the multi-step
modality of which carcinogenesis takes place [1, 2].
Deemed the “Hallmarks of Cancer” by Hanahan and Weinberg in 2000,
the acquired capabilities of cancerous cells necessary for cancer development
and progression can be categorized into six functional traits: self-sufficiency in
growth signals, insensitivity to anti-growth signals, limitless replicative potential,
sustained angiogenesis, evasion of apoptosis, and tissue invasion and
metastasis. It is believed that all cancers acquire these traits during their
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transformation from normal cells, albeit through a tremendous variety of
molecular mechanisms and genetic mutations.

Melanoma epidemiology and carcinogenesis
Skin cancer is the one of the most diagnosed cancers in the United States
with increasing incidence over the past two decades. Different types of skin
cancer include basal cell carcinoma, squamous cell carcinoma, and melanoma.
Of these three types of skin cancer, melanoma is by far the deadliest. It is
estimated that 76,690 new diagnoses of melanoma and 9,480 deaths will occur
in 2013. Melanoma accounts for approximately 1.6% of all cancer related deaths
and is the 5th leading diagnosed cancer in the United States [3]. Metastatic
melanoma is the leading cause of skin cancer related deaths with a poor
prognosis. The mean survival rate of patients diagnosed with metastatic
melanoma is six months, with five year survival rates of less than 5% [4, 5]. The
rise in incidence and diagnoses is due to both increased awareness of cutaneous
lesions and lifestyle changes that have led to increased ultraviolet light exposure
over the past few decades [6, 7]. Melanomas are derived from the malignant
transformation of cutaneous melanocytes, the cells residing in the basal layer of
the epidermis that are solely responsible for human pigmentation [8]. The
majority of melanomas arise de novo although some may originate in existing
nevi [8, 9].
Exposure to ultraviolet light sources such as the sun and an ever
increasing proclivity towards cosmetic enhancement of the skin through the use
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of tanning beds have presented as important causative factors in melanoma
carcinogenesis. Intermittent UV exposure and sunburn history in melanoma
development have been identified as major contributors in epidemiological
studies [5, 7] . The pathogenic effects of UV exposure could involve genotoxic,
mitogenic, or immunosuppressive responses to damage induced by both
Ultraviolet A (UVA) and Ultraviolet B (UVB) radiation. UVA, also known as long
wave radiation, has a particle wavelength of 320-400 nM and can penetrate the
skin past the epidermal layers and into the dermal tissue. UVA radiation indirectly
damages DNA through reactive oxygen species (ROS) generation and formation
of Guanine to Thymine transversion mutations. UVB, also known as short wave
radiation, has a particle wavelength of 290-320 nM and is the chief cause of skin
reddening and sun burning, damage occurring to the more superficial epidermal
tissues of the skin. UVB radiation can directly damage DNA through mutagenesis
at dipyrimidine sites, inducing apoptosis in normal keratinocytes [7, 10].
While the strong correlation between UV exposure and melanoma
development exists, it is extremely difficult to accurately delineate the precise
exposure patterns of individuals and entire populations to both UVA and UVB
exposure. Clinically cutaneous melanomas have been categorized into four
distinct subtypes: superficial spreading melanoma on intermittently exposed skin
such as the upper back, lentigo maligma melanoma in chronically exposed skin,
acral lentiginous melanoma on the hairless skin of the palms and soles, and
nodular melanoma with vertical growth, not associated with a macular
component [7, 11]. The potential targets of UV-induced damage from a molecular
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point of view include the signaling cascades of the melanocortin-1 receptor
(MC1R) and BRAF genes. The BRAF gene is an important molecule in the
mitogen-activated protein kinase (MAPK) pathway, which regulates cell growth,
survival, and invasion. MAPK signaling initiates at the cell membrane through
receptor tyrosine kinases binding their respective ligand or via RAS-GTPase
activation upon adhesion of integrin molecules to extracellular matrices [7, 12].
BRAF, a serine-threonine kinase, can become constitutively activated upon
mutation of a single amino acid substitution of valine with glutamic acid at
position 600 (known as the V600E mutation). This BRAF mutation, which
activates a 500-fold induction of BRAF, constitutively activates downstream
MAPK/ERK signaling in cells without upstream activation of RAS, in a growth
factor-independent manner [13]. Constitutive MAPK/ERK activity stimulates
proliferation, survival, and can induce the expression of the microphthalmiaassociated transcription factor (MITF) gene in cutaneous melanocytes. The MITF
gene has been shown to be the master regulator of melanocytes with induced
activation resulting in increased pigmentation, survival, and proliferation through
a mechanism that triggers cell cycle exit [6, 7, 14-17]. While the discovery of the
BRAF mutations elicit the potential for therapeutic intervention, due to the
extensive heterogeneity of this disease, BRAF mutations have only been
identified in approximately 50-60% of all cutaneous melanomas [6, 13, 18].
Current diagnostic procedures for detecting both melanoma and nonmelanoma related skin cancers remain fickle to this day, even with clinical
knowledge that detection of any form of skin cancer in the early treatable phases

4

is critical for favorable prognosis. The American Cancer Society recommends
“careful skin check by a clinician as part of a routine cancer-related checkup”,
however, many clinicians do not perform any routine skin screenings during
regular checkups [19]. In order to diagnosis a melanocytic lesion on a patient,
clinicians utilize the ABCDE rule to guide naked eye examinations: A= lesion
asymmetry, B= border irregularity, C= color variability, D= diameter usually larger
than 6mm, E= evolution or change in shape, color, size, elevation, or any
emerging symptoms such as bleeding, itching or crusting [19, 20]. Once a
melanoma diagnosis has been given, some clinicians will opt for the utilization of
imaging modalities to rule out any clinically resectable distant disease. This is
done to avoid potential surgery when curative resection is not a viable option, as
well as ease patient anxiety by confirming the absence of distant disease [21].
Currently, the most commonly used imaging modalities for melanoma patients
include chest x-ray, computed tomographic (CT) imaging, magnetic resonance
imaging (MRI), ultrasonography, positron-emission tomographic (PET) imaging,
and PET-CT [21]. While these imaging modalities are powerful tools to help aide
clinicians in patient diagnosis, several studies have demonstrated that the
detection rate of metastatic disease is lower than the rate of false positivity [21,
22]. False positivity rates with staging x-ray studies range from 7-15% as
compared to a 0.0-0.2% detection rate for metastatic disease. Similar results
have been obtained with current CT imaging, ultrasonography, and FDG-PET
scans [21-24]. It is imperative that new diagnostic imaging procedures be
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implemented in order to aide clinicians in successful diagnosis of both primary
melanoma lesions and metastatic disease.

Clinical treatment of metastatic melanoma
Melanoma is notoriously difficult to treat and has been considered as one
of the most therapeutically challenging malignancies due to its genetic
heterogeneity, dysregulation of cell cycle events allowing for evasion of apoptosis
and constitutive proliferative potential, and increased drug resistance to current
chemotherapeutic and immunotherapeutic agents [18, 25-28]. Through the years
many novel systemic therapeutic approaches have been developed to treat
metastatic melanoma but have proven largely ineffective. Cytotoxic
chemotherapeutic agents deployed as the “standard of care” for treatment of
metastatic melanoma include Dacarbazine (DTIC), Temozolomide (TMZ), and
taxanes such as paclitaxel or docetaxel [25, 29, 30]. Dacarbazine is the only FDA
approved chemotherapy agent for metastatic melanoma and is closely related to
its more bioavailable and orally tolerable derivative, TMZ [30-33]. Both
chemotherapeutic agents are prodrugs that are transformed into 5-(3methyltriazen-1-yl)imidazole-4-carboximide (MITC), which can then methylate
guanine residues in the DNA, forming O6-methylguanine adducts, repair of which
is vital and necessary for cell integrity and survival. These adducts work to
generate single and double-strand DNA breaks when repair of adducts is
attempted by cellular mismatch repair enzymes, causing activation of apoptotic
pathways [31, 34]. Response from treatment with these chemotherapeutic
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agents on malignant metastatic melanoma have been less than promising since
their development, with overall response rates ranging between 15-20%, and a
median survival of approximately 7 months [31, 32, 35, 36]. Paclitaxel and
docetaxel are both mitotic inhibitors that can stabilize microtubules, interfering
with the normal breakdown of microtubules during cellular division. Both drugs
have not shown significant activity in melanoma with response rates in metastatic
melanoma not exceeding 15%, and a median survival of 5 months [32, 33, 37,
38]. Multidrug combination therapy of these agents combined with tamoxifen and
cisplatin showed no significant benefit to overall survival and increased toxicity
when compared to DTIC alone [32, 33, 39, 40].
Treatments of metastatic melanoma with systemic immunotherapeutic or
biochemotherapeutic treatment regimens have not encountered much more
success than chemotherapeutic agents alone [32, 33]. Interferon as a single
agent, has shown modest activity against metastatic melanoma with an average
response rate ranging from 10-15%, while high dose interleukin-2 (IL-2), which
has recently garnished FDA approval for late stage metastatic melanoma,
showed an overall response rate of 16%, but can achieve durable complete
remissions in a small percentage of patients [32, 33, 41-43].
Biochemotherapeutic regimens, utilizing both chemotherapeutic and
immunotherapeutic agents, with combined DTIC, cisplatin,IL-2, and IFN have
shown promise in Phase III clinical trials with response rates ranging from 3060% with some durable complete remissions in patients [32, 33, 44]. Targeted
therapies such as Sorafenib or Vemurafenib, FDA approved oral multikinase
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inhibitors targeting the MAPK pathway and oncogenic B-raf V600E mutation,
when added to conventional treatments with paclitaxel and/or carboplatin have
shown a high partial response rate of 40% and median survival of 13.6 months,
but antitumor activity was independent of BRAF mutational status [43, 45-51].

Metastatic melanoma chemo and immunoresistance
Melanoma resistance to exogenous drug and immunotherapies is a
multifaceted and complex problem involving a multitude of molecular
mechanisms. Chemotherapeutic efficacy is often impaired by intrinsic or
acquired tumor resistance, known as multi-drug resistance (MDR). MDR can be
the result of varying mechanistic alterations to cancer cells including changes in
tumor cell cycle checkpoints, impairment of apoptotic pathways, increased repair
of damaged cellular targets, and a vast reduction in drug accumulation within the
tumor cells [25, 30]. The mechanism encountered in the vast majority of
laboratory research has been that of the enhanced efflux of hydrophobic
cytotoxic drugs mediated by one of a family of transporters, known as the ATPbinding cassette (ABC) transporters [25]. The ABC transporters are an energydependent family of proteins that typically efflux exogenous hydrophobic solutes
and structurally diverse molecules out of the cytoplasm of the cell and back into
the extracellular environment [25, 26, 30, 52-55]. In human melanoma, the
transport proteins with elevated mRNA expression in both primary and metastatic
melanoma cells contributing to increased MDR are ABCA5, ABCB2, ABCB6,
ABCD3, ABCD4, ABCF1, ABCF2 and ABCF3 [52, 55]. Expression of the most
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common and extensively studied ABC transport proteins, ABCB1 and ABCC1,
remain controversial and may be induced by chemotherapy treatment itself, but
their role in the high chemoresistance of human melanoma may be limited [52,
56, 57]. The ABCB5 transport protein, which shares high homology with its
structural analog ABCB1, has demonstrated high expression in both clinical
melanomas and specifically within cells of melanocytic origin, and may represent
an novel chemoresistance mediator in human melanoma [52, 58, 59].
Resistance of human melanoma to chemo and immunotherapeutic
regimens may also be conferred by an increased expression and activation of
DNA repair enzymes. Increasing evidence indicates that damage to highly
proliferating cells, such as melanoma, induced by the use of cytostatic drugs can
be counteracted and compensated for by modulation of DNA-repair mechanisms
[30, 60]. Decreased efficacy of cytostatic drugs such as TMZ and other
therapeutic agents can be conferred by the inhibition of the DNA-mismatch repair
pathway (MMR) and over expression of O6-methylguanine-DNA
methyltransferase (MGMT) [30, 54]. DNA-mismatch repair deficiency imparts
drug resistance by enervating the ability of cells to repair DNA damage
generated from alkylating agents and activate cellular apoptosis [30, 60]. In
particular, O6-methylguanine adducts invoked by the use of TMZ or DTIC, are not
properly reconstituted due to the up-regulation of MGMT in melanoma cells.
MGMT encodes the DNA-repair protein O6-alkylguanine DNA alkyltransferase
(AGT) and is a singular protein pathway that recognizes and repairs DNA
through its specificity for O6-substituted purines without the use of any other
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multi-enzyme complexes such as the nucleotide excision repair (NER) pathway
[61, 62]. Specifically, AGT recognizes the O6-guanine base lesion induced by
alkylating agents and transfers the aberrant methyl group to a cysteine residue in
its active site, thus repairing the guanine base. Removal of the methylation on
the guanine residue prevents cytotoxicity by regenerating intact DNA. Regular
cellular replication and transcription is allowed to proceed, while the AGT
molecule is ubiquitinated and eventually degraded [54, 61, 63, 64]. Loss of MMR
protein expression in melanoma cell lines confers resistance to apoptotic stimuli
and causes destabilization of the melanotic genome, resulting in high mutation
rates, increased proliferation, invasion, and survival [30, 60, 65].
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Melanoma targeting via alpha-melanocyte stimulating hormone (α-MSH) ligand
biding to the melanocortin-1 receptor

Melanocortin-1 receptor
The melanocortin-1 receptor (MC1R) is part of a superfamily of G-protein
coupled receptors (GPCR’s) expressed in melanocytes and melanoma cells,
initially authenticated by ligand-binding studies [66-68]. At the present time, five
melanocortin receptors have been identified, namely the MC1R-MC5R. The
MC1R is expressed largely in melanocytes and leukocytes and involved in skin
pigmentation and animal coat coloration [69]. Expression levels of functional
MC1R are 100-fold higher in melanocytes than immune derived lymphoblastoid
cells with an estimated number of MC1R transcripts of 20-200 receptors per cell
for normal melanocytes and 1-10 receptors per cell for normal keratinocytes [70].
The MC2R is expressed in the adrenal glands and regulates
glucocorticoneogenesis [71]. The MC3R and MC4R are expressed in brain
tissues and are found to regulate feeding behavior and energy homeostasis [72].
The MC5R is widely expressed throughout peripheral tissues and may participate
in the mediation of exocrine gland function [73].
The MC1R is an integral membrane protein consisting of 317 amino acids
and harboring all the structural hallmarks of classical GPCR’s; an extra cellular
N-terminus, seven transmembrane (TM) fragments, and an intracellular Cterminus [68, 74]. According to several 3-D ligand-receptor models and site
directed mutagenesis, the ligand binding site of the MC1R forms a pocket located
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below the plasma membrane-extracellular matrix interface [74, 75]. The 3-D
models developed suggest a highly charged region containing a Glu residue from
TM2 and two Asp residues from TM3 interact with an Arg residue on the
pharmacophore binding sequence of the native MCR agonists, the family of
peptide hormone derivatives known as the melanocortins. In addition, a network
of aromatic residues on the extracellular side of TM4, TM5, and TM6 may also
play an important role in agonist binding by interacting with other aromatic
residues of the pharmacophore sequence of the melanocortins (Fig. 1.1) [68,
76].

TM7

Extracellular

TM5

TM1

TM3

Intracellular
TM2

TM4

TM6

Fig. 1.1- Schematic structure of the human melanocortin-1 receptor. (Adapted from
Yang, 1997).

The MC1R is a significant contributor to skin phenotype and sensitivity to
UV light induced DNA damage and photocarcinogenesis through regulation and
production of the amount and type of pigments produced in the skin [68, 77-80].
The total amount of melanin content present and relative contributions of
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pheomelanin (a red/ yellow pigment) and eumelanin (a brown/ black pigment)
synthesized by human epidermal melanocytes are a key contributor of epidermal
pigmentation and UV protection [68, 81]. Epidermal pigmentation is directly
correlated with eumelanin content, which is more abundant in dark pigmented
skin than lighter pigmented skin. Eumelanin is considered to be the primary
photo-protective mechanism as it reduces the penetration of UV radiation (UVR)
through the epidermal layers and into the underlying dermis; known as the
tanning response. Eumelanin is superior to pheomelanin in its photoprotection
properties as it is less resistant to degradation from UVR exposure and boasts
the ability to quench reactive oxygen species generated during UVR that can
cause cellular lipid peroxidation and protein/ DNA damage [77, 78, 81, 82].
Activation of eumelanin production within wild type melanocytes upon
UVR exposure occurs through a cascade of autocrine and paracrine signaling
within the skin. Upon exposure of the human epidermis to UVR, a variety of
factors will be released by keratinocytes, including the native MC1R ligand, αMSH. Binding of α-MSH to the MC1R on melanocytes activates the cAMP/PKA
signaling cascade and production of cAMP through adenylyl cyclase. cAMP
accumulation in the cytoplasm activates the MAPK and ERK1/2 kinases leading
to phosphorylation of cAMP responsive-element-binding protein (CREB)
transcription factor family members. CREB phosphorylation transcriptionally
activates the microphthalmia transcription factor (MITF), which is used to activate
production of tyrosinase and tyrosinase related protein-1 (TRP-1) and TRP-2 as
well as promote survival and proliferation of melanocytes. Cooperatively in a
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storage organelle called the melanosome, tyrosinase, TRP-1, and TRP-2
enzymatically convert the precursor molecule, tyrosine, into eumelanin.
Eumelanin will stay deposited in the melanosome to exert its biological effects of
UV protection and skin pigmentation [68, 77-79, 81-84].
In addition to the important biological role of the MC1R in reducing UV
induced damage in the epidermis, the process of ligand binding induces several
other important molecular mechanisms including cell survival through evasion of
apoptosis and cellular internalization of the ligand-receptor complex. Upon
binding of α-MSH, the MC1R also activates the inositol triphosphate (IP3) kinase
survival pathway, an important survival pathway in many different cell types [77,
85]. Induction of this pathway ultimately leads to the activation of protein kinase
B (Akt/PKB). Activated Akt inhibits apoptosis by phosphorylating and inactivating
pro-apoptotic proteins Bad and caspase 9. This evasion of apoptosis was seen
independent of α-MSH melanogenic or mitogenic effects [77, 85, 86].
Agonist binding to the MC1R triggers an important cellular process of
internalization of the ligand-receptor complex. The process of agonist dependent
internalization is initiated upon MC1R binding of its native agonist, α-MSH.
Binding of the receptor initiates a phosphorylation of the MC1R by the GRK
family of kinases. This phosphorylation targets the receptor, with bound ligand,
for internalization into an endocytic vesicle. This process has been determined
for the MCR4 and can be speculated with the MC1R due to the presence of
melanocortins in melanoma cells following their addition to external medium and
time-dependent appearance of acid-resistant binding [87]. The fate of the
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MC1R-ligand complex remains unclear upon endocytosis into the cell but
evidence has been presented that radiolabeled α-MSH agonists are rapidly
internalized into the cell and translocated to the lysosome, where they remain
within cellular cytoplasm for a prolonged period of time [68, 88, 89].
MC1R expression on both human and murine melanoma cells makes this
receptor system an attractive molecular target for melanoma specific targeting.
Radioligand binding studies have demonstrated functional MC1 receptor
populations ranging from 1,000-6,000 receptor sites per cell on human melanotic
and amelonotic melanoma cells and between 5,000-8,000 receptors sites per cell
for murine melanoma cells [90, 91]. The relatively low number of receptor sites
per cell necessitates the need for high affinity ligand molecules for successful
molecular targeting of the MC1R.

Wild type α-MSH ligand for MC1R
α-melanocyte stimulating hormone (α-MSH) is a tridecapeptide derived
from the posttranslational processing of proopiomelanocortin (POMC) produced
in the pituitary gland [92, 93]. Wild type α-MSH (Ac-Ser1-Tyr2-Ser3-Met4-Glu5His6-Phe7-Arg8-Trp9-Gly10-Lys11-Pro12-Val13-NH2) is a potent MC1R agonist that
exerts its biological effects in the regulation of eumelanin production, as
previously stated. Structure bio-activity analyses have demonstrated that the
four peptide pharmacophore binding sequence of His6-Phe7-Arg8-Trp9, is solely
responsible for binding the MC1R and exerting melanotropic activity [93, 94].
With over 80% of all human melanoma tumor samples obtained from patients
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with metastatic disease harboring receptors for α-MSH and the intrinsic
nanomolar binding affinity of wild-type α-MSH for the MC1R, underscores the
potential use of this ligand-receptor complex for selective delivery of either
diagnostic or therapeutic radiopharmaceuticals for melanoma imaging or therapy
[95].

Radiolabeled α-MSH peptide analogs used in targeting of the MC1R
Linear α-MSH tritium-labeled radiopharmaceuticals were first developed
during the 1970’s and 1980’s for tissue distribution and melanoma detection but
suffered with low specific activity, making tumor targeting inefficient. In addition,
the linear structure of these peptide analogs allowed for increased
conformational freedom attributing to less potent MC1 receptor binding and
decreased in-vivo stability. Currently the “gold standard” in linear α-MSH peptide
analogs is 125I-[Nle4,D-Phe7]-α-MSH (NDP-MSH), due to its sub-nanomolar
binding affinity to the MC1 receptor [93, 96]. Utilization of this peptide analog
was limited to in-vitro studies as dehalogenation of 125I-NDP-MSH occurs in-vivo.
Radiolabeling linear α-MSH peptide analogs through conjugation of radionuclide
chelators was another method employed to develop potent melanoma imaging
probes. 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and
diethylene triamine pentaacetic acid (DTPA) metal chelators conjugated to the Nterminus of the peptides are able to form stable complexes with a variety of
radiometals and were demonstrated to increase melanoma imaging sensitivity,
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tumor uptake, and decrease normal organ uptake compared to their linear
peptide analog counterparts [93, 97, 98].
In more recent years, new targeting peptide design methods have been
employed with increasing promise. Peptide cyclization strategies were employed
to enhance in-vivo stability, receptor selectivity, and receptor binding affinity of
the α-MSH peptides [99-102]. Cyclization of the α-MSH peptide allowed for
decreased conformational freedom due to stabilization of peptide secondary
structures, including beta turns, as compared to the linear peptide. This
decrease in conformational freedom allows for increased receptor binding affinity
[100-102]. Cyclization strategies can be classified into four types: (1) backbone to
backbone; (2) N-terminus to C-terminus; (3) side chain to C-terminus; (4) two
side chains via disulfide, metal, or lactam bridges [4]. Unique lactam bridge
cyclization occurs by an amide bridge formed between two amino acid side
chains within the peptide such as a positively-charged Lysine and a negativelycharged Aspartic acid [101-103]. Lactam bridge, disulfide bond, and metal
cyclization strategies were employed to improve the stability of the α-MSH
peptides against in-vivo proteolytic degradation as well as further enhance the
binding affinity of the α-MSH peptides to the MC1 receptor [104, 105].
Research into the potential use of these cyclized α-MSH radiopeptides
was thoroughly conducted over the last decade. Through this research it was
determined that the different cyclization strategies may have a profound effect on
pharmacokinetic and biodistribution properties of radiopeptides with comparable
in-vitro binding affinities. A comparison of DOTA-conjugated Re-metal-cyclized
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peptides with disulfide bridge-cyclized α-MSH analogs showed that metal
cyclization results in increased receptor-mediated tumor uptake and decreased
renal uptake values compared to disulfide bridge-cyclization, correlating to more
favorable pharmacokinetic and biodistribution properties [106].
Lactam cyclization and substitution of Phe7 with D-Phe7 in α-MSH peptides
along with radiolabeling of

67

Ga and 111In to form 67Ga-DOTA-GlyGlu-CycMSH

and 111In-DOTA-GlyGlu-CycMSH, showed improved cellular internalization and
retention in B16/F1 mouse melanoma cells as well as fast whole body clearance
[100, 104]. In addition, visualization of in-vivo tumor formation in B16/F1
melanoma-bearing C57 mice utilizing whole body SPECT/CT imaging of

111

In-

DOTA-GlyGlu-CycMSH, demonstrated clear potential for diagnostic applications
[104]. The data showed the significant improvement and utilization of the lactam
bridge-cyclized α-MSH radiolabeled peptides as a melanoma specific imaging
and therapeutic agent.
Recent research has been focused on fine tuning the use of the lactam
bridge-cyclized peptides by both adjusting the position of the DOTA metal
chelator and reducing the ring size of the cyclized peptide. DOTA position had
previously been shown to have a profound effect on radiolabeled linear α-MSH
peptide tumor and renal uptake whereas conjugation of the DOTA chelator to the
C-terminus in the 111In-DOTA-NAPamide complex exhibited 75% greater
melanoma uptake and 63% less renal uptake than the N-terminus conjugated
111

In-MSHoct [102]. Thus, alternate conjugation of the DOTA chelator to

labeled lactam bridge-cyclized α-MSH was a logical next step. Indeed
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111

In-

conjugation of the DOTA chelator to the α-amino group of Lys in the cyclic ring of
Ac-GluGlu-CycMSH[DOTA]-111In exhibited increased MC1 receptor binding
affinity of 0.6 nM, high tumor uptake (11.42 ± 2.20 % injected dose/gram (%ID/g)
2 h post injection), increased cellular retention (9.42 ± 2.41 %ID/g 4 h post
injection), and low non-target organ uptake values (<1.3 %ID/g) [102].
Reduction in the ring size of the cyclized α-MSH peptide from 12 amino
acids to 6 amino acids in the 111In-DOTA-Nle-CycMSHhex complex exhibited
increased tumor uptake values (24.94 ± 4.58 %ID/g 0.5 h post injection), rapid
clearance of 82% of injected radioactivity through the urinary system by 2 h post
Injection, and clear, defined whole body melanoma visualization through
SPECT/CT imaging. In addition, linker modifications have demonstrated
profound effects on the melanoma-targeting and pharmacokinetic properties of
the 111In-labeled lactam-bridge cyclized α-MSH peptides. Hydrocarbon, amino
acid, and polyethylene glycol linkers were previously shown to have favorable
pharmacokinetic and melanoma-targeting profiles on radiolabeled
bombesin[107], RGD[108], and α-MSH peptides[100]. Introduction of the GluGlu
linker in the 111In-DOTA-Nle-CycMSHhex peptides produced 111In-DOTA-GGNleCycMSHhex, which demonstrated high melanoma uptake while reducing both
kidney and liver uptake values by 28-42% and 61-68% respectively.
In nuclear medicine, both 111In and 99mTc radionuclides are widely used as
diagnostic imaging agents due to their unique imaging properties.

99m

Tc is an

ideal imaging radionuclide due to its favorable nuclear decay properties and ease
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of coordination with imaging probes, such as small peptides like the α-MSH
peptides previously discussed.
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99m

Tc-radiolabeling of α-MSH peptides

Background of technetium
Technetium, a second-row transition metal and element 43 on the Periodic
Table, was discovered in 1937 by a pair of Italian scientists in a sample of
molybdenum that had been irradiated by deuterons for some years in the U.C.
Berkeley cyclotron [109-111]. Stemming from the Greek word technetos,
meaning artificial, technetium was the first previously unknown element on earth
to be artificially made by man. Since its discovery, 21 isotopes of technetium
have been produced ranging from Tc-90 to Tc-110. All technetium isotopes
produced are radioactive with nuclear half-lives ranging from 0.86 sec (shortlived 110Tc , T1/2= 0.86 sec) to 2.6 x106 years (long-lived 97Tc, T1/2= 2.6 x106 y)
[110, 112].
Currently, 99mTc is the most commonly used radioisotope in diagnostic
nuclear medicine.

99m

Tc can be produced through the use of the 99Mo/99mTc

commercial generator first developed in 1957 at the Brookhaven National
Laboratory (BNL) in Upton, New York [110, 112, 113]. Purification work on the
132

Te/ 132I generator at BNL in the late 1950’s turned up a contaminant which was

discovered to be 99Tc after the presence of 99Mo was found in the chemical
separation process [109, 114]. The 99Mo/99mTc generator uses the parent
isotope (99Mo), obtained as a fission by-product of 235U or by bombardment of
98

Mo with neutrons, loaded onto an alumina column as molybdate, 99MoO42-.

The positively-charged alumina absorbs the negatively-charged molybdate ions.
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Through a β-decay process, 99mTc is produced as 99mTcO4- pertechnetate (Fig.
1.2) [112]. The 99mTcO4- is then eluted off the column with sterile normal saline to
generate the final product of Na99mTcO4-, sodium pertechnetate, at high specific
activity with only diminutive quantities of chemical contaminants such as carrier
molybdate and 99Tc.
β- decay

γ decay
γ decay

β- decay

Fig. 1.2- Generation and decay of 99mTc through the use of the 99Mo/99mTc generator.
(Adapted from Bartholom , 2010).

The 99Mo/99mTc generator can be eluted multiple times per day as
radioactivity remaining on the column continues to decay, yielding fresh

99

Mo

99m

Tc

activity. The worldwide use of this generator system in nuclear medicine is due
to the ease of operation, high elution efficiency, extraordinary radionuclide purity,
and remarkable specific activity [110-112] . Other methods used for separating
99m

Tc from 99Mo include: solvent extraction of “instant technetium” with

methylethyl ketone, sublimation of technetium oxides from Mo complexes at
22

temperatures exceeding 850°C, and elution of

99m

Tc from zirconium molybdate

gel columns [111].
Technetium-99m is an ideal SPECT (single photon emission computed
tomography) imaging radionuclide due to its nuclear decay properties. Decay of
the metastable 99mTc to the ground state, and virtually stable,

99

Tc element,

releases three gamma photons of 2.2, 140, and 143 KeV, with the
monochromatic 140 KeV photon in highest abundance with 89.1% of all nuclear
transitions [110, 113]. The 140 KeV photon emission is strong enough to
penetrate tissues in-vivo but can be readily collimated and absorbed by
commercial gamma camera detectors to give images with superior spatial
resolution. In addition to the 140 KeV photon emission, the convenient physical
half-life of 99mTc (T1/2= 6.03 hours) also renders the radionuclide an ideal SPECT
imaging agent [109, 110, 112, 115]. The physical half-life of this isotope is long
enough to synthesize 99mTc-labeled radiopharmaceuticals, perform quality
controls, administer 99mTc-labeled compounds to a patient as well as allow
compound accumulation in a target tissue and collection of imaging data, while
minimizing the total radiation dose the patient. The wide use of

99m

Tc for

diagnostic radioimaging studies is demonstrated by the fact that 19 million
injections of 99mTc radiopharmaceuticals were performed in the United States in
2007 for cardiac, lung, kidney, bone, liver, and gall bladder studies, representing
nearly 85% of radiopharmaceuticals used as nuclear medicine [112].
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Coordination geometries of technetium
As a transitional metal element, technetium displays some unique
chemistry characteristics, including its rich and diverse redox chemistry, with
compounds of technetium exhibiting all formal oxidation states between +7 and 1 [115, 116]. Table 1.1 summarizes the oxidation states and coordination
geometries of technetium. The existence of technetium in these many oxidation
states suggests an advantage in structural diversity for 99mTc-labeled
radiopharmaceuticals. However, the existence of the technetium in these diverse
redox states also demonstrates the potential reactions for undesirable side
products.
Oxidation State
+7 (d0)
+6 (d1)
+5 (d2)
+4 (d3)
+3 (d4)
+2 (d5)
+1 (d6)
0 (d7)
-1 (d8)

Coordination
Chemistry
trigonal prism
tetrahedron
tetrahedron
square pyramid
octahedron
dodecahedron
octahedron
octahedron
octahedron
octahedron
octahedron
trigonal bipyramid

Example
[TcH9]2TcO4TcO42TcOCl4[Tc(NCS)6][Tc(Diars)2Cl4]+
[TcCl6]2[Tc(diars)2Cl2]+
[TcCl2(PhP(Oet)2)4]
[Tc(CNC(CH3)3)6]+
[Tc2(C0)10]
[Tc(CO)5]-

Coordination
number
9
4
4
5
6
8
6
6
6
6
6
5

Table 1.1- Oxidation states and coordination geometries of technetium. (Adapted from
Liu, 1999).

Technetium must be reduced to a lower oxidation state in order to produce
stable and effective 99mTc-labled biomolecules. The choice of reducing agents
and reaction conditions play a pivotal role on determining the final redox state of
the technetium complex. These reducing agents will be discussed later in
24

99m

Tc

radiolabeling approaches. The most stable oxidation states of technetium for use
in radiopharmaceuticals can be characterized by chemically robust core
structures depicted in Fig. 1.3 [115]. The most studied and utilized core moiety
is that of [99mTcO]3+ (B), characteristic of the Tc(V) oxidation state. Complexes of
this core generally yield a square pyramidal geometry and are stabilized via NxS4x

tetradentate ligands. The use of this technetium core produces

99m

Tc-

complexes containing both syn- and anti- isomers [116]. These isomeric
compounds generally contain different lipophilicity and biodistribution properties
in biological systems, so it is critical to determine the species desired, and
perform optimized radiosynthesis under specific conditions to obtain that single
species.

Fig. 1.3- Technetium cores used in 99mTc labeling of biomolecules. X= N or S, Y= N or S,
L= neutral donor ligand. (Cited from Liu, 1999).
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Design of 99mTc radiopharmaceuticals
The early design of

99m

Tc radiopharmaceuticals in the 1970’s and 1980’s

was directed toward investigating ligands that were able to stabilize technetium in
lower oxidation states for localized direction of the radionuclide in-vivo, known as
technetium-essential radiopharmaceuticals. These compounds use technetium
as the essential core atom around which other conjugating ligands are arranged.
The first stable core structures were demonstrated by a group at MIT in which the
Tc(V)O core could be stabilized utilizing bisdithiolate (S4) or diamidedithiolate
(N2S2) ligands to form square pyramidal complexes [109, 117]. This initial finding
permitted the development of newer generations of technetium-labeled,
technetium-essential radiopharmaceuticals with differing core structures [115,
117]. Many of these core structures are still in use today as the basis for
diagnostic 99mTc radiopharmaceuticals [109, 115, 118].
Throughout the years various strategies have been employed for receptorbased 99mTc radiopharmaceuticals targeting both intra- and extra-cellular
receptors, also known as technetium-tagged receptor targeting
radiopharmaceuticals. As the basis of these compounds, technetium is
conjugated to a receptor-targeting moiety for site specific localized targeting.
Design strategies for these compounds fall into three categories: the integrated
approach, the bifunctional approach, and the peptide-hybrid approach [109, 115,
118]. The integrated approach for receptor-based 99mTc radiopharmaceuticals
integrates or replaces part of a known receptor-binding ligand with the 99mTc
chelate (Fig. 1.4) [115, 118]. In this approach the 99mTc metal chelate becomes
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a pivotal component of the receptor-binding ligand and all parts are arranged in
such a way that the whole metal complex becomes a high affinity receptor ligand.
This approach often results in challenging synthetic synthesis of target molecules
with low receptor binding affinity. Therefore, it is crucial to comprehensively
consider the effects of the 99mTc chelator on a ligand’s size, charge,
conformation, and lipophilicity during the structural design [118].

Fig. 1.4- Schematic representation of the integrated design strategy of receptor targeted
radiopharmaceuticals. M=99mTc, X &Y= donor atoms. (Cited from Liu, 2004).

The second design strategy is the bifunctional approach. In this
approach, a receptor-binding ligand is used as the targeting biomolecule, a
bifunctional coupling agent (BFCA) is used for 99mTc chelation, and a chemical
linker is used to covalently attach the two components (Fig. 1.5) [118]. This
design is a more popular approach for target-specific radiopharmaceutical
development due to the likelihood of retaining high receptor binding affinity with
the targeted tissue. The receptor-targeting biomolecule in this design serves as a
vehicle to carry the radionuclide to the targeted disease tissue, which should be
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known to harbor a substantial concentration of the target receptor. In this design,
the biomolecule can be monoclonal antibodies, small peptides, or other nonpeptide small molecule receptor ligands. The high specificity of receptor binding
to the biomolecule is essential and will result in selective uptake and distribution
of the radiolabeled receptor ligand in the disease tissue. Many biomolecules
including antibody fragments and small peptides have been studied as “carriers”
for radionuclides and have been FDA approved for both diagnostic and
therapeutic treatment of disease. Examples of FDA approved target-specific
radiopharmaceuticals include Octreoscan® (111In-pentetreotide) for imaging of
neuroendocrine tumors and Zevalin® (90Y-Ibitumomab tiuxetan) for treatment of
non-Hodgkin’s lymphoma [118].
Different chemical linkers can be used to modify the binding affinity and
pharmacokinetic properties of the radiolabeled biomolecule as well as structurally
keep the radiometal chelate far enough away from the biomolecule to limit any
possible interference it may have with the receptor binding motif of the
biomolecule. The choice of linker depends on the pharmacokinetic requirements
for the radiopharmaceutical. The linker can range from a simple hydrocarbon
chain to increase lipophilicity, to a poly amino acid sequence to increase
hydrophilicity to facilitate renal clearance, to a long polyethylene glycol (PEG)
molecule to slow extraction by hepatocytes.[115, 118, 119].
The requirements for an ideal BFCA are the selective stability of an
intermediate or lower oxidation state of technetium to minimize the redox
reactions pertaining to the 99mTc complex, formation of a complex with the
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minimum number of isomers possible, ease of attachment to the biomolecule,
and high radiolabeling efficiency [115, 118, 119]. Attachment of the BFCA to the
biomolecule in these complexes is performed by a reactive conjugation group.
These reactive groups can be either intrinsic to the peptide (e.g. an amino group
from lysine, phenol moiety from tyrosine, thiol group from cysteine, or carboxylate
group from aspartic or glutamic acid) or can be chemically introduced into a
peptide. The attachment of the BFCA/ radiometal complex occurs through the
following reactive groups: N-Hydroxysuccinimide (NHS) esters, isothiocyanates,
or maleimide moieties (Fig 1.6) [113]. The NHS-esters can attach to a lysine
amine or linker amino group through an amide bond and is very stable under
physiological conditions. Hence, the NHS-esters are the most widely used and
powerful conjugation groups. The isothiocyanates are amine reactive groups as
well and can form thiourea bonds with primary amino acid amines. The
maleimide moiety is a thiol-reactive group that can selectively react with a thiol
from a peptide to form a thioether bond [115].

Fig. 1.5- Schematic representation of the bifunctional design strategy of receptor
targeted radiopharmaceuticals. (Cited from Liu, 2004).
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Fig. 1.6- Representative conjugation groups capable of attaching the BFCA to the
targeting biomolecule. (Cited from Liu, 1999).

The third radiopharmaceutical design strategy is the peptide-hybrid
approach. In this approach, the

99m

Tc is chelated and conjugated by a tripeptide

sequence (such as Gly-Gly-Gly, Cys-Gly-Gly, Cys-Gly-Cys, or Cys-Cys-Cys)
within the targeting peptide which contain a N4, N3S, N2S2, or NS3 donor set
respectively. The radiometal can be conjugated to either a linear polypeptide or
cyclic peptide backbone, incorporating it as a component of the macrocyclic
peptide framework (Fig. 1.7) [117]. Coordination of the radiometal to a linear
peptide increases receptor binding affinity by creating a constrained macrocyclic
metallopeptide with less conformational freedom to its intended receptor [118,
120]. The site-specific metal cyclization can also improve the stability of the
radiolabeled peptide in-vivo [99, 101].
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Fig. 1.7- Schematic representation of the peptide-hybrid design strategy of receptor
targeted radiopharmaceuticals. M= 99mTc. (Cited from Liu, 2004).

In addition to 99mTc-radiolabeling design on these pharmaceuticals, it is
also important to consider the pharmacokinetics of each compound. The
pharmacokinetic considerations to include are absorption, distribution,
metabolism, and excretion. The main goal of any diagnostic radiopharmaceutical
is to acquire the highest target-to-background ratio possible in the shortest
amount of time. In optimizing this ratio, the patient will receive the least amount
of non-target radiation, as the radioactivity will be quickly excreted from the body
through the urinary system. When applied systematically and in most cases
intravenously, radiopharmaceutical blood residence time should be short enough
to quickly release the diagnostic agent into the target tissue, but long enough to
adequately accumulate in target tissue as well. For receptor-targeting
radiopharmaceuticals, the receptor binding affinity should be extremely high,
binding rate should be fast, and the radiopharmaceutical should have adequate
cellular retention to eliminate the potential of non-targeted radiation doses to
healthy tissue, as well as achieving optimal imaging characteristics in the
targeted tissue [118, 119].
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Radiolabeling approaches of technetium
99m

Tc-radiolabeling techniques have advanced throughout the years, and

labeling approaches depend on the type of biomolecules being used (e.g.
antibodies or small peptides) and the purpose of the study being conducted (e.g.
product development or proof of concept). Many techniques have been
established for 99mTc-radiolabeling of biomolecules such as antibodies, small
peptides, and other non-peptide small molecules. These radiolabeling
approaches usually fall into three main categories: the pre-labeling approach, the
post-labeling (or indirect labeling) approach, and the direct labeling approach.
The pre-labeling approach (also referred to as the pre-formed chelate
approach) involves the chelation of 99mTc with the BFCA, activation of the BFCA,
and conjugation of the 99mTc-BFCA complex to the biomolecule in a separate
step (Fig. 1.8) [109, 119]. This approach has been more extensively researched
and the chemistry involved is better defined than that of the direct labeling
approach. One advantage of this approach is that the peptide or protein being
labeled is not exposed to the harsh environment that is sometimes necessary for
the chelation step (e.g. pH extremes or high temperatures). For research
purposes this labeling approach is very useful for developing proof of concept
studies, but the complex and time consuming radiosynthesis process is not
suitable for routine clinical use or kit formulation. This approach has been
successfully used to 99mTc-radiolabel antibodies and small peptides in a variety of
studies including the use in cyclic platelet glycoprotein GPIIb/IIIa receptor
antagonists coordinated with HYNIC [109, 115, 119, 121].
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Fig. 1.8- Schematic of the 99mTc pre-labeling approach. X & Y= donor atoms. (Cited from
Liu, 2008).

The post-labeling approach (also known as the indirect labeling approach)
involves attachment of the BFCA to the biomolecule, forming a BFCAbiomolecule conjugate. In this instance the BFCA can be attached to either the
C- or N-terminus of the peptide or protein, as well as to an amino acid side chain,
or directly incorporated into the peptide backbone utilizing multi-step organic
synthesis. Once the BFCA-biomolecule conjugate is prepared, radiolabeling with
99m

Tc can be accomplished through multiple mechanisms including direct

reduction of 99mTcO4- in the presence of the BFCA-biomolecule conjugate, ligand
exchange with an intermediate

99m

Tc complex, or a reduction-substitution

reaction (Fig. 1.9) [119]. This labeling approach utilizes the ease of direct
radiolabeling and well-defined chemistry of the pre-labeling approach, making it

33

the most practical approach for development of target-specific
radiopharmaceuticals [109, 115, 119].

Fig. 1.9- Schematic of the 99mTc post-labeling (indirect labeling) approach. X & Y= donor
atoms. (Cited from Liu, 2008).

99m

Tc radiolabeling of the BFCA-biomolecule complex through the direct

reduction approach involves directly reducing 99mTcO4- pertechnetate in one step
by a variety of reducing agents (SnCl2, NaBH4, Na2S2O4, H3PO4, NH2NH2,
ascorbic acid, and HCl, among many others), in the presence of adequate BFCApeptide conjugate. This reaction generally produces mixed 99mTc reduction
species, but can be controlled and prepared into a single

99m

Tc-BFCA-

biomolecule species through the use of a particular reducing agent and BFCA
under well-controlled labeling conditions. The most commonly used reducing
agent is SnCl2 for its rapid reduction kinetics. The use of Sn(II) however can lead
to production of the Tc (VI) intermediate (99mTcO42-) and Tc [122] intermediate (
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99m

TcO2); both of which form unstable complexes capable of undergoing

hydrolysis and compromising the radiolabeling yield of the

99m

Tc-BFCA-

biomolecule complex [109, 115, 119].
Another way of 99mTc radiolabeling the BFCA-biomolecule complex is
through a two-step ligand exchange. In this process, the pertechnetate ion is
reduced by a reducing agent in the presence of a weak chelating agent to form a
99m

Tc-chelate intermediate. This intermediate is then allowed to react with the

BFCA-biomolecule complex under milder conditions to form the final desired
99m

Tc-BFCA-biomolecule complex. This route is often used to limit the exposure

of the BFCA-biomolecule conjugate to the sometimes harsh radiolabeling
conditions. One example of a ligand exchange process is the use of
glucoheptonate (GH) as a weak chelating agent to aid in radiolabeling the α-MSH
peptide with 99mTc. In this process, a reducing agent such as SnCl2 is used to
reduce the pertechnetate ion to the Tc(V) state containing the [99mTcO]3+ core in
the presence of the glucoheptonate. Once reduced, the glucoheptonate chelates
and stabilizes the [99mTcO]3+ core and protects from redox reactions with the
aqueous environment. Once stabilized, the BFCA-biomolecule conjugate (αMSH in this case) is allowed to react and conjugate with [99mTcO]3+ to form the
final radiolabeled product of 99mTc-(Arg11)CCMSH (Fig. 1.10) [115, 119, 123125].
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Fig. 1.10- Schematic representation of ligand-exchange radiolabeling with
glucoheptonate of 99mTc-(Arg11)CCMSH. (Adapted from Miao, 2007 and de Kieviet,
1981).

The direct labeling approach uses a reducing agent to convert disulfide
linkages into free thiols, which are then able to strongly bind technetium (Fig.
1.11). Many reducing agents can be used (e.g. NaBH4, Na2S2O4, H3PO4,
NH2NH2, ascorbic acid, and HCl, among many others) but stannous chloride
(SnCl2) is the most commonly used. SnCl2 is used to break the disulfide linkage
as well as reduce the 99mTcO4-, Tc(VII), to a lower oxidation state such as Tc(V)
[110]. This approach applies mainly to antibodies and antibody fragments as
many small peptides do not have disulfide linkages, or if one exists, the linkage
36

may be critical for maintaining biological properties and therefore should not be
reduced. For this approach however there are some critical questions that must
be addressed: the desired oxidation state of

99m

Tc, the number of 99mTc

conjugations to the biomolecule, purity of the desired

99m

Tc-labeled species, and

impact on the targeting molecules biological activity after

99m

Tc-radiolabeling.

Examples of direct 99mTc-radiolabeling can be seen with many 99mTc-labeled
monoclonal antibodies including those to aid in detection of colorectal and
ovarian cancer.

Fig. 1.11- Schematic of the 99mTc direct labeling approach. (Cited from Liu, 2008).

Recently, our lab has developed a unique one-step radiolabeling
procedure utilized for 99mTc-radiolabeling of hybrid peptides. These hybrid
peptides coordinate the technetium into the cyclic backbone of the peptide via
three cysteine amino acid additions. The sulfhydryl side chains of the cysteine
residues strongly conjugate to the 99mTc(V)O core, stabilizing the technetium
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within the cyclic peptide backbone via an NS3 coordination system.
Radiolabeling of the peptide is performed through direct reduction of

99m

TcO4-

with SnCl2. Since the sulfhydryl side chains on the cysteine residues are already
fully reduced, the 99mTc(V) core, [TcO]3+, is allowed to covalently conjugate
directly to those residues without the need for attachment to a BFCA.
Meanwhile, the hybrid peptide can be simultaneously cyclized during the
radiolabeling of 99mTc, allowing for diminished conformational freedom of the
peptide secondary structure and reduced in-vivo proteolytic degradation. The
cyclization process increases in-vivo stability as well as binding affinity of the
peptide for its targeted receptor. Radiolabeling synthesis is performed by
incubation of the peptide, sodium pertechnetate, SnCl2, and buffer solutions
(NH4OAc/ Na2 tartate•2H2O) for twenty minutes at room temperature. Upon
radiolabeling synthesis, collection of a single species of 99mTc-labeled peptide
can be performed through RP-HPLC (Fig 1.12). This labeling approach is well
suited for use in clinical applications as it can be performed in a single step at
room temperature.
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Fig. 1.12- Structure of 99mTc-RGD-Lys-(Arg11)CCMSH peptide after direct reduction
radiolabeling synthesis. (Adapted from Yang, 2010).

99m

Tc-Labeled α-MSH analogs
Throughout the past two decades, novel

99m

Tc-labeled α-MSH peptide

analogs have been employed for development of diagnostic or therapeutic
targeting molecules for metastatic melanoma with varying success. One of the
first attempts at utilizing 99mTc-labeled α-MSH peptide analogs was the
development of 99mTc-CGCG-NDP, which employed a tetrapeptide chelator of
Cys-Gly-Cys-Gly on the amino terminus of the synthetic α-MSH analog NDPMSH.

99m

Tc-CGCG-NDP showed moderate melanoma uptake in B16/F1

melanoma bearing C57 mice with a peak tumor uptake at 30 minutes postinjection of 6.52 ± 1.11 %ID/g [97, 120]. A novel α-MSH peptide analog,
[Cys3,4,10,D-Phe7]α-MSH3-13 (CCMSH), was created utilizing the peptide-hybrid
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approach of chelation within the backbone of the α-MSH peptide via addition of
three cysteine residues at amino acid positions 3, 4, and 10 [97, 98]. The metal
cyclized portion of the peptide contained the potent α-MSH pharmacophore
consensus sequence. 99mTc-CCMSH exhibited rapid and high tumor uptake as
well as fast whole-body clearance in B16/F1 melanoma bearing mice. The peak
tumor uptake was seen at 30 min post-inject with an uptake value of 12.97 ± 2.38
%ID/g [126]. In an effort to decrease non-specific renal uptake of the 99mTcCCMSH peptide, a substitution to the Lys11 for Arg11 was made to establish the
novel peptide analog (Arg11)CCMSH.

99m

Tc-(Arg11)CCMSH exhibited a peak

tumor uptake value of 14.03 ± 2.58 %ID/g at 1 h post-injection while
demonstrating a 62% reduction in non-specific renal uptake at 4 h post-injection
[97, 125, 126].
Newer generations of 99mTc-labeled α-MSH peptides generated in our lab
emerged as dual receptor targeting molecules. Arg-Gly-Asp-conjugated α-MSH
hybrid peptides were developed to target both the MC1R and the αVβ3 integrin
present on melanoma cells. The cyclized Arg-Gly-Asp (RGD) αVβ3 integrin
binding motif was attached to the hybrid α-MSH peptide containing the MC1R
pharmacophore binding sequence via a Lys amino acid linker, forming a novel
RGD-Lys-(Arg11)CCMSH hybrid peptide [127]. It was hypothesized that targeting
of both the MC1R and αVβ3 integrin would provide for superior melanoma
targeting as compared to MC1R targeting alone. As a control, the cyclic RGD
motif was also substituted into a cyclic RAD motif in order to ablate αVβ3 binding,
producing the RAD-Lys-(Arg11)CCMSH peptide. Receptor binding studies with
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both peptides in human M21 melanoma cells demonstrated that indeed
substitution of the Gly residue in the RGD motif for an Ala residue ablated αVβ3
integrin binding, with IC50 values of 403 nM for RGD-Lys-(Arg11)CCMSH
compared with greater than 100,000 nM for RAD-Lys-(Arg11)CCMSH.
Surprisingly, MC1R binding affinity of the RAD-Lys-(Arg11)CCMSH peptide
was nearly 10-fold higher than the original RGD-Lys-(Arg11)CCMSH M21 human
melanoma cells, with IC50 values of 0.3 nM and 2.0 nM, respectively [127]. This
elevated MC1 receptor binding affinity resulted in enhanced melanoma tumor
uptake of 99mTc-RAD-Lys-(Arg11)CCMSH as compared with 99mTc-RGD-Lys(Arg11)CCMSH (19.91± 4.02 vs 14.83 ± 2.93% ID/g at 2 h post-injection) in
B16/F1 melanoma-bearing C57 mice as well [128]. The minor structural
difference of the addition of one extra methyl group on the Ala residue as
compared to the Gly residue, indicated that the existence of the methyl group
enhanced the in-vivo melanoma tumor uptake of

99m

Tc-RAD-Lys-(Arg11)CCMSH.

Therefore, it was of interest to determine how other minor structural differences
to the 99mTc-RAD-Lys-(Arg11)CCMSH peptide could further enhance the MC1R
binding affinity and in-vivo tumor targeting and pharmacokinetics, as well as
determine the optimal structure for use as a melanoma SPECT imaging probe.
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Purpose, hypothesis, and specific aims

Currently, no curative treatment options exist for metastatic melanoma. A
patient’s best opportunity for a cure is early detection of melanocytic lesions and
prompt surgical removal of cancerous tissues [3, 6, 27]. The development of
novel targeting radiopharmaceuticals capable of both early detection and imaging
of primary melanoma lesions and metastases represents a potential innovative
tool suited for a patient’s best chance at survival. At present, the work being
conducted in the development of novel radiolabeled α-MSH peptide analogs is
still in the pre-clinical stage. Proper optimization and characterization of the
newest generations of these peptides is of importance to ascertain the most
promising compounds capable of utilization in a clinical setting.
The research emphasis for this project entails combining the knowledge
from different biomedical sciences in the fields of oncology, cellular and
molecular biology, chemistry, and radiopharmacology to develop, optimize, and
characterize novel radiolabeled α-MSH peptide analogs for targeting and
radioimaging of melanoma lesions. The development of which can potentially
aide clinicians in determining the location and size of both primary melanoma
lesions and their metastatic counterparts for prompt surgical removal and
monitoring the growth and spread of disease over the periods of progression,
remission, and recurrence.
With the promising results seen by the modification of α-MSH analogs in
respect to increased MC1 receptor binding affinity and increased in-vivo
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melanoma targeting and uptake in B16/F1 melanoma-bearing C57 mice, it was
the purpose of this study to determine the optimal α-MSH peptide structure
necessary for development of an ideal melanoma targeting probe suitable for
diagnostic imaging.
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Central Hypothesis
Our central hypothesis states that structural modifications of novel α-MSH
peptides targeting the melanocortin-1 receptor will enhance melanoma targeting
and pharmacokinetic properties of

99m

Tc-labeled α-MSH peptide analogs for

SPECT radioimaging and may provide a distinct non-invasive tool for early
detection and diagnosis of melanocytic disease, both primary and disseminated.

(2)

(1)

99mTc=O

Lys, β-Ala

(3)
Ala, Ser,
Thr, Val, Glu, Nle
Nle, Phe,
DPhe

Figure 1.13- Schematic representation of the modifications made to the novel αMSH peptides in the RXD motif (1), linker (2), and XAD motif (3).
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Specific aims
I will attempt to examine our central hypothesis through the following
specific aims:
1. To determine the effect of single amino acid substitutions to the RXD
motif on the targeting and biodistribution properties of RXD-Lys(Arg11)CCMSH peptides.

In order to evaluate specific aim #1, α-MSH peptides will be designed and
synthesized containing amino acid substitutions to the Ala residue on the RXD
motif. The in-vitro MC1 receptor targeting properties of the RXD-Lys(Arg11)CCMSH peptides will be determined in the B16/F1 murine melanoma cell
line. The in-vivo melanoma targeting and pharmacokinetic properties of the
99m

Tc-RXD-Lys-(Arg11)CCMSH peptides will be evaluated in B16/F1 melanoma-

bearing C57 mice.

2. To reduce in-vivo non-specific renal uptake of α-MSH peptide analogs
via L-Lys co-injection and linker modification through substitution of the
positively charged Lys linker with a neutral β-Ala linker, without
disrupting melanoma tumor uptake.

In order to evaluate specific aim #2, as a proof of concept study, reduction
of in-vivo non-specific renal uptake of the 99mTc-RXD-Lys-(Arg11)CCMSH
peptides will be determined with the use of a purified L-Lys co-injection. Based
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on the results of the L-Lys co-injection study, α-MSH peptides will then be
designed and synthesized containing an amino acid substitution of the positively
charged Lys linker with a neutral β-Ala linker. The in-vitro MC1 receptor targeting
properties of the RXD-β-Ala-(Arg11)CCMSH peptides will be determined in the
B16/F1 murine melanoma cell line. The in-vivo reduction of renal
radiopharmaceutical uptake and pharmacokinetic properties of the 99mTc-RXD-βAla-(Arg11)CCMSH peptides will be evaluated in B16/F1 melanoma-bearing C57
mice.

3. To further reduce in-vivo non-specific renal uptake of α-MSH peptides
by amino acid substitutions to XAD motif on XAD-β-Ala-(Arg11)CCMSH
peptides, without disrupting melanoma tumor uptake.

In order to evaluate specific aim #3, α-MSH peptides will be designed and
synthesized containing amino acid substitutions to reduce the overall net charge
of the peptides by replacing the Arg residue in the RXD motif, creating the XADβ-Ala-(Arg11)CCMSH peptides. The in-vitro MC1 receptor targeting properties of
the XAD-β-Ala-(Arg11)CCMSH peptides will be determined in the B16/F1 murine
melanoma cell line. The further in-vivo reduction of renal radiopharmaceutical
uptake and pharmacokinetic properties of the 99mTc-XAD-β-Ala-(Arg11)CCMSH
peptides will be evaluated in B16/F1 melanoma-bearing C57 mice.
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Chapter 2
Evaluation of new Tc-99m-labeled Arg-X-Asp-conjugated α-melanocyte
stimulating hormone peptides for melanoma imaging

Introduction
Malignant melanoma is the most lethal form of skin cancer with an
increasing incidence [3]. Melanoma leads to greater than 75% of deaths from
skin cancer although it only accounts for less than 5% of skin cancer cases.
There is no curative treatment available for metastatic melanoma. Both
melanocortin-1 (MC1) and αvβ3 integrin receptors have been utilized as targets
for developing melanoma imaging probes [91, 100, 103, 105, 129-145]. The
radiolabeled α-melanocyte stimulating hormone (α-MSH) peptides were used to
target the MC1 receptors [91, 100, 103, 105, 129-137], whereas the radiolabeled
Arg-Gly-Asp (RGD) peptides were reported to target the αvβ3 integrin receptors
[138-145]. In our previous report, we developed a novel Arg-Gly-Asp (RGD)conjugated α-MSH hybrid peptide {RGD-Lys-(Arg11)CCMSH} to target both MC1
and αvβ3 integrin receptors for M21 human melanoma imaging [127]. The dual
receptor-targeting 99mTc-RGD-Lys-(Arg11)CCMSH exhibited significantly higher
melanoma uptake than single receptor-targeting 99mTc-RAD-Lys-(Arg11)CCMSH
or 99mTc-RGD-Lys-(Arg11)CCMSHscramble in M21 human melanoma-xenografted
nude mice. Interestingly, the switch from RGD to Arg-Ala-Asp (RAD) in the hybrid
peptide dramatically improved the MC1 receptor binding affinity of RAD-Lys(Arg11)CCMSH as compared to RGD-Lys-(Arg11)CCMSH (0.3 vs. 2.0 nM) in M21
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melanoma cells [127]. The stronger MC1 receptor binding resulted in enhanced
melanoma uptake of

99m

Tc-RAD-Lys-(Arg11)CCMSH as compared with 99mTc-

RGD-Lys-(Arg11)CCMSH (19.91 ± 4.02 vs. 14.83 ± 2.93% ID/g at 2 h postinjection) in B16/F1 melanoma-bearing C57 mice [128].
The minor structural difference between

99m

Tc-RAD-Lys-(Arg11)CCMSH

and 99mTc-RGD-Lys-(Arg11)CCMSH is Ala and Gly. The Ala has one more methyl
group as compared with the Gly. The biodistribution results indicated that the
existence of methyl group in Ala enhanced the melanoma uptake of

99m

Tc-RAD-

Lys-(Arg11)CCMSH [128]. Therefore, we were interested in whether the
substitution of Gly with other amino acids could affect the melanoma targeting
and pharmacokinetic properties of

99m

Tc-labeled peptides. In this study, we

replaced the Gly with Thr and Val to generate RTD-Lys-(Arg11)CCMSH and RVDLys-(Arg11)CCMSH peptides. The MC1 receptor binding affinities of RTD-Lys(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH were examined in B16/F1
melanoma cells. Thereafter, we determined the biodistribution and imaging
properties of 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH
in B16/F1 melanoma-bearing C57 mice.
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Experimental design and methods

Chemicals and Reagents

Amino acids and resin were purchased from Advanced ChemTech Inc.
(Louisville, KY) and Novabiochem (San Diego, CA). 125I-Tyr2-[Nle4, DPhe7]-αMSH {125I-(Tyr2)-NDP-MSH} was obtained from PerkinElmer, Inc. (Waltham, MA)
for receptor binding assay. 99mTcO4- was purchased from Cardinal Health
(Albuquerque, NM). L-lysine was purchased from Sigma-Aldrich (St. Louis, MO).
All other chemicals used in this study were purchased from Thermo Fischer
Scientific (Waltham, MA) and used without further purification. B16/F1 murine
melanoma cells were obtained from American Type Culture Collection
(Manassas, VA).

Peptide Synthesis and In Vitro Competitive Binding Assay

The RTD-Lys-(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH peptides were
synthesized according to our previously published procedure [146] with slight
modification on Sieber amide resin by an Advanced ChemTech multiple-peptide
synthesizer (Louisville, KY). Briefly, 70 µmol of Sieber amide resin and 210 µmol
of Fmoc-protected amino acids were used for the synthesis. Fmoc-Lys(Boc) was
used to generate a Lys linker in the hybrid peptide. The RTD-Lys-(Arg11)CCMSH
and RVD-Lys-(Arg11)CCMSH were purified by reverse phase-high performance
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liquid chromatography (RP-HPLC) and characterized by liquid chromatographymass spectroscopy (LC-MS).
The IC50 values RTD-Lys-(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH for
the MC1 receptor were determined in B16/F1 melanoma cells. The receptor
binding assay was replicated in triplicate for each peptide. The B16/F1 cells were
seeded into a 24-well cell culture plate at a density of 2.5 × 105 cells/well and
incubated at 37° C overnight. After being washed with binding medium {modified
Eagle’s medium with 25 mM N-(2-hydroxyethyl)-piperazine-N′-(2-ethanesulfonic
acid) (HEPES), pH 7.4, 0.2% bovine serum albumin (BSA), 0.3 mM 1,10phenathroline}, the cells were incubated at 25 °C for 2 h with approximately
30,000 counts per minute (cpm) of 125I-(Tyr2)-NDP-MSH in the presence of
increasing concentrations (10-13 M to 10-6 M) of RTD-Lys-(Arg11)CCMSH or RVDLys-(Arg11)CCMSH in 0.3 mL of binding medium. The reaction medium was
aspirated after the incubation. The cells were rinsed twice with 0.5 mL of ice-cold
pH 7.4, 0.2% BSA/0.01 M phosphate buffered saline (PBS) to remove any
unbound radioactivity and lysed in 0.5 mL of 1 M NaOH for 5 min. The activities
associated with the cells were measured in a Wallac 1480 automated gamma
counter (PerkinElmer, NJ). The IC50 value for each peptide was calculated using
Prism software (GraphPad Software, La Jolla, CA).

50

Peptide Radiolabeling

RTD-Lys-(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH peptides were
labeled with 99mTc via a direct reduction reaction with SnCl2. Briefly, 10 μL of 1
mg/mL SnCl2 in 0.1 M HCl, 40 μL of 0.5 M NH4OAc (pH 5.2), 100 μL of 0.2 M
Na2tartate (pH 9.2), 100 μL of fresh 99mTcO4- solution (37-74 MBq), and 10 μL of
1 mg/mL RTD-Lys-(Arg11)CCMSH or RVD-Lys-(Arg11)CCMSH peptide in
aqueous solution were added into a reaction vial and incubated at 25 °C for 20
min to form 99mTc-labeled peptide. Each 99mTc-peptide was purified to a single
species by Waters RP-HPLC (Milford, MA) on a Grace Vydac C-18 reverse
phase analytic column (Deerfield, IL) using a 20-min gradient of 16-26%
acetonitrile in 20 mM HCl aqueous solution at a flow rate of 1 mL/min. Each
purified peptide was purged with N2 gas for 20 mins to remove the acetonitrile.
The pH of final peptide solution was adjusted to 7.4 with 0.1 N NaOH and sterile
normal saline for stability, biodistribution and imaging studies. The serum stability
of 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH was
determined by incubation in mouse serum at 37 C for 24 h and monitored for
degradation by RP-HPLC. Briefly, 100 µL of HPLC-purified peptide solution (~7.4
MBq) was added into 100 µL of mouse serum (Sigma-Aldrich Corp, St. Louis,
MO) and incubated at 37 oC for 24 h. After the incubation, 200 µL of a mixture of
ethanol and acetonitrile (V:V = 1:1) was added to precipitate the serum proteins.
The resulting mixture was centrifuged at 16,000 g for 5 min to collect the
supernatant. The supernatant was purged with N2 gas for 30 min to remove the
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ethanol and acetonitrile. The resulting sample was mixed with 500 µL of water
and injected into RP-HPLC for analysis using the gradient described above.

Cellular Internalization and Efflux

Cellular internalization and efflux of
99m

99m

Tc-RTD-Lys-(Arg11)CCMSH and

Tc-RVD-Lys-(Arg11)CCMSH were evaluated in B16/F1 melanoma cells. The

B16/F1 cells were seeded into a 24-well cell culture plate at a density of 2.5 × 105
cells/well and incubated at 37° C overnight. After being washed twice with
binding medium [modified Eagle's medium with 25 mM N-(2-hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid), pH 7.4, 0.2% bovine serum albumin (BSA),
0.3 mM 1,10-phenathroline], the B16/F1 cells were incubated at 25C for 20, 40,
60, 90 and 120 min (n=3) in the presence of approximate 200,000 counts per
minute (cpm) of HPLC-purified of 99mTc-RTD-Lys-(Arg11)CCMSH or 99mTc-RVDLys-(Arg11)CCMSH. After incubation, the reaction medium was aspirated and the
cells were rinsed with 2  0.5 mL of ice-cold pH 7.4, 0.2% BSA / 0.01 M PBS.
Cellular internalization was assessed by washing the cells with acidic buffer [40
mM sodium acetate (pH 4.5) containing 0.9% NaCl and 0.2% BSA] to remove the
membrane-bound radioactivity. The remaining internalized radioactivity was
obtained by lysing the cells with 0.5 mL of 1 N NaOH for 5 min. Membrane-bound
and internalized activities were counted in a gamma counter. Cellular efflux was
determined by incubating the B16/F1 cells with
99m

99m

Tc-RTD-Lys-(Arg11)CCMSH or

Tc-RVD-Lys-(Arg11)CCMSH for 2 h at 25C, removing non-specific-bound
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activity with 2  0.5 mL of ice-cold PBS rinse, and monitoring radioactivity
released into cell culture medium. At time points of 20, 40, 60, 90 and 120 min,
the radioactivities on the cell surface and inside the cells were separately
collected and counted in a gamma counter.

Biodistribution Studies

All the animal studies were conducted in compliance with Institutional
Animal Care and Use Committee approval. The biodistribution properties of
99m

Tc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH were

determined in B16/F1 melanoma-bearing C57 female mice (Harlan, Indianapolis,
IN). Each C57 mouse was subcutaneously inoculated on the right flank with
1106 B16/F1 cells. The weight of tumors reached approximately 0.2 g 10 days
post cell inoculation. Each melanoma-bearing mouse was injected with 0.037
MBq of 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH via
the tail vein. Groups of 4 mice were sacrificed at 0.5, 2, 4 and 24 h post-injection,
and tumors and organs of interest were harvested, weighed and counted. Blood
values were taken as 6.5% of the body weight. The specificity of tumor uptake
was determined by co-injecting 99mTc-RTD-Lys-(Arg11)CCMSH or 99mTc-RVDLys-(Arg11)CCMSH with 10 g (6.1 nmol) of unlabeled NDP-MSH at 2 h postinjection.
L-lysine co-injection is effective in decreasing the renal uptake of
radiolabeled α-MSH peptides. To determine the effect of L-lysine co-injection on
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the renal uptake of 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys(Arg11)CCMSH, a group of 4 mice were injected with a mixture of 0.037 MBq of
99m

Tc-RTD-Lys-(Arg11)CCMSH or 99mTc-RVD-Lys-(Arg11)CCMSH and 15 mg of

L-lysine. The mice were sacrificed at 2 h post-injection, and tumors and organs of
interest were harvested, weighed and counted in a gamma counter.

Melanoma Imaging with 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys(Arg11)CCMSH

To determine the melanoma imaging properties, approximately 7.4 MBq of
99m

Tc-RTD-Lys-(Arg11)CCMSH or 99mTc-RVD-Lys-(Arg11)CCMSH was injected

into two B16/F1 melanoma-bearing C57 mice via the tail vein, respectively. The
mice were euthanized for small animal SPECT/CT (Nano-SPECT/CT®, Bioscan,
Washington DC) imaging 2 h post-injection. The 9-min CT imaging was
immediately followed by the SPECT imaging of whole-body. The SPECT scans
of 24 projections were acquired. Reconstructed data from SPECT and CT were
visualized and co-registered using InVivoScope (Bioscan, Washington DC).

Urinary Metabolites of 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys(Arg11)CCMSH

Approximately 3.7 MBq of

99m

Tc-RTD-Lys-(Arg11)CCMSH or 99mTc-RVD-

Lys-(Arg11)CCMSH was injected into two B16/F1 melanoma-bearing C57 mice
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via the tail vein to determine the urinary metabolites. The mice were euthanized
to collect urine at 2 h post-injection. The collected urine samples were
centrifuged at 16,000 g for 5 min before the HPLC analysis. Thereafter, aliquots
of the urine were injected into the HPLC. A 20-minute gradient of 16-26%
acetonitrile / 20 mM HCl with a flow rate of 1 mL/min was used for urine analysis.

Statistical Analysis

Statistical analysis was performed using the Student’s t-test for unpaired
data to determine the significance of differences in tumor and kidney uptake
with/without peptide blockade or with/without L-lysine co-injection in
biodistribution studies described above. Differences at the 95% confidence level
(p<0.05) were considered significant.
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Results
The schematic structures of RTD-Lys-(Arg11)CCMSH and RVD-Lys(Arg11)CCMSH are presented in Figure 2.1. RTD-Lys-(Arg11)CCMSH and RVDLys-(Arg11)CCMSH were synthesized and purified by RP-HPLC. The overall
synthetic yields were 30% for RTD-Lys-(Arg11)CCMSH and RVD-Lys(Arg11)CCMSH. The chemical purities of RTD-Lys-(Arg11)CCMSH and RVD-Lys(Arg11)CCMSH were greater than 95% after the HPLC purification. The peptide
identities were confirmed by electrospray mass spectrometry. The measured
molecular weights for RTD-Lys-(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH
were 2194 and 2192. The competitive binding curves of the peptides are shown
in Figure 2.2. The IC50 values of RTD-Lys-(Arg11)CCMSH and RVD-Lys(Arg11)CCMSH were 0.7 ± 0.07 and 1.0 ± 0.3 nM in B16/F1 melanoma cells.
RTD-Lys-(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH were readily
radiolabeled with 99mTc with greater than 95% radiolabeling yields. The

99m

Tc-

RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH peptides were
purified and separated from their excess non-labeled peptides by RP-HPLC. The
retention times of

99m

Tc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-

(Arg11)CCMSH were 12.7 and 14.6 min. 99mTc-RTD-Lys-(Arg11)CCMSH and
99m

Tc-RVD-Lys-(Arg11)CCMSH were stable in mouse serum at 37°C for 24 h

(Figure 2.3). Cellular internalization and efflux properties of

99m

Tc-RTD-Lys-

(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH were examined in B16/F1
cells. Figure 2.4 illustrates the internalization and efflux properties of

99m

Tc-RTD-

Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH. 99mTc-RTD-Lys-
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(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH exhibited rapid cellular
internalization and prolonged cellular retention. Approximately 71% of
RTD-Lys-(Arg11)CCMSH and 72% of

99m

99m

Tc-

Tc-RVD-Lys-(Arg11)CCMSH activities

were internalized in the cells after 20 min of incubation. Cellular efflux results
indicated that 75% of

99m

Tc-RTD-Lys-(Arg11)CCMSH and 70% of 99mTc-RVD-Lys-

(Arg11)CCMSH activities remained inside the cells at 2 h of incubation in the
culture medium.
The melanoma targeting and pharmacokinetic properties of

99m

Tc-RTD-

Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH are shown in Tables 2.1
and 2.2. Both 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH
exhibited rapid and high tumor uptake in B16/F1 melanoma-bearing C57 mice.
99m

Tc-RTD-Lys-(Arg11)CCMSH exhibited the peak tumor uptake of 18.77 ± 5.13%

ID/g at 2 h post-injection, whereas 99mTc-RVD-Lys-(Arg11)CCMSH reached the
peak tumor uptake of 19.63 ± 4.68% ID/g at 4 h post-injection. The tumor uptake
values gradually decreased to 5.84 ± 0.50 and 8.81 ± 2.13% ID/g by 24 h postinjection. The tumor blocking studies (Tables 2.1-2.2) demonstrated that coinjection of 10 μg (6.1 nM) of non-radiolabeled NDP-MSH with 99mTc-RTD-Lys(Arg11)CCMSH or 99mTc-RVD-Lys-(Arg11)CCMSH decreased their tumor uptake
values to 2.85 ± 1.43 and 1.51 ± 0.6% ID/g at 2 h post-injection, demonstrating
that the tumor uptake was MC1 receptor-mediated.
Renal uptake values of 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVDLys-(Arg11)CCMSH were 135.14 ± 23.62 and 94.01 ± 18.31% ID/g at 2 h post
injection, respectively. The renal uptake values of
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99m

Tc-RTD-Lys-

(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH decreased to 46.84 ± 14.83
and 44.34 ± 12.11% ID/g at 24 h post-injection. The effect of L-lysine co-injection
on renal uptake is presented in Figure 2.5. Co-injection of 15 mg L-lysine
significantly (p<0.05) decreased the renal uptake values of 99mTc-RTD-Lys(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH to 60.66 ± 12.09 and 55.74 ±
9.14% ID/g at 2 h post-injection, respectively. The L-lysine co-injection didn't
affect the tumor uptake of

99m

Tc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-

(Arg11)CCMSH (p>0.05) at 2 h post-injection. Whole-body clearance of 99mTcRTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH was rapid, with
approximately 55% and 59% of the injected radioactivity clearance through the
urinary system by 2 h post-injection (Tables 2.1-2.2). At 24 h post-injection, 82%
of 99mTc-RTD-Lys-(Arg11)CCMSH and 77% of 99mTc-RVD-Lys-(Arg11)CCMSH
activity cleared out the body. Normal organ uptakes of

99m

Tc-RTD-Lys-

(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH was minimal (<2.1% ID/g)
except for the kidneys after 2 h post-injection (Tables 2.1-2.2).
Whole-body SPECT/CT images are presented in Figure 2.6. Flank
B16/F1 melanoma lesions were clearly visualized by SPECT using

99m

Tc-RTD-

Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH) peptides as imaging
probes. The SPECT image of tumor accurately matched its anatomical location
obtained in the CT image. The SPECT image showed high contrast of tumor to
normal organ except for kidneys, which was consistent with the biodistribution
results. The urinary metabolites of 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTcRVD-Lys-(Arg11)CCMSH at 2 h post-injection are shown in Figure 2.7.
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Approximately 70% of 99mTc-RTD-Lys-(Arg11)CCMSH or 99mTc-RVD-Lys(Arg11)CCMSH remained intact in the urine at 2 h post-injection, while 30% of the
99m

Tc-RTD-Lys-(Arg11)CCMSH or 99mTc-RVD-Lys-(Arg11)CCMSH was

transformed to a more hydrophobic compound.
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Discussion
We have been interested in developing MC1 receptor-targeting α-MSH
peptides for melanoma imaging [11-14, 23-25]. Recently, we have found that the
substitution of RGD with RAD resulted in nearly a 10-fold increase in MC1
receptor binding affinity for RAD-Lys-(Arg11)CCMSH as compared to RGD-Lys(Arg11)CCMSH in B16/F1 melanoma cells [128]. Furthermore, 99mTc-RAD-Lys(Arg11)CCMSH displayed higher melanoma uptake than

99m

Tc-RGD-Lys-

(Arg11)CCMSH (19.91 ± 4.02 vs. 14.83 ± 2.93% ID/g at 2 h post-injection) in
B16/F1 melanoma-bearing C57 mice [128]. Because the only structural
difference between 99mTc-RAD-Lys-(Arg11)CCMSH and 99mTc-RGD-Lys(Arg11)CCMSH was the extra methyl group in Ala as compared to Gly, the
enhanced melanoma uptake of

99m

Tc-RAD-Lys-(Arg11)CCMSH suggested that

the methyl group in Ala dramatically affected the MC1 receptor binding motif
(His-DPhe-Trp-Arg) in the (Arg11)CCMSH moiety. Thus, we were interested in
whether and how the replacement of Gly with other amino acids could affect the
melanoma targeting and pharmacokinetic properties of

99m

Tc-labeled RXD-Lys-

(Arg11)CCMSH peptides. Specifically, we substituted the Gly with Thr and Val to
examine the effects of -CH(CH3)OH and -CH(CH3)2 groups on the biodistribution
properties of

99m

Tc-labeled RTD-Lys-(Arg11)CCMSH and RVD-Lys-

(Arg11)CCMSH peptides in this study.
The substitution of Gly with Thr and Val retained low nanomolar MC1
receptor binding affinities of the peptides in B16/F1 melanoma cells. RTD-Lys(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH exhibited stronger MC1 receptor
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binding affinities than RGD-Lys-(Arg11)CCMSH and weaker MC1 receptor
binding affinities than RAD-Lys-(Arg11)CCMSH. The differences in MC1 receptor
binding affinities among these peptides were attributed to the subtle structural
differences among the amino acids (Gly, Ala, Thr and Val). We further
radiolabeled RTD-Lys-(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH with 99mTc
and determined their biodistribution and tumor imaging properties in B16/F1
melanoma-bearing C57 mice. Both 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTcRVD-Lys-(Arg11)CCMSH were stable in mouse serum for 24 h at 37 C. 99mTcRTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH showed similar
patterns in cellular internalization and efflux in B16/F1 melanoma cells.

99m

Tc-

RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH exhibited
comparable high receptor-mediated melanoma uptake as 99mTc-RAD-Lys(Arg11)CCMSH. However, the tumor uptake pattern was different between

99m

Tc-

RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH. 99mTc-RTD-Lys(Arg11)CCMSH showed the highest tumor uptake of 18.77 ± 5.13% ID/g at 2 h
post-injection, whereas 99mTc-RVD-Lys-(Arg11)CCMSH reached the highest
tumor uptake of 19.63 ± 4.68% ID/g at 4 h post-injection. Meanwhile, 99mTc-RVDLys-(Arg11)CCMSH exhibited lower renal uptake than 99mTc-RTD-Lys(Arg11)CCMSH at 0.5, 2, and 4 h post-injection. The renal uptake of 99mTc-RVDLys-(Arg11)CCMSH was 62, 70, and 70% of the renal uptake of

99m

Tc-RTD-Lys-

(Arg11)CCMSH at 0.5, 2, and 4 h post-injection, respectively.
The B16/F1 melanoma lesions could be clearly visualized by SPECT
using 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH as
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imaging probes. Moreover, switching from the diagnostic 99mTc to therapeutic
188

Re/186Re could further expand their therapeutic applications. Since

188

Re/186Re

share similar coordination chemistry with 99mTc, both RTD-Lys-(Arg11)CCMSH
and RVD-Lys-(Arg11)CCMSH should be readily labeled with 188Re/186Re without
structural modification of the peptides. Because the renal uptake of
Lys-(Arg11)CCMSH was about 30% less than that of

99m

99m

Tc-RVD-

Tc-RTD-Lys-

(Arg11)CCMSH, RVD-Lys-(Arg11)CCMSH could be a better candidate for
melanoma therapy when labeled with 188Re/186Re. However, 99mTc-RVD-Lys(Arg11)CCMSH displayed high non-specific renal uptake in this study. Thus, it is
desirable to reduce the renal uptake to facilitate its therapeutic application. Llysine co-injection dramatically decreased the renal uptake of

99m

Tc-RTD-Lys-

(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH by 40-50% (Figure 2.5),
suggesting that the overall positive charges of the 99mTc-RXD-Lys-(Arg11)CCMSH
peptides played key roles in their non-specific renal uptake. The reduction of the
overall positive charge of

111

In-DOTA-GlyGlu-CycMSH via a negatively-charged

glutamic acid linker resulted in a decrease in renal uptake by 44% as compared
to 111In-DOTA-GlyGlu-CycMSH [100]. Accordingly, it is likely that the reduction of
the overall positive charges of the 99mTc-RXD-Lys-(Arg11)CCMSH peptides
through the structural modification would decrease their non-specific renal
uptake. It is worthwhile to note that four positively-charged amino acids, namely
three arginines and one lysine linker, contributed to the overall positive charges
of the 99mTc-RXD-Lys-(Arg11)CCMSH peptides. Because two arginines in the
(Arg11)CCMSH motif are critical for MC1 receptor binding, the structural
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modification on the arginines in the (Arg11)CCMSH motif would likely decrease
the receptor binding affinity of the peptide. Alternatively, the replacement of
lysine linker or arginine in the RXD motif by neutral or negatively-charged amino
acids would likely reduce the overall positive charges of

99m

Tc-RXD-Lys-

(Arg11)CCMSH peptides without sacrificing their receptor binding affinities. It will
be interesting to examine how the structural modification on the lysine linker or
arginine in the RXD motif affects the tumor and renal uptake in future studies.
In conclusion, the substitution of Gly with Thr and Val retained low
nanomolar MC1 receptor binding affinities of the peptides in B16/F1 melanoma
cells. 99mTc-RVD-Lys-(Arg11)CCMSH exhibited comparable high melanoma
uptake as 99mTc-RTD-Lys-(Arg11)CCMSH, but 30% less renal uptake than

99m

Tc-

RTD-Lys-(Arg11)CCMSH. In spite of high receptor-mediated melanoma uptake,
high non-specific renal uptake of

99m

Tc-RVD-Lys-(Arg11)CCMSH needs to be

reduced to facilitate its future application.
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Tables
Table 2.1. Biodistribution of 99mTc-RTD-Lys-(Arg11)CCMSH
Biodistribution of 99mTc-RTD-Lys-(Arg11)CCMSH in B16/F1 melanoma-bearing
C57 mice. The data was presented as percent injected dose/gram or as
percent injected dose (mean  SD, n=4).

2h

4h

24 h

2 h NDP
Blockade

Tissue

0.5 h

Tumor
Brain
Blood
Heart
Lung
Liver
Skin
Spleen
Stomach
Kidneys
Muscle
Pancreas
Bone

14.56 ± 5.31
0.14 ± 0.04
15.95 ± 3.97
1.86 ± 0.21
4.27 ± 0.27
2.09 ± 0.04
3.99 ± 0.42
1.04 ± 0.33
1.87 ± 0.21
144.56 ± 24.64
0.80 ± 0.38
0.83 ± 0.40
1.66 ± 0.10

Percent injected dose/gram (%ID/g)
18.77 ± 5.13
13.84 ± 3.10
5.84 ± 0.50
0.03 ± 0.01
0.02 ± 0.01
0.03 ± 0.01
0.44 ± 0.13
0.55 ± 0.41
0.40 ± 0.21
0.29 ± 0.08
0.19 ± 0.05
0.12 ± 0.02
0.51 ± 0.37
0.39 ± 0.24
0.23 ± 0.04
1.62 ± 0.14
2.01 ± 0.39
1.03 ± 0.10
0.50 ± 0.19
0.27 ± 0.13
1.01 ± 0.31
0.48 ± 0.20
0.47 ± 0.18
0.19 ± 0.13
0.67 ± 0.16
0.70 ± 0.23
0.21 ± 0.04
135.14 ± 23.62 105.54 ± 27.67 46.84 ± 14.83
0.15 ± 0.05
0.07 ± 0.02
0.52 ± 0.10
0.11 ± 0.04
0.09 ± 0.05
0.13 ± 0.07
0.46 ± 0.11
0.39 ± 0.12
0.23 ± 0.09

2.85 ± 1.43*
0.08 ± 0.06
0.50 ± 0.20
0.42 ± 0.26
1.18 ± 0.40
2.09 ± 0.64
1.21 ± 0.64
0.64 ± 0.37
1.11 ± 0.82
96.23 ± 28.13
0.33 ± 0.03
0.44 ± 0.34
0.91 ± 0.59

Intestines
Urine

1.73 ± 0.17
28.64 ± 8.85

Percent injected dose (%ID)
0.84 ± 0.20
0.72 ± 0.18
0.48 ± 0.13
54.76 ± 5.65
61.21 ± 5.56
82.19 ± 4.69

1.16 ± 0.61
48.53 ± 21.62

Uptake ratio of tumor/normal tissue
Tumor/Blood
Tumor/Kidneys
Tumor/Lung
Tumor/Liver
Tumor/Muscle

0.91
0.10
3.41
6.97
18.20

42.66
0.14
36.80
11.59
125.13

25.16
0.13
35.49
6.89
197.71

14.60
0.12
25.39
5.67
11.23

5.70
0.03
2.42
1.36
8.64

*p<0.05 (p=0.01) for determining the significance of differences in tumor and
kidney uptake between

99m

Tc-RTD-Lys-(Arg11)CCMSH with or without NDP-

MSH peptide blockade at 2 h post-injection.
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Table 2.2. Biodistribution of 99mTc-RVD-Lys-(Arg11)CCMSH
Biodistribution of

99m

Tc-RVD-Lys-(Arg11)CCMSH in B16/F1 melanoma-

bearing C57 mice. The data was presented as percent injected dose/gram or
as percent injected dose (mean  SD, n=4).

Tissue

0.5 h

2h

4h

24 h

Tumor
Brain
Blood
Heart
Lung
Liver
Skin
Spleen
Stomach
Kidneys
Muscle
Pancreas
Bone

16.70 ± 5.31
0.15 ± 0.05
1.50 ± 0.52
0.74 ± 0.43
2.01 ± 0.97
1.86 ± 0.17
9.59 ± 0.62
0.82 ± 0.43
1.92 ± 0.53
90.19 ± 15.41
11.25 ± 6.02
0.62 ± 0.25
1.6 ± 0.73

Percent injected dose/gram (%ID/g)
17.10 ± 3.82
19.63 ± 4.68
8.81 ± 2.13
0.04 ± 0.01
0.02 ± 0.01
0.03 ± 0.01
0.49 ± 0.05
0.54 ± 0.45
0.07 ± 0.02
0.26 ± 0.15
0.16 ± 0.03
0.10 ± 0.07
0.87 ± 0.40
0.49 ± 0.43
0.19 ± 0.10
1.40 ± 0.34
1.59 ± 0.13
1.21 ± 0.26
0.69 ± 0.18
0.35 ± 0.08
0.42 ± 0.27
0.40 ± 0.10
0.50 ± 0.15
0.34 ± 0.06
1.21 ± 0.61
0.96 ± 0.27
0.40 ± 0.13
94.01 ± 18.31 73.92 ± 3.73
44.34 ± 12.11
0.17 ± 0.10
0.10 ± 0.07
0.26 ± 0.02
0.10 ± 0.02
0.08 ± 0.08
0.18 ± 0.07
0.57 ± 0.08
0.54 ± 0.28
0.47 ± 0.05

Intestines
Urine

1.36 ± 0.27
44.47 ± 3.12

Percent injected dose (%ID)
1.59 ± 1.08
0.95 ± 0.30
0.44 ± 0.22
59.2 ± 9.65
67.47 ± 10.00 76.85 ± 8.21

2 h NDP Blockade
1.51 ± 0.6*
0.03 ± 0.01
0.55 ± 0.35
0.26 ± 0.11
0.83 ± 0.24
1.32 ± 0.14
0.65 ± 0.10
0.18 ± 0.14
1.39 ± 0.79
67.24 ± 9.72
0.03 ± 0.02
0.06 ± 0.03
0.46 ± 0.10
1.36 ± 0.48
76.07 ± 3.55

Uptake ratio of tumor/normal tissue
Tumor/Blood
Tumor/Kidneys
Tumor/Lung
Tumor/Liver
Tumor/Muscle

11.13
0.19
8.31
8.98
1.48

34.89
0.18
19.66
12.21
100.59

36.35
0.27
40.06
12.35
196.30

125.86
0.20
46.37
7.28
33.88

2.75
0.02
1.82
1.14
50.33

*p<0.05 (p=0.002) for determining the significance of differences in tumor and
kidney uptake between

99m

Tc-RVD-Lys-(Arg11)CCMSH with or without NDP-

MSH peptide blockade at 2 h post-injection.
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Figure Legends
Figure 2.1. Schematic structures of RTD-Lys-(Arg11)CCMSH and RVD-Lys(Arg11)CCMSH.
Figure 2.2. The competitive binding curves of RTD-Lys-(Arg11)CCMSH (■) and
RVD-Lys-(Arg11)CCMSH (▲) in B16/F1 melanoma cells. The IC50 value of RTDLys-(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH was 0.7 ± 0.07 and 1.0 ± 0.3
nM, respectively.

Figure 2.3. Radioactive HPLC profiles of

99m

Tc-RTD-Lys-(Arg11)CCMSH (A)

and 99mTc-RVD-Lys-(Arg11)CCMSH (B) in mouse serum after incubation at 37 °C
for 24 h. The arrows denote the original retention times of

99m

Tc-RTD-Lys-

(Arg11)CCMSH (12.7 min) and 99mTc-RVD-Lys-(Arg11)CCMSH (14.6 min) prior to
the incubation in mouse serum.

Figure 2.4. Cellular internalization and efflux of

99m

Tc-RTD-Lys-(Arg11)CCMSH

(A and B) and 99mTc-RVD-Lys-(Arg11)CCMSH (C and D) in B16/F1 melanoma
cells. Total bound radioactivity (♦), internalized radioactivity (▲) and cell
membrane radioactivity (■) were presented as counts per minute (cpm).

Figure 2.5. Effect of L-lysine co-injection on the tumor and kidney uptakes of
99m

Tc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH at 2 h post-

injection in B16/F1 melanoma-bearing C57 mice. The white ( ) and light grey
( ) columns represented the tumor and renal uptake of

99m

Tc-RTD-Lys-

11

(Arg )CCMSH with or without L-lysine co-injection. The heavy grey ( ) and
black ( ) columns represented the tumor and renal uptake of

99m

Tc-RVD-Lys-

(Arg11)CCMSH with or without L-lysine co-injection. L-lysine co-injection
significantly (*p<0.05) reduced the renal uptake of

99m

Tc-RTD-Lys-(Arg11)CCMSH

by 55% and the renal uptake of 99mTc-RVD-Lys-(Arg11)CCMSH by 41% at 2 h
post-injection without affecting their tumor uptake.
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Figure 2.6. Representative whole-body SPECT/CT images of B16/F1
melanoma- bearing C57 mice 2 h post injection of 7.4 MBq of
11

(Arg )CCMSH (A) and

99m

99m

Tc-RTD-Lys-

11

Tc-RVD-Lys-(Arg )CCMSH (B). Flank melanoma

lesions (T) and kidneys (K) were highlighted with arrows on the images.

Figure 2.7. Radioactive HPLC profiles of urinary metabolites at 2 h postinjection of 99mTc-RTD-Lys-(Arg11)CCMSH (A) and 99mTc-RVD-Lys(Arg11)CCMSH (B). The arrows denote the original retention times of
11

Lys-(Arg )CCMSH (12.7 min) and

99m

11

99m

Tc-RTD-

Tc-RVD-Lys-(Arg )CCMSH (14.6 min)

prior to tail vein injection.
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Figure 2.1
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Figure 2.2
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Figure 2.4
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Figure 2.5
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Figure 2.6
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Chapter 3
Effects of amino acids on melanoma targeting and clearance properties of
Tc-99m-labeled Arg-X-Asp-conjugated α-melanocyte stimulating hormone
peptides

Introduction
Malignant melanoma is the most lethal form of skin cancer with an
increasing incidence [3]. Unfortunately, no curative treatment exists for
metastatic melanoma. It is of great interest to develop receptor-targeting imaging
probes for melanoma. Both melanocortin-1 (MC1) and αvβ3 integrin receptors
have been attractive molecular targets for developing melanoma imaging probes
[91, 100, 103, 105, 125, 129, 130, 132-134, 136-145, 147]. Generally, the
radiolabeled α-melanocyte stimulating hormone (α-MSH) peptides could target
the MC1 receptors [91, 100, 103, 105, 129-137], whereas the radiolabeled ArgGly-Asp (RGD) peptides could bind to the αvβ3 integrin receptors [138-145]. In
2010, we reported a novel α-MSH hybrid peptide which could target both MC1
and αvβ3 integrin receptors [127]. Specifically, a cyclic RGD motif {Arg-Gly-AspDTyr-Asp}

was attached to [Cys3,4,10, D-Phe7, Arg11]-MSH3-13 peptide via a lysine

linker to yield RGD-Lys-(Arg11)CCMSH peptide. The dual receptor-targeting
99m

Tc-RGD-Lys-(Arg11)CCMSH displayed enhanced melanoma uptake as

compared to single receptor-targeting 99mTc-RAD-Lys-(Arg11)CCMSH or 99mTcRGD-Lys-(Arg11)CCMSHscramble in M21 human melanoma-xenografts [127].
Interestingly, the substitution of Gly in 99mTc-RGD-Lys-(Arg11)CCMSH with Ala,
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Thr and Val improved the MC1 receptor binding affinities and enhanced the
melanoma uptake in B16/F1 melanoma-bearing C57 mice [127, 128, 148].These
interesting findings suggested that the single amino acid at that specific position
generated a profound impact on the MC1 receptor binding affinity.
The structural differences among Gly, Ala, Thr and Val were minimal. As
compared to Gly, the Ala has one extra -CH3 group, the Thr has one extra CH(OH)CH3 group, whereas the Val has one extra -CH(CH3)2 group. The
comparison in biodistribution results of

99m

Tc-RXD-Lys-(Arg11)CCMSH (X = Gly,

Ala, Thr and Val) demonstrated that such subtle structural modification retained
high melanoma uptake in B16/F1 melanoma-bearing C57 mice. Thus, we were
interested in whether and how other amino acids could affect the melanoma
targeting and pharmacokinetic properties of

99m

Tc-RXD-Lys-(Arg11)CCMSH

peptide. For instance, whether and how a long hydrocarbon chain and a bulky
benzene ring could affect the receptor binding and melanoma targeting
properties of the peptides. In this study, we replaced the Gly with Ser, Nle, Phe
and DPhe to generate four new peptides, namely RSD-Lys-(Arg11)CCMSH,
RNleD-Lys-(Arg11)CCMSH, RFD-Lys-(Arg11)CCMSH and RfD-Lys(Arg11)CCMSH peptides. The MC1 receptor binding affinities of these four
peptides were examined in B16/F1 melanoma cells. Based on the receptor
binding affinities, we further radiolabeled RSD-Lys-(Arg11)CCMSH, RFD-Lys(Arg11)CCMSH and RfD-Lys-(Arg11)CCMSH with 99mTc. Then we determined the
cellular internalization and efflux in B16/F1 melanoma cells and biodistribion
properties in B16/F1 melanoma-bearing C57 mice for these three 99mTc-peptides.
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Thereafter, we determined the imaging property of

99m

Tc-RSD-Lys-

(Arg11)CCMSH in B16/F1 melanoma-bearing C57 mice.
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Experimental design and methods

Chemicals and Reagents

Amino acids and resin were purchased from Advanced ChemTech Inc.
(Louisville, KY) and Novabiochem (San Diego, CA). 125I-Tyr2-[Nle4, DPhe7]-αMSH {125I-(Tyr2)-NDP-MSH} was obtained from PerkinElmer, Inc. (Waltham, MA)
for receptor binding assay. 99mTcO4- was purchased from Cardinal Health
(Albuquerque, NM). L-lysine was purchased from Sigma-Aldrich (St. Louis, MO).
All other chemicals used in this study were purchased from Thermo Fischer
Scientific (Waltham, MA) and used without further purification. B16/F1 murine
melanoma cells were obtained from American Type Culture Collection
(Manassas, VA).

Peptide Synthesis and In Vitro Competitive Binding Assay

The RSD-Lys-(Arg11)CCMSH, RNleD-Lys-(Arg11)CCMSH, RFD-Lys(Arg11)CCMSH and RfD-Lys-(Arg11)CCMSH peptides were synthesized using
fluorenylmethyloxycarbonyl (Fmoc) chemistry according to our previously
published procedure [146] with slight modification on Sieber amide resin by an
Advanced ChemTech multiple-peptide synthesizer (Louisville, KY). Briefly, 70
µmol of Sieber amide resin and 210 µmol of Fmoc-protected amino acids were
used for the synthesis. Fmoc-Lys(Boc) was used to generate a Lys linker in each
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peptide. Intermediate scaffolds of H2N-Arg(Pbf)-Ser/Nle/Phe/DPhe-Asp(OtBu)DTyr(tBu)-Asp(O-2-phenylisopropyl)-Lys(Boc)-Cys(Trt)-Cys(Trt)-Glu(OtBu)His(Trt)-DPhe-Arg(Pbf)-Trp(Boc)-Cys(Trt)-Arg(Pbf)-Pro-Val were synthesized on
Sieber amide resin. The protecting group of 2-phenylisopropyl of each scaffold
was removed and each peptide was cleaved from the resin treating with a
mixture of 2.5% of trifluoroacetic acid (TFA) and 5% of triisopropylsilane. After
the precipitation with ice-cold ether and characterization by MS, each protected
peptide was dissolved in H2O/CH3CN (50:50) and lyophilized to remove the
reagents such as TFA and triisopropylsilane. Each protected peptide was further
cyclized by coupling the carboxylic group from the Asp with the alpha amino
group from the Arg at the N-terminus. The cyclization reaction was achieved by
overnight reaction in dimethylformamide (DMF) using benzotriazole-1-yl-oxy-trispyrrolidino-phosphonium-hexafluorophosphate (PyBOP) as a coupling agent in
the presence of N,N-diisopropylethylamine (DIPEA). The protecting groups were
totally removed by treating with a mixture of TFA, thioanisole, phenol, water,
ethanedithiol and triisopropylsilane (87.5:2.5:2.5:2.5:2.5:2.5) for 2 h at room
temperature (25 °C). Each peptide was precipitated and washed with ice-cold
ether for four times, purified by RP-HPLC and characterized by MS. The
chemical purity of each peptide was determined by Waters RP-HPLC (Milford,
MA) on a Grace Vydac C-18 reverse phase analytic column (Deerfield, IL) using
a 20-min gradient of 16-26% acetonitrile in 20 mM HCl aqueous solution at a flow
rate of 1 mL/min. The purities of all four peptides were greater than 95%.
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The IC50 values of RSD-Lys-(Arg11)CCMSH, RNleD-Lys-(Arg11)CCMSH,
RFD-Lys-(Arg11)CCMSH and RfD-Lys-(Arg11)CCMSH peptides for the MC1
receptor were determined in B16/F1 melanoma cells. The receptor binding assay
was replicated in triplicate for each peptide. The B16/F1 cells were seeded into a
24-well cell culture plate at a density of 2.5 × 105 cells/well and incubated at 37°
C overnight. After being washed with binding medium {modified Eagle’s medium
with 25 mM N-(2-hydroxyethyl)-piperazine-N′-(2-ethanesulfonic acid) (HEPES),
pH 7.4, 0.2% bovine serum albumin (BSA), 0.3 mM 1,10-phenathroline}, the cells
were incubated at 25 °C for 2 h with approximately 30,000 counts per minute
(cpm) of 125I-(Tyr2)-NDP-MSH in the presence of increasing concentrations (10-13
M to 10-6 M) of each peptide in 0.3 mL of binding medium. The reaction medium
was aspirated after the incubation. The cells were rinsed twice with 0.5 mL of icecold pH 7.4, 0.2% BSA/0.01 M phosphate buffered saline (PBS) to remove any
unbound radioactivity and lysed in 0.5 mL of 1 M NaOH for 5 min. The activities
associated with the cells were measured in a Wallac 2480 automated gamma
counter (PerkinElmer, NJ). The IC50 value for each peptide was calculated using
Prism software (GraphPad Software, La Jolla, CA).

Peptide Radiolabeling

Because RNleD-Lys-(Arg11)CCMSH exhibited lowest receptor binding
affinity among four peptides, we only further evaluated the other three peptides.
RSD-Lys-(Arg11)CCMSH, RFD-Lys-(Arg11)CCMSH and RfD-Lys-(Arg11)CCMSH
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peptides were labeled with 99mTc via a direct reduction reaction with SnCl2.
Briefly, 10 μL of 1 mg/mL SnCl2 in 0.1 M HCl, 40 μL of 0.5 M NH4OAc (pH 5.2),
100 μL of 0.2 M Na2tartate (pH 9.2), 100 μL of fresh 99mTcO4- solution (37-74
MBq), and 10 μL of 1 mg/mL of each peptide in aqueous solution were added
into a reaction vial and incubated at 25 °C for 20 min to form 99mTc-labeled
peptide. Each 99mTc-peptide was purified to a single species by Waters RP-HPLC
(Milford, MA) on a Grace Vydac C-18 reverse phase analytic column (Deerfield,
IL) using a 20-min gradient of 16-26% acetonitrile in 20 mM HCl aqueous
solution at a flow rate of 1 mL/min. Each purified peptide was purged with N 2 gas
for 20 min to remove the acetonitrile. The pH of final peptide solution was
adjusted to 7.4 with 0.1 N NaOH and sterile normal saline for stability,
biodistribution and imaging studies. The serum stabilities of
(Arg11)CCMSH,

99m

99m

Tc-RSD-Lys-

Tc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-

(Arg11)CCMSH were determined by incubation in mouse serum at 37 C for 24 h
and monitored for degradation by RP-HPLC. Briefly, 100 µL of HPLC-purified
peptide solution (~7.4 MBq) was added into 100 µL of mouse serum (SigmaAldrich Corp, St. Louis, MO) and incubated at 37 oC for 24 h. After the
incubation, 200 µL of a mixture of ethanol and acetonitrile (V:V = 1:1) was added
to precipitate the serum proteins. The resulting mixture was centrifuged at 16,000
g for 5 min to collect the supernatant. The supernatant was purged with N2 gas
for 30 min to remove the ethanol and acetonitrile. The resulting sample was
mixed with 500 µL of water and injected into RP-HPLC for analysis using the
gradient described above.
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Cellular Internalization and Efflux

Cellular internalization and efflux of
99m

99m

Tc-RSD-Lys-(Arg11)CCMSH,

Tc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH were

evaluated in B16/F1 melanoma cells. The B16/F1 cells were seeded into a 24well cell culture plate at a density of 2.5 × 105 cells/well and incubated at 37° C
overnight. After being washed twice with binding medium [modified Eagle's
medium with 25 mM N-(2-hydroxyethyl)-piperazine-N’-(2-ethanesulfonic acid), pH
7.4, 0.2% bovine serum albumin (BSA), 0.3 mM 1,10-phenathroline], the B16/F1
cells were incubated at 25C for 20, 40, 60, 90 and 120 min (n=3) in the
presence of approximate 300,000 counts per minute (cpm) of HPLC-purified of
99m

Tc-RSD-Lys-(Arg11)CCMSH,

99m

Tc-RFD-Lys-(Arg11)CCMSH or 99mTc-RfD-

Lys-(Arg11)CCMSH. After incubation, the reaction medium was aspirated and the
cells were rinsed with 2  0.5 mL of ice-cold pH 7.4, 0.2% BSA / 0.01 M PBS.
Cellular internalization was assessed by washing the cells with acidic buffer [40
mM sodium acetate (pH 4.5) containing 0.9% NaCl and 0.2% BSA] to remove the
membrane-bound radioactivity. The remaining internalized radioactivity was
obtained by lysing the cells with 0.5 mL of 1 N NaOH for 5 min. Membrane-bound
and internalized activities were counted in a gamma counter. Cellular efflux was
determined by incubating the B16/F1 cells with
99m

99m

Tc-RSD-Lys-(Arg11)CCMSH,

Tc-RFD-Lys-(Arg11)CCMSH or 99mTc-RfD-Lys-(Arg11)CCMSH for 2 h at 25C,

removing non-specific-bound activity with 2  0.5 mL of ice-cold PBS rinse, and
monitoring radioactivity released into cell culture medium. At time points of 20,
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40, 60, 90 and 120 min, the radioactivities on the cell surface and inside the cells
were separately collected and counted in a gamma counter.

Biodistribution Studies

All the animal studies were conducted in compliance with Institutional
Animal Care and Use Committee approval. The biodistribution properties of
99m

Tc-RSD-Lys-(Arg11)CCMSH,

99m

Tc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-

Lys-(Arg11)CCMSH were determined in B16/F1 melanoma-bearing C57 female
mice (Harlan, Indianapolis, IN). Each C57 mouse was subcutaneously inoculated
on the right flank with 1106 B16/F1 cells. The weight of tumors reached
approximately 0.2 g 10 days post cell inoculation. Each melanoma-bearing
mouse was injected with 0.037 MBq of

99m

Tc-RSD-Lys-(Arg11)CCMSH,

99m

Tc-

RFD-Lys-(Arg11)CCMSH or 99mTc-RfD-Lys-(Arg11)CCMSH via the tail vein.
Groups of 4 mice were sacrificed at 0.5, 2, 4 and 24 h post-injection, and tumors
and organs of interest were harvested, weighed and counted. Blood values were
taken as 6.5% of the body weight. The specificity of tumor uptake was
determined by co-injecting 99mTc-RSD-Lys-(Arg11)CCMSH,

99m

Tc-RFD-Lys-

(Arg11)CCMSH or 99mTc-RfD-Lys-(Arg11)CCMSH with 10 g (6.1 nmol) of
unlabeled NDP-MSH at 2 h post-injection.
L-lysine co-injection is effective in decreasing the renal uptake of
radiolabeled α-MSH peptides. Because 99mTc-RSD-Lys-(Arg11)CCMSH exhibited
the highest tumor uptake and fastest urinary clearance among three
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99m

Tc-

peptdes, we only examined the effect of L-lysine co-injection on the renal uptake
of 99mTc-RSD-Lys-(Arg11)CCMSH. Briefly, a group of 4 mice were injected with a
mixture of 0.037 MBq of

99m

Tc-RSD-Lys-(Arg11)CCMSH and 15 mg of L-lysine.

The mice were sacrificed at 2 h post-injection, and tumors and organs of interest
were harvested, weighed and counted in a gamma counter.

Melanoma Imaging with 99mTc-RSD-Lys-(Arg11)CCMSH

99m

Tc-RSD-Lys-(Arg11)CCMSH was the lead peptide due to its higher

tumor uptake and faster urinary clearance. Thus, we further determined the
melanoma imaging property of 99mTc-RSD-Lys-(Arg11)CCMSH. Approximately
4.1 MBq of 99mTc-RSD-Lys-(Arg11)CCMSH was injected into a B16/F1
melanoma-bearing C57 mouse via the tail vein. The mouse was euthanized for
small animal SPECT/CT (Nano-SPECT/CT®, Bioscan, Washington DC) imaging
2 h post-injection. The 9-min CT imaging was immediately followed by the
SPECT imaging of whole-body. The SPECT scans of 24 projections were
acquired. Reconstructed data from SPECT and CT were visualized and coregistered using InVivoScope (Bioscan, Washington DC).

Urinary Metabolites of 99mTc-RSD-Lys-(Arg11)CCMSH

We also examined the urinary metabolites of
(Arg11)CCMSH. Approximately 3.7 MBq of

84

99m

99m

Tc-RSD-Lys-

Tc-RSD-Lys-(Arg11)CCMSH was

injected into a B16/F1 melanoma-bearing C57 mouse via the tail vein to
determine the urinary metabolites. The mouse was euthanized to collect urine at
2 h post-injection. The collected urine sample was centrifuged at 16,000 g for 5
min before the HPLC analysis. Thereafter, an aliquot of the urine was injected
into the HPLC. A 20-minute gradient of 16-26% acetonitrile / 20 mM HCl with a
flow rate of 1 mL/min was used for urine analysis.

Statistical Analysis

Statistical analysis was performed using the Student’s t-test for unpaired
data to determine the significance of differences in tumor and kidney uptake
with/without peptide blockade or with/without L-lysine co-injection in
biodistribution studies described above. Differences at the 95% confidence level
(p<0.05) were considered significant.
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Results
The schematic structures of RSD-Lys-(Arg11)CCMSH, RNleD-Lys(Arg11)CCMSH, RFD-Lys-(Arg11)CCMSH and RfD-Lys-(Arg11)CCMSH are
presented in Figure 3.1. The peptides were synthesized and purified by reverse
phase-high performance liquid chromatography (RP-HPLC). The overall
synthetic yields were 30% for all four peptides. The chemical purities of RSDLys-(Arg11)CCMSH, RNleD-Lys-(Arg11)CCMSH, RFD-Lys-(Arg11)CCMSH and
RfD-Lys-(Arg11)CCMSH were greater than 95% after the HPLC purification. The
peptide identities were confirmed by electrospray mass spectrometry (MS). The
measured molecular weight was 2180 for RSD-Lys-(Arg11)CCMSH, 2206 for
RNleD-Lys-(Arg11)CCMSH, 2240 for RFD-Lys-(Arg11)CCMSH and RfD-Lys(Arg11)CCMSH (Table 3.1). The competitive binding curves of the peptides are
shown in Figure 3.2. The IC50 value was 1.30 ± 0.36 nM for RSD-Lys(Arg11)CCMSH, 2.99 ± 0.26 nM for RNleD-Lys-(Arg11)CCMSH, 0.82 ± 0.06 nM
for RFD-Lys-(Arg11)CCMSH, and 1.35 ± 0.08 nM for RfD-Lys-(Arg11)CCMSH in
B16/F1 melanoma cells, respectively.
Because RNleD-Lys-(Arg11)CCMSH exhibited lowest receptor binding
affinity among four peptides, as well as lower receptor binding affinity than that of
RGD-Lys-(Arg11)CCMSH in our previous report [146], we only further evaluated
the other three peptides. RSD-Lys-(Arg11)CCMSH, RFD-Lys-(Arg11)CCMSH and
RfD-Lys-(Arg11)CCMSH were readily radiolabeled with 99mTc with greater than
95% radiolabeling yields. All three

99m

Tc-peptides were separated from their

excess non-labeled peptides by RP-HPLC. The radiochemical purities of three
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99m

Tc-peptides were greater than 99% (Table 3.1). The specific activities of

99m

Tc-RSD-Lys-(Arg11)CCMSH, 99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-

Lys-(Arg11)CCMSH were 8.834  109, 8.598  109 , 8.598  109 MBq/g,
respectively. The retention times of

99m

Tc-RSD-Lys-(Arg11)CCMSH, 99mTc-RFD-

Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH were 12.5, 18.4 and 20.8
min, respectively. 99mTc-RSD-Lys-(Arg11)CCMSH, 99mTc-RFD-Lys-(Arg11)CCMSH
and 99mTc-RfD-Lys-(Arg11)CCMSH were stable in mouse serum at 37°C for 24 h
(Figure 3.3). Cellular internalization and efflux properties of

99m

Tc-RSD-Lys-

(Arg11)CCMSH, 99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys(Arg11)CCMSH were examined in B16/F1 cells. Figure 3.4 illustrates the
internalization and efflux properties of 99mTc-RSD-Lys-(Arg11)CCMSH, 99mTcRFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH. All three 99mTcpeptides exhibited rapid cellular internalization and prolonged cellular retention.
Approximately 69% of 99mTc-RSD-Lys-(Arg11)CCMSH, 87% of 99mTc-RFD-Lys(Arg11)CCMSH and 87% of

99m

Tc-RfD-Lys-(Arg11)CCMSH activities were

internalized in the cells after 20 min of incubation. Cellular efflux results indicated
that 76% of 99mTc-RSD-Lys-(Arg11)CCMSH, 73% of 99mTc-RFD-Lys(Arg11)CCMSH and 46% of

99m

Tc-RfD-Lys-(Arg11)CCMSH activities remained

inside the cells after 2 h of incubation in the culture medium.
The melanoma targeting and pharmacokinetic properties of

99m

Tc-RSD-

Lys-(Arg11)CCMSH, 99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys(Arg11)CCMSH are shown in Tables 3.2-3.4. Both 99mTc-RFD-Lys-(Arg11)CCMSH
and 99mTc-RfD-Lys-(Arg11)CCMSH exhibited similar tumor uptake pattern in
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B16/F1 melanoma-bearing C57 mice. 99mTc-RFD-Lys-(Arg11)CCMSH exhibited
its highest tumor uptake of 15.01 ± 4.40% ID/g at 4 h post-injection, whereas
99m

Tc-RfD-Lys-(Arg11)CCMSH reached its highest tumor uptake of 13.11 ± 1.21%

ID/g at 4 h post-injection. The tumor uptake values of

99m

Tc-RFD-Lys-

(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH decreased to 7.19 ± 1.02 and
6.29 ± 1.39% ID/g by 24 h post-injection. The tumor blocking studies revealed
that co-injection of 10 μg (6.1 nM) of non-radiolabeled NDP-MSH with 99mTcRFD-Lys-(Arg11)CCMSH or 99mTc-RfD-Lys-(Arg11)CCMSH decreased their tumor
uptake values to 2.82 ± 0.48 and 1.57 ± 0.48% ID/g at 2 h post-injection,
demonstrating that the tumor uptake was MC1 receptor-mediated. 99mTc-RSDLys-(Arg11)CCMSH displayed a different tumor uptake pattern as compared to
99m

Tc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH. 99mTc-RSD-

Lys-(Arg11)CCMSH exhibited rapid and high melanoma uptake of 18.01 ± 4.22%
ID/g at 30 min post-injection. The tumor uptake of

99m

Tc-RSD-Lys-(Arg11)CCMSH

gradually reduced to 8.04 ± 1.80% ID/g at 24 h post-injection. Furthermore, coinjection of 10 μg (6.1 nM) of non-radiolabeled NDP-MSH with 99mTc-RSD-Lys(Arg11)CCMSH decreased their tumor uptake value to 2.35 ± 0.01% ID/g at 2 h
post-injection, demonstrating that the tumor uptake was MC1 receptor-mediated.
Kidneys were the excretion pathways for 99mTc-RSD-Lys-(Arg11)CCMSH,
99m

Tc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH. The renal

uptake values of 99mTc-RSD-Lys-(Arg11)CCMSH, 99mTc-RFD-Lys-(Arg11)CCMSH
and 99mTc-RfD-Lys-(Arg11)CCMSH were 80.01 ± 15.67, 88.08 ± 9.31 and 111.54
± 10.19% ID/g at 2 h post injection, respectively. At 24 h post-injection, The renal
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uptake values of for 99mTc-RSD-Lys-(Arg11)CCMSH, 99mTc-RFD-Lys(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH decreased to 23.15 ± 2.94,
51.01 ± 3.62 and 73.05 ± 9.87% ID/g, respectively. Liver uptake was different
among these three 99mTc-peptides. 99mTc-RSD-Lys-(Arg11)CCMSH demonstrated
lower liver uptake than 99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys(Arg11)CCMSH. The liver uptake of

99m

Tc-RSD-Lys-(Arg11)CCMSH, 99mTc-RFD-

Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH were 1.22 ± 0.12, 9.87 ±
1.26 and 5.29 ± 1.30% ID/g at 2 h post injection, respectively.
99m

Tc-RSD-Lys-(Arg11)CCMSH exhibited faster whole-body clearance

than 99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH.
Approximately 68% of 99mTc-RSD-Lys-(Arg11)CCMSH cleared through the urinary
system by 2 h post-injection, whereas approximately 43% of 99mTc-RFD-Lys(Arg11)CCMSH and 44% of

99m

Tc-RfD-Lys-(Arg11)CCMSH washed through the

urinary system by 2 h post-injection. At 24 h post-injection, 84% of 99mTc-RSDLys-(Arg11)CCMSH, 76% of 99mTc-RFD-Lys-(Arg11)CCMSH and 73% of

99m

Tc-

RfD-Lys-(Arg11)CCMSH cleared out the body. 99mTc-RSD-Lys-(Arg11)CCMSH
also displayed lower normal organ uptake than

99m

Tc-RFD-Lys-(Arg11)CCMSH

and 99mTc-RfD-Lys-(Arg11)CCMSH. Normal organ uptake of 99mTc-RSD-Lys(Arg11)CCMSH was minimal (<1.2% ID/g) except for the kidneys after 2 h postinjection.
Since 99mTc-RSD-Lys-(Arg11)CCMSH showed higher tumor uptake and
faster urinary clearance than 99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys(Arg11)CCMSH, the effect of L-lysine co-injection on the tumor and renal uptake
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of 99mTc-RSD-Lys-(Arg11)CCMSH was examined in B16/F1 melanoma-bearing
C57 mice. L-lysine co-injection significantly (*p<0.05) reduced the renal uptake of
99m

Tc-RSD-Lys-(Arg11)CCMSH by 37% at 2 h post-injection without affecting the

tumor uptake (Figure 3.5). Whole-body single photon emission computed
tomography (SPECT)/CT image at 2 h post-injection are presented in Figure 3.6.
Flank B16/F1 melanoma lesions were clearly visualized by SPECT using

99m

Tc-

RSD-Lys-(Arg11)CCMSH peptide as an imaging probe. The SPECT image of
tumor accurately matched its anatomical location obtained in the CT image. The
SPECT image showed high contrast of tumor to normal organ except for kidneys,
which was consistent with the biodistribution results. The urinary metabolites of
99m

Tc-RSD-Lys-(Arg11)CCMSH at 2 h post-injection are shown in Figure 3.7.

Approximately 70% of 99mTc-RSD-Lys-(Arg11)CCMSH remained intact in the
urine at 2 h post-injection, while 30% of the 99mTc-RSD-Lys-(Arg11)CCMSH was
transformed to a more hydrophobic compound.
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Discussion
In our previous reports [24-26] we have found the important role of Gly in
the tumor targeting property of 99mTc-RGD-Lys-(Arg11)CCMSH in B16/F1
melanoma-bearing C57 mice. Despite the minimal structural differences among
Gly, Ala, Thr and Val amino acids, the replacement of Gly in RGD-Lys(Arg11)CCMSH with Ala, Thr and Val enhanced the MC1 receptor binding
affinities and B16/F1 melanoma uptake of the peptides [24-26]. In this study, we
further investigated whether the substitution of Gly with a longer hydrocarbon
chain (Nle) and a bulky benzene ring (Phe or DPhe) could affect the receptor
binding and melanoma targeting properties of the peptides. On the other hand,
we hypothesized that the replacement of Gly with Ser would facilitate the urinary
clearance of the peptide as compared to hydrophobic Nle, Phe and DPhe. Thus,
we synthesized and evaluated RSD-Lys-(Arg11)CCMSH, RNleD-Lys(Arg11)CCMSH, RFD-Lys-(Arg11)CCMSH and RfD-Lys-(Arg11)CCMSH peptides
in this study.
The introduction of Ser, Nle, Phe and DPhe generated different impact on
the MC1 receptor binding affinities of the peptides. The linear long hydrocarbon
chain from Nle decreased the MC1 receptor binding affinity of the peptide,
whereas the short CH2OH group from Ser and the bulky benzene ring from Phe
and DPhe increased the MC1 receptor binding affinity of the peptides. Among
these four new peptides, RNleD-Lys-(Arg11)CCMSH displayed the weakest MC1
receptor binding affinity of 2.99 ± 0.26 nM, whereas RSD-Lys-(Arg11)CCMSH and
RfD-Lys-(Arg11)CCMSH exhibited similar strong MC1 receptor binding affinities of
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1.30 ± 0.36 and 1.35 ± 0.08 nM. Overall, RfD-Lys-(Arg11)CCMSH showed the
strongest MC1 receptor binding affinity of 0.82 ± 0.06 nM. Despite that the -HisDPhe-Arg-Trp-

motif is the binding moiety to MC1 receptor, the difference in

receptor binding affinity indicated that the Ser, Nle, Phe and DPhe interacted with
the receptor binding moiety. Such subtle interactions were likely related to the
flexibility of lactam bonds among amino acid residues in the peptides. In our
previous report [25,26], the MC1 receptor binding affinities were 2.1, 0.3, 0.7 and
1.0 nm for RGD-Lys-(Arg11)CCMSH, RAD-Lys-(Arg11)CCMSH, RTD-Lys(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH in B16/F1 cells, respectively.
Clearly, RNleD-Lys-(Arg11)CCMSH displayed the weakest MC1 receptor binding
affinity among all RXD-Lys-(Arg11)CCMSH peptides. Thus, we further
radiolabeled RSD-Lys-(Arg11)CCMSH, RFD-Lys-(Arg11)CCMSH and RfD-Lys(Arg11)CCMSH with 99mTc and evaluated their cellular internalization and efflux
properties, as well as their in vivo biodistribution and clearance properties. It is
worthwhile to note that three cysteine residues in each peptide provide a NS 3
chelating system for 99mTc. It was reported that non-radioactive rheniumconjugated (Arg11)CCMSH retained comparable nanomolar MC1 receptor
binding affinity as (Arg11)CCMSH peptide (1.9 vs. 1.7 nM) [149]. Accordingly, the
radiolabeling of three RXD-Lys-(Arg11)CCMSH peptides with 99mTc should retain
their nanomolar binding affinities.
99m

Tc-RSD-Lys-(Arg11)CCMSH, 99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-

RfD-Lys-(Arg11)CCMSH exhibited similar rapid internalization and prolonged
efflux properties in B16/F1 melanoma cells. Despite the similar pattern in cellular
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internalization and efflux properties, 99mTc-RSD-Lys-(Arg11)CCMSH displayed a
different tumor uptake pattern as compared to

99m

Tc-RFD-Lys-(Arg11)CCMSH

and 99mTc-RfD-Lys-(Arg11)CCMSH. 99mTc-RSD-Lys-(Arg11)CCMSH exhibited
rapid and high melanoma uptake of 18.01 ± 4.22% ID/g at 30 min post-injection.
Meanwhile, 99mTc-RSD-Lys-(Arg11)CCMSH displayed lower renal uptake than
99m

Tc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH. The renal

uptake of 99mTc-RSD-Lys-(Arg11)CCMSH was 45% of the renal uptake of
RFD-Lys-(Arg11)CCMSH, and 32% of the renal uptake of

99m

99m

Tc-

Tc-RfD-Lys-

(Arg11)CCMSH at 24 h post-injection. Not surprisingly, 99mTc-RSD-Lys(Arg11)CCMSH also showed lower liver uptake than 99mTc-RFD-Lys(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH. The liver uptake of
RSD-Lys-(Arg11)CCMSH was 12% of the liver uptake of
(Arg11)CCMSH, and 23% of the liver uptake of

99m

99m

99m

Tc-

Tc-RFD-Lys-

Tc-RfD-Lys-(Arg11)CCMSH at 2

h post-injection. Furthermore, 99mTc-RSD-Lys-(Arg11)CCMSH exhibited faster
urinary clearance than 99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys(Arg11)CCMSH. Interestingly, the stereochemistry of Phe and DPhe affected the
renal and liver uptake. 99mTc-RFD-Lys-(Arg11)CCMSH displayed higher liver
uptake than that of 99mTc-RfD-Lys-(Arg11)CCMSH, whereas 99mTc-RfD-Lys(Arg11)CCMSH displayed higher renal uptake than that of

99m

Tc-RFD-Lys-

(Arg11)CCMSH. Clearly, the tumor targeting and clearance properties of

99m

Tc-

RSD-Lys-(Arg11)CCMSH were more favorable than those of 99mTc-RFD-Lys(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH.
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The B16/F1 melanoma lesions could be clearly visualized by SPECT/CT
using 99mTc-RSD-Lys-(Arg11)CCMSH as an imaging probe. However, the image
also indicated very high renal uptake. In fact, extremely high renal uptake (67135% ID/g at 2 h post-injection) appears to be a common issue for all reported
99m

Tc-RXD-Lys-(Arg11)CCMSH peptides [128, 146, 148]. Despite that 99mTc-

RSD-Lys-(Arg11)CCMSH exhibited the second lowest renal uptake (80.01 ±
15.67% ID/g at 2 h post-injection) among all reported 99mTc-RXD-Lys(Arg11)CCMSH peptides, it is desirable to reduce the non-specific renal uptake in
future studies to facilitate its potential therapeutic application. In this study, Llysine co-injection significantly (*p<0.05) reduced the renal uptake of 99mTc-RSDLys-(Arg11)CCMSH by 37% at 2 h post-injection without affecting its tumor
uptake. Obviously, L-lysine co-injection can be utilized to decrease the renal
uptake of 99mTc-RSD-Lys-(Arg11)CCMSH in future studies. The effect of L-lysine
co-injection also highlighted the contribution of the overall positive charge of
99m

Tc-RSD-Lys-(Arg11)CCMSH to its renal uptake. Clearly, the substitution of the

positively-charged Lys linker with a neutral or negatively-charged amino acid (i.e.
Gly or Glu) can decrease the overall charge of

99m

Tc-RSD-Lys-(Arg11)CCMSH.

According to the effect of L-lysine co-injection in this study, it is very likely that
the substitution of Lys with a neutral or negatively-charged amino acid will
decrease the renal uptake.
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Conclusions
In summary, the substitution of Gly with Ser, Phe and DPhe increased the
MC1 receptor binding affinities of the peptides, whereas the substitution of Gly
with Nle decreased the MC1 receptor binding affinity of the peptide in B16/F1
melanoma cells. 99mTc-RSD-Lys-(Arg11)CCMSH exhibited higher melanoma
uptake and lower kidney and liver uptake than those of

99m

Tc-RFD-Lys-

(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH. The B16/F1 melanoma
lesions could be clearly visualized by SPECT/CT using 99mTc-RSD-Lys(Arg11)CCMSH as an imaging probe. It is desirable to reduce the non-specific
renal uptake of 99mTc-RSD-Lys-(Arg11)CCMSH to facilitate its potential
therapeutic application.
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Tables

Table 3.1. Peptide properties
Capacity factors, chemical/radiochemical purities and measured molecular
weights of RXD-Lys-(Arg11)CCMSH peptides and their 99mTc-conjugates.

Peptide

Capacity
factor (k’)

Chemical/Radiochemical
Purity (%)

Measured
Molecular Weight
(Da)

RSD-Lys-(Arg11)CCMSH
RNleD-Lys-(Arg11)CCMSH
RFD-Lys-(Arg11)CCMSH
RfD-Lys-(Arg11)CCMSH
99m
Tc-RSD-Lys-(Arg11)CCMSH
99m
Tc-RFD-Lys-(Arg11)CCMSH
99m
Tc-RfD-Lys-(Arg11)CCMSH

2.19
4.36
3.77
3.86
3.18
4.93
5.13

97.01
95.83
98.25
95.75
99.75
99.27
99.78

2180
2206
2240
2240
ND
ND
ND

ND = not determined.
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Table 3.2. Biodistribution of 99mTc-RSD-Lys-(Arg11)CCMSH
Biodistribution of

99m

Tc-RSD-Lys-(Arg11)CCMSH in B16/F1 melanoma-bearing

C57 mice. The data was presented as percent injected dose/gram or as percent
injected dose (mean  SD, n=4).

Tissue

0.5 h

2h

4h

24 h

2 h NDP Blockade

8.04 ± 1.80
0.06 ± 0.01
2.01 ± 1.52
0.14 ± 0.05
0.27 ± 0.13
0.70 ± 0.14
2.19 ± 0.58
0.22 ± 0.07
0.30 ± 0.17
23.15 ± 2.94
1.01 ± 0.50
0.17 ± 0.07
0.59 ± 0.09

2.35 ± 0.01*
0.05 ± 0.01
0.69 ± 0.42
0.46 ± 0.30
0.65 ± 0.16
1.54 ± 0.11
0.75 ± 0.02
0.28 ± 0.10
1.19 ± 0.04
90.41 ± 19.21
0.09 ± 0.06
0.15 ± 0.03
0.47 ± 0.13

0.66 ± 0.27
84.03 ± 2.67

1.06 ± 0.79
69.99 ± 4.72

Percent injected dose/gram (%ID/g)
Tumor
Brain
Blood
Heart
Lung
Liver
Skin
Spleen
Stomach
Kidneys
Muscle
Pancreas
Bone

18.01 ± 4.22
0.25 ± 0.12
13.59 ± 1.25
2.14 ± 0.49
3.69 ± 1.18
2.25 ± 0.20
5.31 ± 0.63
1.73 ± 0.17
2.31 ± 0.31
98.25 ± 13.78
1.42 ± 0.57
0.68 ± 0.27
2.11 ± 0.67

17.42 ± 1.52
0.02 ± 0.01
0.19 ± 0.11
0.14 ± 0.05
0.33 ± 0.13
1.22 ± 0.12
0.33 ± 0.10
0.18 ± 0.10
0.73 ± 0.08
80.01 ± 15.67
0.09 ± 0.04
0.04 ± 0.04
0.44 ± 0.18

10.12 ± 1.72
0.01 ± 0.01
0.06 ± 0.04
0.09 ± 0.04
0.22 ± 0.06
1.57 ± 0.81
0.27 ± 0.05
0.38 ± 0.15
0.61 ± 0.18
69.23 ± 17.41
0.07 ± 0.04
0.09 ± 0.06
0.32 ± 0.19

Percent injected dose (%ID)
Intestines
Urine

2.02 ± 0.17
36.01 ± 2.73

0.63 ± 0.08
68.19 ± 9.80

1.48 ± 0.22
74.72 ± 6.63

Uptake ratio of tumor/normal tissue
Tumor/Blood
Tumor/Kidneys
Tumor/Lung
Tumor/Liver
Tumor/Muscle

1.33
0.18
4.88
8.00
12.68

91.68
0.22
52.79
14.28
193.56

168.67
0.15
46.00
6.45
144.57

4.02
0.35
29.78
11.49
8.04

3.41
0.03
3.62
1.53
26.11

*p<0.05 (p=0.002) for determining the significance of differences in tumor and
kidney uptake between

99m

Tc-RSD-Lys-(Arg11)CCMSH with or without NDP-MSH

peptide blockade at 2 h post-injection.
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Table 3.3. Biodistribution of 99mTc-RFD-Lys-(Arg11)CCMSH
Biodistribution of

99m

Tc-RFD-Lys-(Arg11)CCMSH in B16/F1 melanoma-bearing

C57 mice. The data was presented as percent injected dose/gram or as percent
injected dose (mean  SD, n=4).

Tissue

0.5 h

2h

4h

24 h

2 h NDP Blockade

Percent injected dose/gram (%ID/g)
Tumor
Brain
Blood
Heart
Lung
Liver
Skin
Spleen
Stomach
Kidneys
Muscle
Pancreas
Bone

7.42 ± 3.56
0.21 ± 0.01
6.78 ± 3.79
2.63 ± 1.13
7.51 ± 1.60
6.75 ± 2.44
4.27 ± 1.16
4.82 ± 1.31
6.21 ± 0.37
56.86 ± 16.58
1.27 ± 0.42
1.17 ± 0.23
1.97 ± 0.32

11.22 ± 1.53
0.07 ± 0.01
1.99 ± 0.24
0.94 ± 0.11
3.38 ± 0.48
9.87 ± 1.26
1.54 ± 0.20
4.40 ± 0.72
4.40 ± 3.33
88.08 ± 9.31
0.31 ± 0.19
0.38 ± 0.17
1.11 ± 0.07

13.11 ± 1.21
0.04 ± 0.01
0.91 ± 0.38
0.88 ± 0.35
2.11 ± 0.51
12.11 ± 1.86
0.87 ± 0.17
4.85 ± 1.33
3.80 ± 1.14
81.89 ± 23.37
0.21 ± 0.01
0.45 ± 0.01
0.44 ± 0.25

6.29 ± 1.39
0.01 ± 0.01
0.23 ± 0.01
0.14 ± 0.02
0.38 ± 0.17
4.73 ± 1.53
0.46 ± 0.05
2.56 ± 0.45
0.92 ± 0.44
51.01 ± 3.62
0.01 ± 0.01
0.20 ± 0.08
0.41 ± 0.25

1.57 ± 0.48*
0.08 ± 0.01
1.61 ± 0.01
0.76 ± 0.17
2.10 ± 0.29
6.34 ± 2.19
1.48 ± 0.44
2.40 ± 1.11
10.65 ± 2.76
72.29 ± 6.08
0.33 ± 0.15
0.19 ± 0.08
0.05 ± 0.01

Percent injected dose (%ID)
Intestines
Urine

3.23 ± 1.73
30.19 ± 11.73

4.69 ± 1.24
42.61 ± 2.89

7.02 ± 2.79
61.42 ± 0.29

1.50 ± 0.50
75.8 ± 5.02

13.77 ± 11.25
39.05 ± 10.35

Uptake ratio of tumor/normal tissue
Tumor/Blood
Tumor/Kidneys
Tumor/Lung
Tumor/Liver
Tumor/Muscle

1.09
0.13
0.99
1.10
5.84

5.64
0.13
3.38
1.14
36.19

14.41
0.16
6.21
1.08
62.43

27.35
0.12
16.55
1.33
629.00

0.98
0.02
0.75
0.25
4.76

*p<0.05 (p=0.001) for determining the significance of differences in tumor and
kidney uptake between

99m

Tc-RFD-Lys-(Arg11)CCMSH with or without NDP-MSH

peptide blockade at 2 h post-injection.
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Table 3.4. Biodistribution of 99mTc-RfD-Lys-(Arg11)CCMSH
Biodistribution of

99m

Tc-RfD-Lys-(Arg11)CCMSH in B16/F1 melanoma-bearing

C57 mice. The data was presented as percent injected dose/gram or as percent
injected dose (mean  SD, n=4).

Tissue

0.5 h

2h

4h

24 h

2 h NDP Blockade

Percent injected dose/gram (%ID/g)
Tumor
Brain
Blood
Heart
Lung
Liver
Skin
Spleen
Stomach
Kidneys
Muscle
Pancreas
Bone

9.56 ± 2.36
0.16 ± 0.01
7.85 ± 2.12
2.67 ± 0.89
6.44 ± 1.81
6.59 ± 0.61
4.87 ± 0.41
2.98 ± 1.23
3.37 ± 1.40
103.75 ± 11.26
0.45 ± 0.12
0.48 ± 0.16
0.07 ± 0.06

12.68 ± 2.39
0.04 ± 0.01
1.01 ± 0.11
0.50 ± 0.17
2.73 ± 1.08
5.29 ± 1.30
1.25 ± 0.29
1.26 ± 0.45
2.71 ± 0.75
111.54 ± 10.19
0.04 ± 0.03
0.38 ± 0.15
0.43 ± 0.07

Intestines
Urine

2.49 ± 0.60
22.56 ± 12.86

2.58 ± 1.38
44.49 ± 12.39

15.01 ± 4.40
0.03 ± 0.02
0.45 ± 0.12
0.45 ± 0.12
1.19 ± 0.44
4.47 ± 1.63
0.85 ± 0.11
0.86 ± 0.19
1.86 ± 0.46
104.95 ± 8.06
0.02 ± 0.01
0.18 ± 0.03
0.15 ± 0.03

7.19 ± 1.02
0.01 ± 0.01
0.06 ± 0.01
0.21 ± 0.08
0.47 ± 0.22
4.57 ± 0.45
0.34 ± 0.08
0.76 ± 0.08
0.51 ± 0.11
73.05 ± 9.87
0.04 ± 0.03
0.05 ± 0.01
0.19 ± 0.14

2.82 ± 0.48*
0.04 ± 0.01
0.74 ± 0.01
0.60 ± 0.09
1.83 ± 0.35
3.77 ± 1.53
1.30 ± 0.43
0.93 ± 0.36
4.49 ± 0.85
111.34 ± 12.41
0.03 ± 0.01
0.31 ± 0.11
0.38 ± 0.30

Percent injected dose (%ID)
3.18 ± 1.08
50.50 ± 8.66

0.82 ± 0.14
72.74 ± 7.36

2.65 ± 1.53
54.88 ± 2.72

Uptake ratio of tumor/normal tissue
Tumor/Blood
Tumor/Kidneys
Tumor/Lung
Tumor/Liver
Tumor/Muscle

1.22
0.09
1.48
1.45
21.24

12.55
0.11
4.64
2.40
317.00

33.36
0.14
12.61
3.36
750.50

119.83
0.10
15.30
1.57
179.75

3.81
0.03
1.54
0.75
94.00

*p<0.05 (p=0.002) for determining the significance of differences in tumor and
kidney uptake between

99m

Tc-RfD-Lys-(Arg11)CCMSH with or without NDP-MSH

peptide blockade at 2 h post-injection.
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Figure Legends
Figure 3.1. Schematic structures of RXD-Lys-(Arg11)CCMSH peptides.
Figure 3.2. The competitive binding curves of RSD-Lys-(Arg11)CCMSH (●),
RNleD-Lys-(Arg11)CCMSH (▲), RFD-Lys-(Arg11)CCMSH (■), and RfD-Lys(Arg11)CCMSH (♦) in B16/F1 murine melanoma cells. The IC 50 value was 1.30 ±
0.36 nM for RSD-Lys-(Arg11)CCMSH, 2.99 ± 0.26 nM for RNleD-Lys(Arg11)CCMSH, 0.82 ± 0.06 nM for RFD-Lys-(Arg11)CCMSH, and 1.35 ± 0.08 nM
for RfD-Lys-(Arg11)CCMSH, respectively.

Figure 3.3. Radioactive HPLC profiles of

99m

99m

Tc-RfD-Lys-(Arg11)CCMSH (C) in

Tc-RFD-Lys-(Arg11)CCMSH (B) and

99m

Tc-RSD-Lys-(Arg11)CCMSH (A),

mouse serum after incubation at 37 °C for 24 h. The arrows denote the original
retention times of

99m

Tc-RSD-Lys-(Arg11)CCMSH (12.5 min),

(Arg11)CCMSH (18.4 min) and

99m

99m

Tc-RFD-Lys-

Tc-RfD-Lys-(Arg11)CCMSH (20.8 min) prior to

the incubation in mouse serum.

Figure 3.4. Cellular internalization and efflux of
(A and B),

99m

99m

Tc-RSD-Lys-(Arg11)CCMSH

Tc-RFD-Lys-(Arg11)CCMSH (C and D) and

99m

Tc-RfD-Lys-

11

(Arg )CCMSH (E and F) in B16/F1 melanoma cells. Total bound radioactivity
(♦), internalized radioactivity (■) and cell membrane radioactivity (▲) were
presented as counts per minute (cpm).

Figure 3.5. Effect of L-lysine co-injection on the tumor and kidney uptakes of
99m

Tc-RSD-Lys-(Arg11)CCMSH at 2 h post-injection in B16/F1 melanoma-bearing

C57 mice. The white ( ) and black ( ) columns represent the tumor and renal
uptake of

99m

Tc-RSD-Lys-(Arg11)CCMSH with or without L-lysine co-injection. L-

lysine co-injection significantly (*p<0.05) reduced the renal uptake of

99m

Tc-RSD-

Lys-(Arg11)CCMSH by 37% at 2 h post-injection without affecting the tumor
uptake.
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Figure 3.6. Representative

whole-body

SPECT/CT

image

melanoma- bearing C57 mice 2 h post injection of 7.4 MBq of

99m

of

B16/F1

Tc-RSD-Lys-

11

(Arg )CCMSH. Flank melanoma lesions (T) are highlighted with an arrow on the
image.

Figure 3.7. Radioactive HPLC profiles of urinary metabolites at 2 h postinjection of

99m

Tc-RSD-Lys-(Arg11)CCMSH. The arrow denotes the original

retention time of

99m

Tc-RSD-Lys-(Arg11)CCMSH (12.5 min) prior to tail vein

injection.

101

Figure 3.1
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Figure 3.3
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Figure 3.4
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Chapter 4
Substitution of the Lys linker with the β-Ala linker dramatically decreased
the renal uptake of Tc-99m-labeled Arg-X-Asp-conjugated and X-Ala-Aspconjugated α-MSH peptides

Introduction
Melanocortin-1 (MC1) receptor is an attractive molecular target for
melanoma imaging due to its over-expression on both murine and human
melanoma cells [90, 91, 95, 100, 101, 105, 127, 129-137]. Recently, we have
identified a class of 99mTc-labeled α-melanocyte stimulating hormone (α-MSH)
peptides to target MC1 receptors for melanoma imaging. Specifically, the cyclic
RXD motifs {Arg-X-Asp-DTyr-Asp, X = Gly, Ala, Val, Thr, Ser, Nle, Phe and DPhe}
were attached to [Cys3,4,10, DPhe7, Arg11]-MSH3-13 via a lysine linker to yield
RXD-Lys-(Arg11)CCMSH peptides. Interestingly, single amino acid substitutions
at the X position yielded a profound impact on the melanoma targeting and
clearance properties of 99mTc-RXD-Lys-(Arg11)CCMSH peptides. For instance,
the substitution of Gly in 99mTc-RGD-Lys-(Arg11)CCMSH with Ala, Thr, Val and
Ser improved the MC1 receptor binding affinities and enhanced the melanoma
uptake in B16/F1 melanoma-bearing C57 mice [128, 150, 151]. On the other
hand, the substitution of Gly in 99mTc-RGD-Lys-(Arg11)CCMSH with Nle
decreased the MC1 receptor binding affinity. Although the substitution of Gly in
99m

Tc-RGD-Lys-(Arg11)CCMSH with Phe and DPhe increased the MC1 receptor

binding affinities, both 99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-
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(Arg11)CCMSH exhibited much higher liver uptake as compared to 99mTc-RGDLys-(Arg11)CCMSH [151].
Despite the promising melanoma targeting results, extremely high renal
uptake (67-135% ID/g at 2 h post-injection) is a common issue associated with all
99m

Tc-RXD-Lys-(Arg11)CCMSH peptides [128, 150, 151]. Thus, it is desirable to

reduce the non-specific renal uptake of 99mTc-RXD-Lys-(Arg11)CCMSH peptides
to facilitate their potential therapeutic applications. In our previous reports, Llysine co-injection significantly reduced the renal uptake of

99m

Tc-RXD-Lys-

(Arg11)CCMSH peptides by 37%-51% at 2 h post-injection without affecting their
tumor uptake [128, 150, 151]. L-lysine is a positively-charged amino acid. The
effect of L-lysine co-injection in reducing the renal uptake indicated that the
overall positive charge of the 99mTc-RXD-Lys-(Arg11)CCMSH peptides contributed
their non-specific renal uptake. Obviously, the substitution of the positivelycharged Lys linker with a neutral amino acid can decrease the overall charges of
99m

Tc-RXD-Lys-(Arg11)CCMSH peptides. According to the effect of L-lysine co-

injection in decreasing the renal uptake, we hypothesized that the substitution of
the Lys linker with a neutral β-Ala linker would decrease the renal uptake of the
99m

Tc-RXD-Lys-(Arg11)CCMSH peptides. To examine our hypothesis, we

synthesized six peptides with β-Ala linkers, namely RSD-β-Ala-(Arg11)CCMSH,
RTD-β-Ala-(Arg11)CCMSH, RVD-β-Ala-(Arg11)CCMSH, RAD-β-Ala(Arg11)CCMSH, NAD-β-Ala-(Arg11)CCMSH and EAD-β-Ala-(Arg11)CCMSH. The
MC1 receptor binding affinities of these six peptides were examined in B16/F1
melanoma cells. The peptides were readily radiolabeled with
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99m

Tc using SnCl2

as a reducing agent. We further determined the cellular internalization and efflux
in B16/F1 melanoma cells and biodistribution properties in B16/F1 melanomabearing C57 mice for these six 99mTc-peptides. Thereafter, we determined the
imaging properties of 99mTc-RAD-β-Ala-(Arg11)CCMSH in B16/F1 melanomabearing C57 mice.
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Experimental Design and Methods

Chemicals and Reagents

Amino acids and resin were purchased from Advanced ChemTech Inc.
(Louisville, KY) and Novabiochem (San Diego, CA). 125I-Tyr2-[Nle4, DPhe7]-αMSH {125I-(Tyr2)-NDP-MSH} was obtained from PerkinElmer, Inc. (Waltham, MA)
for receptor binding assay. 99mTcO4- was purchased from Cardinal Health
(Albuquerque, NM). All other chemicals used in this study were purchased from
Thermo Fischer Scientific (Waltham, MA) and used without further purification.
B16/F1 murine melanoma cells were obtained from American Type Culture
Collection (Manassas, VA).

Peptide Synthesis and In Vitro Competitive Binding Assay

RSD-β-Ala-(Arg11)CCMSH, RTD-β-Ala-(Arg11)CCMSH, RVD-β-Ala(Arg11)CCMSH, RAD-β-Ala-(Arg11)CCMSH, NAD-β-Ala-(Arg11)CCMSH and EADβ-Ala-(Arg11)CCMSH were synthesized using fluorenylmethyloxycarbonyl (Fmoc)
chemistry according to our previously published procedures17-19 with slight
modification on Sieber amide resin by an Advanced ChemTech multiple-peptide
synthesizer (Louisville, KY). Briefly, 70 µmol of Sieber amide resin and 210 µmol
of Fmoc-protected amino acids were used for the synthesis. Fmoc-β-Ala was
used to generate a β-Ala linker in the hybrid peptide. Each peptide was purified
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by RP-HPLC and characterized by liquid chromatography-mass spectroscopy
(LC-MS).
The IC50 values of RSD-β-Ala-(Arg11)CCMSH, RTD-β-Ala-(Arg11)CCMSH,
RVD-β-Ala-(Arg11)CCMSH, RAD-β-Ala-(Arg11)CCMSH, NAD-β-Ala(Arg11)CCMSH and EAD-β-Ala-(Arg11)CCMSH for the MC1 receptor were
determined in B16/F1 melanoma cells. The receptor binding assay was
replicated in triplicate for each peptide. The B16/F1 cells were seeded into a 24well cell culture plate at a density of 2.5 × 105 cells/well and incubated at 37° C
overnight. After being washed with binding medium {modified Eagle’s medium
with 25 mM N-(2-hydroxyethyl)-piperazine-N′-(2-ethanesulfonic acid) (HEPES),
pH 7.4, 0.2% bovine serum albumin (BSA), 0.3 mM 1,10-phenathroline}, the cells
were incubated at 25 °C for 2 h with approximately 30,000 counts per minute
(cpm) of 125I-(Tyr2)-NDP-MSH in the presence of increasing concentrations (10-13
M to 10-6 M) of each peptide in 0.3 mL of binding medium. The reaction medium
was aspirated after the incubation. The cells were rinsed twice with 0.5 mL of icecold pH 7.4, 0.2% BSA/0.01 M phosphate buffered saline (PBS) to remove any
unbound radioactivity and lysed in 0.5 mL of 1 M NaOH for 5 min. The activities
associated with the cells were measured in a Wallac 2480 automated gamma
counter (PerkinElmer, NJ). The IC50 value for each peptide was calculated using
Prism software (GraphPad Software, La Jolla, CA).
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Peptide Radiolabeling

RSD-β-Ala-(Arg11)CCMSH, RTD-β-Ala-(Arg11)CCMSH, RVD-β-Ala(Arg11)CCMSH, RAD-β-Ala-(Arg11)CCMSH, NAD-β-Ala-(Arg11)CCMSH and EADβ-Ala-(Arg11)CCMSH were labeled with 99mTc via a direct reduction reaction
using SnCl2 as a reducing agent. Briefly, 10 μL of 1 mg/mL SnCl2 in 0.1 M HCl,
40 μL of 0.5 M NH4OAc (pH 5.2), 100 μL of 0.2 M Na2tartate (pH 9.2), 100 μL of
fresh 99mTcO4- solution (37-74 MBq), and 10 μL of 1 mg/mL of each peptide in
aqueous solution were added into a reaction vial and incubated at 25 °C for 20
min to form the 99mTc-labeled peptide. Each 99mTc-peptide was purified to a
single species by Waters RP-HPLC (Milford, MA) on a Grace Vydac C-18
reverse phase analytic column (Deerfield, IL) using a 20-min gradient of 18-28%
acetonitrile in 20 mM HCl aqueous solution at a flow rate of 1 mL/min. Each
purified peptide was purged with N2 gas for 20 min to remove the acetonitrile.
The pH of final peptide solution was adjusted to 7.4 with 0.1 N NaOH and sterile
normal saline for stability, biodistribution and imaging studies. The serum
stabilities of 99mTc-RSD-β-Ala-(Arg11)CCMSH, 99mTc-RTD-β-Ala-(Arg11)CCMSH,
99m

Tc-RVD-β-Ala-(Arg11)CCMSH, 99mTc-RAD-β-Ala-(Arg11)CCMSH, 99mTc-NAD-

β-Ala-(Arg11)CCMSH and 99mTc-EAD-β-Ala-(Arg11)CCMSH were determined by
incubation in mouse serum at 37C for 24 h and monitored for degradation by
RP-HPLC. Briefly, 100 µL of each HPLC-purified peptide solution (~7.4 MBq)
was added into 100 µL of mouse serum (Sigma-Aldrich Corp, St. Louis, MO) and
incubated at 37 oC for 24 h. After the incubation, 200 µL of a mixture of ethanol
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and acetonitrile (V:V = 1:1) was added to precipitate the serum proteins. The
resulting mixture was centrifuged at 16,000 g for 5 min to collect the supernatant.
The supernatant was purged with N2 gas for 30 min to remove the ethanol and
acetonitrile. The resulting sample was mixed with 500 µL of water and injected
into RP-HPLC for analysis using the gradient described above.

Biodistribution Studies

All the animal studies were conducted in compliance with Institutional
Animal Care and Use Committee approval. The biodistribution properties of
99m

Tc-RSD-β-Ala-(Arg11)CCMSH, 99mTc-RTD-β-Ala-(Arg11)CCMSH, 99mTc-RVD-

β-Ala-(Arg11)CCMSH, 99mTc-RAD-β-Ala-(Arg11)CCMSH, 99mTc-NAD-β-Ala(Arg11)CCMSH and 99mTc-EAD-β-Ala-(Arg11)CCMSH were determined in B16/F1
melanoma-bearing C57 female mice (Harlan, Indianapolis, IN). Each C57 mouse
was subcutaneously inoculated on the right flank with 1106 B16/F1 cells. The
weight of tumors reached approximately 0.2 g 10 days post cell inoculation. Each
melanoma-bearing mouse was injected with 0.037 MBq of

99m

Tc-RSD-β-Ala-

(Arg11)CCMSH, 99mTc-RTD-β-Ala-(Arg11)CCMSH, 99mTc-RVD-β-Ala(Arg11)CCMSH, 99mTc-RAD-β-Ala-(Arg11)CCMSH, 99mTc-NAD-β-Ala(Arg11)CCMSH or 99mTc-EAD-β-Ala-(Arg11)CCMSH via the tail vein. Groups of 4
mice were sacrificed at 0.5, 2, 4 and 24 h post-injection, and tumors and organs
of interest were harvested, weighed and counted. Blood values were taken as
6.5% of the body weight. The specificity of tumor uptake was determined by co-
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injecting each 99mTc-peptide with 10 g (6.1 nmol) of unlabeled NDP-MSH at 2 h
post-injection.

Melanoma Imaging with 99mTc-RAD-β-Ala-(Arg11)CCMSH

99m

Tc-RAD-β-Ala-(Arg11)CCMSH was the lead peptide due to its highest

tumor uptake and the lowest renal uptake. Thus, we further determined the
melanoma imaging property of 99mTc-RAD-β-Ala-(Arg11)CCMSH. Approximately
4.1 MBq of 99mTc-RAD-β-Ala-(Arg11)CCMSH was injected into a B16/F1
melanoma-bearing C57 mouse via the tail vein. The mouse was euthanized for
small animal SPECT/CT (Nano-SPECT/CT®, Bioscan, Washington DC) imaging
2 h post-injection. The 9-min CT imaging was immediately followed by the
SPECT imaging of whole-body. The SPECT scans of 24 projections were
acquired. Reconstructed data from SPECT and CT were visualized and coregistered using InVivoScope (Bioscan, Washington DC).

Urinary Metabolites of 99mTc-RAD-β-Ala-(Arg11)CCMSH

We also examined the urinary metabolites of
(Arg11)CCMSH. Approximately 3.7 MBq of

99m

99m

Tc-RAD-β-Ala-

Tc-RAD-β-Ala-(Arg11)CCMSH was

injected into a B16/F1 melanoma-bearing C57 mouse via the tail vein to
determine the urinary metabolites. The mouse was euthanized to collect urine at
2 h post-injection. The collected urine sample was centrifuged at 16,000 g for 5
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min before the HPLC analysis. Thereafter, an aliquot of the urine was injected
into the HPLC. A 20-minute gradient of 16-26% acetonitrile / 20 mM HCl with a
flow rate of 1 mL/min was used for urine analysis.

Statistical Analysis

Statistical analysis was performed using the Student’s t-test for unpaired
data to determine the significance of differences in tumor and kidney uptake
with/without peptide blockade in biodistribution studies described above.
Differences at the 95% confidence level (p<0.05) were considered significant.
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Results
The schematic structures of RSD-β-Ala-(Arg11)CCMSH, RTD-β-Ala(Arg11)CCMSH, RVD-β-Ala-(Arg11)CCMSH, RAD-β-Ala-(Arg11)CCMSH, NAD-βAla-(Arg11)CCMSH and EAD-β-Ala-(Arg11)CCMSH are presented in Figure 4.1.
The peptides were synthesized and purified by reverse phase-high performance
liquid chromatography (RP-HPLC) according to our previously published
procedures [150, 151]. The overall synthetic yields were 30% for all six peptides.
The chemical purities of RSD-β-Ala-(Arg11)CCMSH, RTD-β-Ala-(Arg11)CCMSH,
RVD-β-Ala-(Arg11)CCMSH, RAD-β-Ala-(Arg11)CCMSH, NAD-β-Ala(Arg11)CCMSH and EAD-β-Ala-(Arg11)CCMSH were greater than 95% after the
HPLC purification. The peptide identities were confirmed by electrospray mass
spectrometry. The measured molecular weight was 2123 Da for RSD-β-Ala(Arg11)CCMSH, 2137 Da for RTD-β-Ala-(Arg11)CCMSH, 2135 Da for RVD-β-Ala(Arg11)CCMSH, 2107 Da for RAD-β-Ala-(Arg11)CCMSH, 2064 Da for NAD-β-Ala(Arg11)CCMSH and 2080 Da for EAD-β-Ala-(Arg11)CCMSH (Table 4.1). The
competitive binding curves of the peptides are shown in Figure 4.2. The IC50
value was 2.76 ± 0.51 nM for RSD-β-Ala-(Arg11)CCMSH, 1.56 ± 0.63 nM for
RTD-β-Ala-(Arg11)CCMSH, 1.99 ± 0.16 nM for RVD-β-Ala-(Arg11)CCMSH, 0.35 ±
0.01 nM for RAD-β-Ala-(Arg11)CCMSH, 3.34 ± 0.28 nM for NAD-β-Ala(Arg11)CCMSH and 3.83 ± 0.71 nM for EAD-β-Ala-(Arg11)CCMSH in B16/F1
melanoma cells, respectively.
RSD-β-Ala-(Arg11)CCMSH, RTD-β-Ala-(Arg11)CCMSH, RVD-β-Ala(Arg11)CCMSH, RAD-β-Ala-(Arg11)CCMSH, NAD-β-Ala-(Arg11)CCMSH and EAD-
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β-Ala-(Arg11)CCMSH were readily radiolabeled with

99m

Tc with greater than 95%

radiolabeling yields (Table 4.1). All six 99mTc-peptides were separated from their
excess non-labeled peptides by RP-HPLC. The retention times of

99m

Tc-RSD-β-

Ala-(Arg11)CCMSH, 99mTc-RTD-β-Ala-(Arg11)CCMSH, 99mTc-RVD-β-Ala(Arg11)CCMSH, 99mTc-RAD-β-Ala-(Arg11)CCMSH, 99mTc-NAD-β-Ala(Arg11)CCMSH and 99mTc-EAD-β-Ala-(Arg11)CCMSH were 13.1, 13.0, 14.1, 13.7,
17.0 and 14.2 min, respectively. All six 99mTc-peptides were stable in mouse
serum at 37°C for 24 h (Figure 4.3).
Cellular internalization and efflux properties of 99mTc-RSD-β-Ala(Arg11)CCMSH, 99mTc-RTD-β-Ala-(Arg11)CCMSH, 99mTc-RVD-β-Ala(Arg11)CCMSH, 99mTc-RAD-β-Ala-(Arg11)CCMSH, 99mTc-NAD-β-Ala(Arg11)CCMSH, and 99mTc-EAD-β-Ala-(Arg11)CCMSH were examined in B16/F1
cells. Figure 4.4-4.5 illustrates the internalization and efflux properties of

99m

Tc-

RSD-β-Ala-(Arg11)CCMSH, 99mTc-RTD-β-Ala-(Arg11)CCMSH, 99mTc-RVD-β-Ala(Arg11)CCMSH, 99mTc-RAD-β-Ala-(Arg11)CCMSH, 99mTc-NAD-β-Ala(Arg11)CCMSH, and 99mTc-EAD-β-Ala-(Arg11)CCMSH. All six 99mTc-peptides
exhibited rapid cellular internalization and prolonged cellular retention.
Approximately 64% of 99mTc-RSD-β-Ala-(Arg11)CCMSH, 66% of 99mTc-RTD-βAla-(Arg11)CCMSH, 70% of 99mTc-RVD-β-Ala-(Arg11)CCMSH, 77% of 99mTc-RADβ-Ala-(Arg11)CCMSH, 70% of 99mTc-NAD-β-Ala-(Arg11)CCMSH and 67% of
99m

Tc-EAD-β-Ala-(Arg11)CCMSH activities were internalized in the cells after 20

min of incubation. Cellular efflux results indicated that 76% of 99mTc-RSD-β-Ala(Arg11)CCMSH, 56% of 99mTc-RTD-β-Ala-(Arg11)CCMSH, 70% of 99mTc-RVD-β-
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Ala-(Arg11)CCMSH, 66% of 99mTc-RAD-β-Ala-(Arg11)CCMSH, 70% of 99mTc-NADβ-Ala-(Arg11)CCMSH and 54% of 99mTc-EAD-β-Ala-(Arg11)CCMSH activities
remained inside the cells after 2 h of incubation in the culture medium.
The melanoma targeting and pharmacokinetic properties of

99m

Tc-RSD-β-

Ala-(Arg11)CCMSH, 99mTc-RTD-β-Ala-(Arg11)CCMSH, 99mTc-RVD-β-Ala(Arg11)CCMSH, 99mTc-RAD-β-Ala-(Arg11)CCMSH, 99mTc-NAD-β-Ala(Arg11)CCMSH and 99mTc-EAD-β-Ala-(Arg11)CCMSH are shown in Tables 4.24.7. All six 99mTc-peptides exhibited similar tumor uptake pattern in B16/F1
melanoma-bearing C57 mice. The highest tumor uptake appeared either at 2 or 4
h post-injection. Among these six 99mTc-peptides, 99mTc-RAD-β-Ala(Arg11)CCMSH showed the highest tumor uptake of 15.66 ± 6.19% ID/g at 2 h
post-injection. The tumor uptake of

99m

Tc-RAD-β-Ala-(Arg11)CCMSH gradually

decreased to 14.67 ± 3.81 and 7.79 ± 2.68% ID/g at 4 and 24 h post-injection.
Co-injection of 10 μg (6.1 nM) of non-radiolabeled NDP-MSH with 99mTc-RAD-βAla-(Arg11)CCMSH decreased the tumor uptake to 2.43 ± 0.53% ID/g at 2 h postinjection, demonstrating that the tumor uptake was MC1 receptor-mediated.
Kidneys were the excretion routes for all six 99mTc-peptides. Among these
six 99mTc-peptides, 99mTc-RAD-β-Ala-(Arg11)CCMSH showed the lowest renal
uptake of 20.18 ± 3.86% ID/g at 2 h post-injection. The renal uptake of

99m

Tc-

RAD-β-Ala-(Arg11)CCMSH gradually decreased to 19.83 ± 6.34 and 3.92 ±
0.99% ID/g at 4 and 24 h post-injection. Co-injection of 10 μg (6.1 nM) of nonradiolabeled NDP-MSH with 99mTc-RAD-β-Ala-(Arg11)CCMSH didn't significantly
reduce the renal uptake (p>0.05) at 2 h post-injection, indicating that the renal
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uptake was non-specific. The substitution of the positively-charged Lys linker with
the neutral β-Ala dramatically decreased the renal uptake of

99m

Tc-RXD-β-Ala-

(Arg11)CCMSH peptides. Interestingly, further reduction of the overall positive
charge of 99mTc-NAD-β-Ala-(Arg11)CCMSH and 99mTc-EAD-β-Ala-(Arg11)CCMSH
peptides did not further decrease the renal uptake as compared to

99m

Tc-RAD-β-

Ala-(Arg11)CCMSH. All six 99mTc-peptides displayed fast urinary clearance.
Approximately 68-78% of 99mTc-peptides cleared through the urinary system by 2
h post-injection, whereas approximately 77-86% of 99mTc-peptides washed out
through the urinary system by 4 h post-injection. Normal organ uptake of all
99m

Tc-peptides was minimal (<3.1 % ID/g) except for kidneys after 2 h post-

injection.
Because 99mTc-RAD-β-Ala-(Arg11)CCMSH showed the highest tumor
uptake and the lowest renal uptake than the other five

99m

Tc-peptides at 2 h post-

injection, we further determined the imaging property and urinary metabolites of
99m

Tc-RAD-β-Ala-(Arg11)CCMSH in B16/F1 melanoma-bearing C57 mice. Whole-

body single photon emission computed tomography (SPECT)/CT image at 2 h
post-injection is presented in Figure 4.6. Flank B16/F1 melanoma lesions were
clearly visualized by SPECT using 99mTc-RAD-β-Ala-(Arg11)CCMSH peptide as
an imaging probe. The SPECT image of tumor accurately matched its anatomical
location obtained in the CT image. The SPECT image showed high contrast of
tumor to normal organ except for kidneys, which was consistent with the
biodistribution results. The urinary metabolites of 99mTc-RAD-β-Ala-
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(Arg11)CCMSH at 2 h post-injection are shown in Figure 4.7. 99mTc-RAD-β-Ala(Arg11)CCMSH remained intact in the urine at 2 h post-injection.
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Discussion
In our previous reports [128, 150, 151], we have found the importance of
single amino acid at the X position in the tumor targeting properties of

99m

Tc-

RXD-Lys-(Arg11)CCMSH peptides in B16/F1 melanoma-bearing C57 mice.
Specifically, the substitution of Gly in

99m

Tc-RGD-Lys-(Arg11)CCMSH with Ala,

Thr, Val and Ser improved the MC1 receptor binding affinities and enhanced the
melanoma uptake in B16/F1 melanoma-bearing C57 mice [128, 150, 151].
Despite the promising melanoma targeting results associated with 99mTc-RXDLys-(Arg11)CCMSH peptides, it is desirable to reduce the non-specific renal
uptake (67-135% ID/g at 2 h post-injection) of 99mTc-RXD-Lys-(Arg11)CCMSH
peptides to facilitate their potential therapeutic applications. In this study, we
substituted the positively-charged Lys linker with the neutral β-Ala linker to
determine whether such linker change could reduce the renal uptake of

99m

Tc-

RXD-β-Ala-(Arg11)CCMSH peptides. Furthermore, we replaced the RAD moiety
with NAD and EAD moieties to examine whether the further reduction of the
overall positive changes of

99m

Tc-NAD-β-Ala-(Arg11)CCMSH and 99mTc-EAD-β-

Ala-(Arg11)CCMSH could decrease their renal uptake further.
The substitution of Lys linker with β-Ala linker slightly affected the receptor
binding affinities of RXD-β-Ala-(Arg11)CCMSH peptides. The receptor binding
affinities of RXD-β-Ala-(Arg11)CCMSH peptides were approximately 2-fold
weaker than RXD-Lys-(Arg11)CCMSH peptides, respectively. Despite the fact the
-His-DPhe-Arg-Trp- motif is the binding moiety to the MC1 receptor, the decrease
in receptor binding affinity with the β-Ala linker substitution indicated that the
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linker might somehow interact with the receptor binding moiety. Such interaction
might be related to the side chain of the Lys linker. The decrease in receptor
binding affinities of RXD-β-Ala-(Arg11)CCMSH peptides also resulted in the
reduction in tumor uptake of

99m

Tc-RXD-β-Ala-(Arg11)CCMSH peptides by 21-

45% in B16/F1 melanoma-bearing C57 mice. Specifically, the tumor uptake of
99m

Tc-RAD-β-Ala-(Arg11)CCMSH was 79% of the tumor uptake of 99mTc-RAD-

Lys-(Arg11)CCMSH at 2 h post-injection [128].
The substitution of Lys linker with β-Ala linker dramatically decreased the
renal uptake of 99mTc-RXD-β-Ala-(Arg11)CCMSH peptides by 64-79% in B16/F1
melanoma-bearing C57 mice. For instance, the renal uptake of
(Arg11)CCMSH was only 22% of the renal uptake of

99m

99m

Tc-RAD-β-Ala-

Tc-RAD-Lys-

(Arg11)CCMSH at 2 h post-injection [128]. It is worthwhile to note that there is a
positively-charged Arg residue in the RAD moiety of

99m

Tc-RAD-Lys-

(Arg11)CCMSH. Thus, we were interested whether the replacement of Arg with
Nle (neutral) and Glu (negatively-charged) could further decrease the renal
uptake of 99mTc-NAD-β-Ala-(Arg11)CCMSH and 99mTc-EAD-β-Ala-(Arg11)CCMSH
as compared to 99mTc-RAD-β-Ala-(Arg11)CCMSH. Interestingly, the replacement
of Arg with Nle and Glu did not further decrease the renal uptake of

99m

Tc-NAD-

β-Ala-(Arg11)CCMSH and 99mTc-EAD-β-Ala-(Arg11)CCMSH as compared to
99m

Tc-RAD-β-Ala-(Arg11)CCMSH. Clearly, the tumor targeting and clearance

properties of 99mTc-RAD-β-Ala-(Arg11)CCMSH were more favorable than the
other 99mTc-peptides investigated in this study. Thus, we further examined its
melanoma imaging property and urinary metabolites. The B16/F1 melanoma
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lesions could be clearly visualized by SPECT/CT using 99mTc-RAD-β-Ala(Arg11)CCMSH as an imaging probe.
The dramatic reduction in renal uptake with the substitution of the neutral
β-Ala linker demonstrates the importance of the electrostatic interactions of the
positive charges on the peptides in renal handling and non-specific uptake invivo. It is imperative to maintain high contrast of tumor uptake to normal organ
tissues for enhanced diagnostic imaging and potential therapeutic applications
utilizing radiolabeled peptide conjugates as targeting molecules.

99m

Tc-labeled

radiopharmaceuticals can be readily translated to therapeutic
radiopharmaceuticals through the replacement of

99m

Tc with 186Re/ 188Re [152,

153]. Both 99mTc and 186Re/ 188Re have similar coordination chemistry. The
same biomolecule can be labeled with 186Re/ 188Re without structural
modification. The combined use of

99m

Tc- and 186Re/ 188Re-labeled

radiopharmaceuticals for imaging and therapy will enhance the success of
targeted radionuclide treatment for individual patients.
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Conclusions
The substitution of the Lys linker with the β-Ala linker dramatically
decreased the renal uptake of

99m

Tc-RXD-β-Ala-(Arg11)CCMSH peptides. Among

these four 99mTc-RXD-β-Ala-(Arg11)CCMSH peptides, 99mTc-RAD-β-Ala(Arg11)CCMSH exhibited the highest tumor uptake and the lowest renal uptake at
2 h post-injection. The replacement of Arg with Nle and Glu didn't further
decrease the renal uptake of 99mTc-NAD-β-Ala-(Arg11)CCMSH and 99mTc-EAD-βAla-(Arg11)CCMSH as compared to 99mTc-RAD-β-Ala-(Arg11)CCMSH. The tumor
targeting and clearance properties of 99mTc-RAD-β-Ala-(Arg11)CCMSH
highlighted it as a lead peptide for future studies.
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Tables

Table 4.1. Peptide properties
Capacity factors, chemical/ radiochemical purities, measured molecular weights,
and IC50 values of RXD-β-Ala-(Arg11)CCMSH and XAD-β-Ala-(Arg11)CCMSH
peptides and their 99mTc-conjugates.

Peptide
RSD-β-Ala-(Arg11)CCMSH
RTD-β-Ala-(Arg11)CCMSH
RVD-β-Ala-(Arg11)CCMSH
RAD-β-Ala-(Arg11)CCMSH
NAD-β-Ala-(Arg11)CCMSH
EAD-β-Ala-(Arg11)CCMSH
99m
Tc-RSD-β-Ala-(Arg11)CCMSH
99m
Tc-RTD-β-Ala-(Arg11)CCMSH
99m
Tc-RVD-β-Ala-(Arg11)CCMSH
99m
Tc-RAD-β-Ala-(Arg11)CCMSH
99m
Tc-NAD-β-Ala-(Arg11)CCMSH
99m
Tc-EAD-β-Ala-(Arg11)CCMSH

Capacity
factor (k')

Chemical/Radiochemical
Purity (%)

Measured Molecular
Weight (Da)

95.32
95.36
95.89
96.51
95.62
95.59
99.91
98.12
99.98
98.40
98.29
98.11

2123
2137
2135
2107
2064
2080
ND
ND
ND
ND
ND
ND

1.35
0.98
1.94
3.32
3.17
2.28
3.34
3.29
3.40
4.18
4.63
3.47

ND= Not Determined
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Table 4.2. Biodistribution of 99mTc-RSD-β-Ala-(Arg11)CCMSH
Biodistribution of 99mTc-RSD-β-Ala-(Arg11)CCMSH in B16/F1 melanoma-bearing
C57 mice. The data was presented as percent injected dose/gram or as percent
injected dose (mean  SD, n=4).

Tissue

0.5 h

2h

4h

24 h

2h NDPBlock

Percentage Injected Dose/Gram (%ID/g)
Tumor

9.64 ± 1.52

9.62 ± 1.53

12.15 ± 2.36

3.62 ± 1.10

1.12 ± 0.01*

Brain

0.15 ± 0.01

0.02 ± 0.01

0.02 ± 0.02

0.02 ± 0.01

0.02 ± 0.01

Blood

2.66 ± 0.84

0.50 ± 0.14

0.06 ± 0.02

0.61 ± 0.46

0.03 ± 0.01

Heart

1.56 ± 0.13

0.23 ± 0.04

0.10 ± 0.06

0.07 ± 0.03

0.17 ± 0.01

Lung

3.85 ± 0.40

0.64 ± 0.15

0.34 ± 0.11

0.29 ± 0.12

0.48 ± 0.06

Liver

1.41 ± 0.13

0.74 ± 0.08

0.86 ± 0.08

0.31 ± 0.08

0.57 ± 0.05

Skin

3.07 ± 1.85

0.52 ± 0.40

0.32 ± 0.13

0.48 ± 0.24

0.29 ± 0.18

Spleen

1.34 ± 0.15

0.32 ± 0.05

0.35 ± 0.05

0.18 ± 0.06

0.22 ± 0.06

Stomach

1.83 ± 0.20

0.62 ± 0.17

0.77 ± 0.21

0.32 ± 0.16

0.62 ± 0.23

Kidneys

30.5 ± 5.18

28.73 ± 3.40

28.70 ± 5.22

8.12 ± 2.34

13.67 ± 2.54

Muscle

0.25 ± 0.02

0.04 ± 0.03

0.02 ± 0.01

0.05 ± 0.02

0.05 ± 0.07

Pancreas

0.68 ± 0.28

0.11 ± 0.01

0.04 ± 0.02

0.04 ± 0.01

0.08 ± 0.01

Bone

0.93 ± 0.45

0.19 ± 0.06

0.05 ± 0.01

0.42 ± 0.28

0.16 ± 0.09

Percentage Injected Dose (%ID)
Intestines

1.71 ± 0.21

1.11 ± 0.60

1.59 ± 0.41

0.63 ± 0.19

0.76 ± 0.23

Urine

53.37 ± 4.23

68.46 ± 9.28

83.96 ± 0.88

84.33 ± 3.37

90.95 ± 0.59

Uptake Ratio of Tumor/Normal Tissue
Tumor/Blood

3.62

19.24

202.50

5.93

37.33

Tumor/Kidneys

0.32

0.33

0.42

0.45

0.08

Tumor/Lung

2.50

15.03

35.74

12.48

2.33

Tumor/Liver

6.84

13.00

14.13

11.68

1.96

Tumor/Muscle

38.56

240.50

607.50

72.40

22.40

*p<0.05 (*p=0.001,) for determining the significance of differences in
tumor and kidney uptake between

99m

Tc-RSD-β-Ala-(Arg11)CCMSH with

or without NDP-MSH peptide blockade at 2 h post-injection.
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Table 4.3. Biodistribution of 99mTc-RTD-β-Ala-(Arg11)CCMSH
Biodistribution of 99mTc-RTD-β-Ala-(Arg11)CCMSH in B16/F1 melanoma-bearing
C57 mice. The data was presented as percent injected dose/gram or as percent
injected dose (mean  SD, n=4).

Tissue

0.5 h

2h

4h

24 h

2h NDP-Block

Percentage Injected Dose/Gram (%ID/g)
Tumor

13.29 ± 2.36

13.85 ± 1.43

9.40 ± 2.86

5.23 ± 1.81

1.19 ± 0.30*

Brain

0.20 ± 0.01

0.02 ± 0.01

0.01 ± 0.01

0.01 ± 0.01

0.01 ± 0.01

Blood

7.53 ± 0.99

1.48 ± 0.02

0.27 ± 0.17

0.06 ± 0.05

3.69 ± 0.01

Heart

2.38 ± 1.75

0.27 ± 0.07

0.14 ± 0.05

0.09 ± 0.02

0.22 ± 0.01

Lung

4.61 ± 3.16

0.53 ± 0.13

0.30 ± 0.01

0.16 ± 0.03

0.39 ± 0.14

Liver

1.36 ± 0.10

0.78 ± 0.02

0.73 ± 0.07

0.43 ± 0.11

0.61 ± 0.08

Skin

6.44 ± 2.64

1.33 ± 0.59

0.22 ± 0.15

0.22 ± 0.04

0.38 ± 0.08

Spleen

1.19 ± 0.58

0.31 ± 0.15

0.27 ± 0.14

0.23 ± 0.06

0.21 ± 0.07

Stomach

2.01 ± 0.72

0.83 ± 0.23

0.66 ± 0.20

0.37 ± 0.26

0.92 ± 0.37

Kidneys

35.79 ± 2.11

28.60 ± 5.14

26.17 ± 4.83

11.50 ± 2.81

18.09 ± 1.89^

Muscle

0.46 ± 0.19

0.06 ± 0.05

0.02 ± 0.01

0.03 ± 0.03

0.04 ± 0.01

Pancreas

1.25 ± 1.00

0.11 ± 0.09

0.02 ± 0.02

0.05 ± 0.03

0.07 ± 0.03

Bone

0.90 ± 0.90

0.29 ± 0.20

0.09 ± 0.07

0.11 ± 0.06

0.11 ± 0.04
0.84 ± 0.22
90.63 ±
2.07**

Percentage Injected Dose (%ID)
Intestines

2.28 ± 1.24

0.93 ± 0.21

1.29 ± 0.47

2.03 ± 1.42

Urine

53.46 ± 7.42

77.83 ± 2.83

84.94 ± 2.10

90.45 ± 3.66

Uptake Ratio of Tumor/Normal Tissue
Tumor/Blood

1.76

9.36

34.81

87.17

0.32

Tumor/Kidneys

0.37

0.48

0.36

0.45

0.07

Tumor/Lung

2.88

26.13

31.33

32.69

3.05

Tumor/Liver

9.77

17.76

12.88

12.16

1.95

Tumor/Muscle

28.89

230.83

470.00

174.33

29.75

*p<0.05 (*p=0.003, ^p=.015, **p=0.01) for determining the significance of
differences in tumor and kidney uptake between

99m

Tc-RTD-β-Ala-

(Arg11)CCMSH with or without NDP-MSH peptide blockade at 2 h postinjection.
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Table 4.4. Biodistribution of 99mTc-RVD-β-Ala-(Arg11)CCMSH
Biodistribution of 99mTc-RVD-β-Ala-(Arg11)CCMSH in B16/F1 melanoma-bearing
C57 mice. The data was presented as percent injected dose/gram or as percent
injected dose (mean  SD, n=4).

Tissue

0.5 h

2h

4h

24 h

2h NDPBlock

Percentage Injected Dose/Gram (%ID/g)
Tumor

12.49 ± 2.10

13.11 ± 4.78

11.18 ± 2.76

4.66 ± 1.92

1.30 ± 0.46*

Brain

0.14 ± 0.01

0.03 ± 0.01

0.01 ± 0.01

0.03 ± 0.02

0.02 ± 0.01

Blood

6.11 ± 0.56

0.78 ± 0.06

0.14 ± 0.08

0.06 ± 0.01

0.43 ± 0.01

Heart

1.99 ± 0.11

0.35 ± 0.07

0.15 ± 0.02

0.08 ± 0.02

0.32 ± 0.06

Lung

2.61 ± 0.26

1.13 ± 0.09

0.41 ± 0.13

0.11 ± 0.02

0.64 ± 0.12

Liver

2.22 ± 0.05

1.36 ± 0.33

1.62 ± 0.34

0.50 ± 0.06

1.34 ± 0.23

Skin

4.86 ± 2.81

0.98 ± 0.44

0.16 ± 0.07

0.34 ± 0.05

0.82 ± 0.18

Spleen

1.36 ± 0.38

0.27 ± 0.14

0.31 ± 0.09

0.08 ± 0.02

0.34 ± 0.08

Stomach

2.82 ± 0.60

1.02 ± 0.48

0.85 ± 0.29

0.39 ± 0.15

1.74 ± 0.27

Kidneys

30.77 ± 2.40

30.37 ± 6.04

27.03 ± 0.71

7.58 ± 1.78

17.96 ± 5.92

Muscle

0.44 ± 0.11

0.17 ± 0.05

0.02 ± 0.02

0.14 ± 0.04

0.12 ± 0.07

Pancreas

0.76 ± 0.36

0.14 ± 0.01

0.10 ± 0.06

0.08 ± 0.06

0.10 ± 0.11

Bone

0.46 ± 0.12

0.60 ± 0.38

0.09 ± 0.09

0.17 ± 0.15

0.10 ± 0.05

Percentage Injected Dose (%ID)
Intestines

1.89 ± 0.32

0.87 ± 0.22

1.33 ± 0.47

1.00 ± 0.59

0.90 ± 0.17

Urine

49.29 ± 2.66

74.19 ± 7.90

84.10 ± 4.44

84.47 ± 6.30

86.59 ± 4.94

Uptake Ratio of Tumor/Normal Tissue
Tumor/Blood

2.04

16.81

79.86

77.67

3.02

Tumor/Kidneys

0.41

0.43

0.41

0.61

0.07

Tumor/Lung

4.79

11.60

27.27

42.36

2.03

Tumor/Liver

5.63

9.64

6.90

9.32

0.97

Tumor/Muscle

28.39

77.12

559.00

33.29

10.83

*p<0.05 (*p=0.001) for determining the significance of differences in tumor
and kidney uptake between

99m

Tc-RVD-β-Ala-(Arg11)CCMSH with or

without NDP-MSH peptide blockade at 2 h post-injection.
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Table 4.5. Biodistribution of 99mTc-RAD-β-Ala-(Arg11)CCMSH
Biodistribution of

99m

Tc-RAD-β-Ala-(Arg11)CCMSH in B16/F1 melanoma-

bearing C57 mice. The data was presented as percent injected dose/gram
or as percent injected dose (mean  SD, n=4).

Tissue

0.5 h

2h

4h

24 h

2h NDPBlock

Percentage Injected Dose/Gram (%ID/g)
Tumor

12.55 ± 3.37

15.66 ± 6.19

14.67 ± 3.81

7.79 ± 2.68

2.43 ± 0.53*

Brain

0.19 ± 0.04

0.05 ± 0.01

0.03 ± 0.01

0.05 ± 0.05

0.02 ± 0.02

Blood

3.82 ± 0.62

1.01 ± 0.42

0.60 ± 0.29

0.46 ± 0.44

0.51 ± 0.10

Heart

2.28 ± 0.29

0.90 ± 0.34

0.69 ± 0.33

0.31 ± 0.21

0.73 ± 0.23

Lung

7.22 ± 1.60

3.15 ± 0.79

2.34 ± 1.19

1.01 ± 0.48

3.12 ± 1.13

Liver

2.39 ± 0.62

1.09 ± 0.13

1.05 ± 0.26

0.56 ± 0.23

1.17 ± 0.33

Skin

5.50 ± 0.60

1.38 ± 0.41

0.70 ± 0.13

0.42 ± 0.24

1.29 ± 0.42

Spleen

1.39 ± 0.51

0.80 ± 0.31

0.55 ± 0.34

0.60 ± 0.38

0.64 ± 0.43

Stomach

7.11 ± 2.20

2.61 ± 1.04

1.88 ± 0.63

0.44 ± 0.20

2.88 ± 0.65

Kidneys

25.64 ± 4.06

20.18 ± 3.86

19.83 ± 6.34

3.92 ± 0.99

19.82 ± 9.39

Muscle

0.90 ± 0.48

0.23 ± 0.14

0.18 ± 0.11

0.34 ± 0.32

0.17 ± 0.08

Pancreas

0.84 ± 0.35

0.29 ± 0.09

0.12 ± 0.08

0.20 ± 0.14

0.14 ± 0.05

Bone

1.60 ± 0.27

0.59 ± 0.16

0.24 ± 0.20

0.50 ± 0.42

0.33 ± 0.20

Percentage Injected Dose (%ID)
Intestines

2.93 ± 0.44

2.58 ± 1.25

1.90 ± 0.39

0.89 ± 1.10

1.46 ± 0.26

Urine

49.54 ± 2.65

78.28 ± 2.36

83.80 ± 3.67

94.25 ± 1.90

83.61 ± 5.94

Uptake Ratio of Tumor/Normal Tissue
Tumor/Blood

3.29

15.50

24.45

16.93

4.76

Tumor/Kidneys

0.49

0.78

0.74

1.99

0.12

Tumor/Lung

1.74

4.97

6.27

7.71

0.78

Tumor/Liver

5.25

14.37

13.97

13.91

2.08

Tumor/Muscle

13.94

68.09

81.50

22.91

14.29

*p<0.05 (p=0.002) for determining the significance of differences in tumor
and kidney uptake between

99m

Tc-RAD-β-Ala-(Arg11)CCMSH with or

without NDP-MSH peptide blockade at 2 h post-injection.
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Table 4.6. Biodistribution of 99mTc-NAD-β-Ala-(Arg11)CCMSH
Biodistribution of 99mTc-NAD-β-Ala-(Arg11)CCMSH in B16/F1 melanoma-bearing
C57 mice. The data was presented as percent injected dose/gram or as percent
injected dose (mean  SD, n=4).

Tissue

0.5 h

2h

4h

24 h

2h NDPBlock

Percentage Injected Dose/Gram (%ID/g)
Tumor

3.43 ± 1.75

11.38 ± 1.29

10.81 ± 5.48

4.17 ± 1.14

2.06 ± 0.85*

Brain

0.17 ± 0.01

0.01 ± 0.01

0.02 ± 0.01

0.01 ± 0.01

0.05 ± 0.01

Blood

10.13 ± 1.66

1.02 ± 0.48

0.87 ± 0.43

0.14 ± 0.02

1.22 ± 0.01

Heart

1.85 ± 0.56

0.62 ± 0.03

0.56 ± 0.31

0.11 ± 0.03

0.48 ± 0.25

Lung

5.68 ± 1.37

2.31 ± 0.55

1.28 ± 0.27

0.74 ± 0.30

1.92 ± 0.41

Liver

2.03 ± 0.41

1.67 ± 0.39

1.37 ± 0.45

0.50 ± 0.08

1.93 ± 0.77

Skin

3.71 ± 1.95

1.14 ± 0.23

0.62 ± 0.10

0.16 ± 0.04

1.47 ± 0.68

Spleen

1.71 ± 0.74

0.76 ± 0.21

0.55 ± 0.08

0.20 ± 0.13

0.33 ± 0.20

Stomach

2.45 ± 1.72

1.14 ± 0.37

0.75 ± 0.06

0.25 ± 0.09

2.11 ± 0.84

Kidneys

32.37 ± 5.90

37.23 ± 9.69

32.68 ± 6.55

8.39 ± 2.56

22.48 ± 9.23

Muscle

0.33 ± 0.10

0.06 ± 0.06

0.15 ± 0.04

0.05 ± 0.01

0.39 ± 0.29

Pancreas

0.37 ± 0.23

0.22 ± 0.08

0.01 ± 0.01

0.01 ± 0.01

0.25 ± 0.14

Bone

0.75 ± 0.40

0.35 ± 0.29

0.03 ± 0.01

0.09 ± 0.07

0.19 ± 0.08

Percentage Injected Dose (%ID)
Intestines

1.29 ± 0.67

2.84 ± 1.98

4.77 ± 3.46

0.59 ± 0.18

2.28 ± 0.78

Urine

53.93 ± 19.61

73.27 ± 5.41

77.67 ± 5.88

93.77 ± 1.03

74.78 ± 10.44

Uptake Ratio of Tumor/Normal Tissue
Tumor/Blood

0.34

11.16

12.43

29.79

1.69

Tumor/Kidneys

0.11

0.31

0.33

0.50

0.09

Tumor/Lung

0.60

4.93

8.45

5.64

1.07

Tumor/Liver

1.69

6.81

7.89

8.34

1.07

Tumor/Muscle

10.39

189.67

72.07

83.40

5.28

*p<0.05 (*p=0.003) for determining the significance of differences in tumor
and kidney uptake between

99m

Tc-NAD-β-Ala-(Arg11)CCMSH with or

without NDP-MSH peptide blockade at 2 h post-injection.
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Table 4.7. Biodistribution of 99mTc-EAD-β-Ala-(Arg11)CCMSH
Biodistribution of 99mTc-EAD-β-Ala-(Arg11)CCMSH in B16/F1 melanoma-bearing
C57 mice. The data was presented as percent injected dose/gram or as percent
injected dose (mean  SD, n=4).

Tissue

0.5 h

2h

4h

24 h

2h NDPBlock

Percentage Injected Dose/Gram (%ID/g)
Tumor

12.25 ± 1.86

10.13 ± 3.60

13.36 ± 4.12

3.71 ± 1.59

1.20 ± 0.25*

Brain

0.15 ± 0.01

0.02 ± 0.01

0.01 ± 0.01

0.01 ± 0.01

0.01 ± 0.01

Blood

5.94 ± 1.42

0.86 ± 0.04

0.38 ± 0.12

0.08 ± 0.01

0.47 ± 0.01

Heart

1.73 ± 0.35

0.44 ± 0.08

0.35 ± 0.03

0.14 ± 0.08

0.29 ± 0.15

Lung

3.50 ± 1.96

2.57 ± 1.00

1.35 ± 0.51

0.35 ± 0.08

1.73 ± 0.74

Liver

2.06 ± 0.73

1.08 ± 0.41

0.93 ± 0.16

0.26 ± 0.08

0.86 ± 0.03

Skin

5.92 ± 0.76

0.55 ± 0.03

0.64 ± 0.05

0.24 ± 0.02

0.86 ± 0.15

Spleen

1.95 ± 1.15

0.59 ± 0.25

0.49 ± 0.18

0.14 ± 0.11

0.26 ± 0.05

Stomach

2.91 ± 1.36

0.70 ± 0.12

0.89 ± 0.06

0.12 ± 0.02

1.16 ± 0.30

Kidneys

25.65 ± 8.27

25.25 ± 9.26

24.37 ± 7.66

4.12 ± 1.14

25.93 ± 1.62

Muscle

0.85 ± 0.26

0.05 ± 0.03

0.03 ± 0.01

0.10 ± 0.08

0.04 ± 0.04

Pancreas

0.72 ± 0.39

0.14 ± 0.07

0.06 ± 0.04

0.02 ± 0.01

0.07 ± 0.02

Bone

1.43 ± 0.32

0.27 ± 0.12

0.07 ± 0.03

0.14 ± 0.06

0.10 ± 0.05

Percentage Injected Dose (%ID)
Intestines

2.19 ± 0.72

1.38 ± 0.92

2.29 ± 0.66

0.55 ± 0.16

2.51 ± 0.34

Urine

42.67 ± 21.25

75.09 ± 11.87

86.51 ± 3.43

92.30 ± 1.33

85.18 ± 0.53

Uptake Ratio of Tumor/Normal Tissue
Tumor/Blood

2.06

11.78

35.16

46.38

2.55

Tumor/Kidneys

0.48

0.40

0.55

0.90

0.05

Tumor/Lung

3.50

3.94

9.90

10.60

0.69

Tumor/Liver

5.95

9.38

14.37

14.27

1.40

Tumor/Muscle

14.41

202.60

445.33

37.10

30.00

*p<0.05 (*p=0.003) for determining the significance of differences in tumor
and kidney uptake between

99m

Tc-EAD-β-Ala-(Arg11)CCMSH with or

without NDP-MSH peptide blockade at 2 h post-injection.
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Figure Legends
Figure 4.1. Schematic structures of RXD-β-Ala-(Arg11)CCMSH & XAD-βAla-(Arg11)CCMSH peptides.
Figure 4.2. The competitive binding curves of RSD-β-Ala-(Arg11)CCMSH
(●), RTD-β-Ala-(Arg11)CCMSH (■), RVD-β-Ala-(Arg11)CCMSH (▲), RAD-βAla-(Arg11)CCMSH (□), NAD-β-Ala-(Arg11)CCMSH (
11

(Arg )CCMSH (

)

and EAD-β-Ala-

), and in B16/F1 murine melanoma cells. The IC50 value

was 2.76 ± 0.51 nM for RSD-β-Ala-(Arg11)CCMSH, 1.56 ± 0.63 nM for RTD-βAla-(Arg11)CCMSH, 1.99 ± 0.16 nM for RVD-β-Ala-(Arg11)CCMSH, 0.35 ±
0.01 nM for RAD-β-Ala-(Arg11)CCMSH, 3.34 ± 0.28 nM for NAD-β-Ala(Arg11)CCMSH

and

3.84

±

0.71

nM

for

EAD-β-Ala-(Arg11)CCMSH

respectively.

Figure 4.3. Radioactive HPLC profiles of
(A),
(C),

99m

Tc-RTD-β-Ala-(Arg11)CCMSH (B),

99m

Tc-RAD-β-Ala-(Arg11)CCMSH (D),

99m

Tc-RSD-β-Ala-(Arg11)CCMSH

99m

Tc-RVD-β-Ala-(Arg11)CCMSH

99m

Tc-NAD-β-Ala-(Arg11)CCMSH

(E), and 99mTc-EAD-β-Ala-(Arg11)CCMSH (F) in mouse serum after incubation
at 37 °C for 24 h. The arrows denote the original peak retention times of
99m

Tc-RSD-β-Ala-(Arg11)CCMSH (13.1 min),

(13.0 min),

99m

Tc-RTD-β-Ala-(Arg11)CCMSH

Tc-RVD-β-Ala-(Arg11)CCMSH (14.1 min),

(Arg11)CCMSH (13.7 min),
99m

99m

99m

99m

Tc-RAD-β-Ala-

Tc-NAD-β-Ala-(Arg11)CCMSH (17.0 min), and

Tc-EAD-β-Ala-(Arg11)CCMSH (14.2 min), prior to the incubation in mouse

serum.

Figure 4.4. Cellular

internalization

(Arg11)CCMSH (A and B),
99m

99m

and

efflux

of

99m

Tc-RSD-β-Ala-

Tc-RTD-β-Ala-(Arg11)CCMSH (C and D) and

Tc-RVD-β-Ala-(Arg11)CCMSH (E and F) in B16/F1 melanoma cells. Total

bound radioactivity (♦), internalized radioactivity (■) and cell membrane
radioactivity (▲) were presented as counts per minute (cpm).
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Figure 4.5. Cellular

internalization

(Arg11)CCMSH (G and H),
99m

99m

and

efflux

of

99m

Tc-RAD-β-Ala-

Tc-NAD-β-Ala-(Arg11)CCMSH (I and J) and

Tc-EAD-β-Ala-(Arg11)CCMSH (K and L) in B16/F1 melanoma cells. Total

bound radioactivity (♦), internalized radioactivity (■) and cell membrane
radioactivity (▲) were presented as counts per minute (cpm).

Figure 4.6. Representative whole-body SPECT/CT image of
melanoma- bearing C57 mice 2 h post injection of 7.4 MBq of

99m

B16/F1

Tc-RAD-β-

11

Ala-(Arg )CCMSH. Flank melanoma lesions (T) are highlighted with an arrow
on the image.

Figure 4.7. Radioactive HPLC profiles of urinary metabolites at 2 h postinjection of

99m

Tc-RAD-β-Ala-(Arg11)CCMSH. The arrow denotes the original

retention time of

99m

Tc-RAD-β-Ala-(Arg11)CCMSH (15.98 min) prior to tail vein

injection.
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Figure 4.1
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Figure 4.2
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Figure 4.3
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Figure 4.5
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Chapter 5
Project Summary
The development of receptor-targeting diagnostic or therapeutic
radiopharmaceuticals, has taken a near herculean effort; understanding the
coordination chemistry involved within the metal complexes, determining optimal
radiolabeling procedures, and designing the structures of the targeting
biomolecules. At the present time, many 99mTc-labeled radiopharmaceuticals
have been widely used as diagnostic imaging agents in various disease states
such as cancer, thrombosis, infection, and inflammation. Administration of sitespecific targeted radiopharmaceuticals provides the prospect of treating widely
disseminated diseases, such as metastatic cancer. Ideally, the targeted
radiopharmaceutical is designed to locate with high specificity to cancerous foci
at locations undetected and unknown within the human body [152]. The use of
small peptides in targeting of radiopharmaceuticals provides a mechanism of
targeting specific overexpressed receptors on the cancerous cell surface,
enabling high specificity targeting of the cancer cell while minimizing radiation to
healthy tissues.
In this project, we developed novel iterations of α-melanocyte stimulating
hormone peptides capable of binding the melanoma specific, melanocortin-1
receptor, in order to characterize and determine the most effective small peptides
for melanoma targeting. Through previous research, it was determined that a
single amino acid substitution of Gly to Ala in the RXD motif of the RGD-Lys(Arg11)CCMSH peptide greatly improved MC1R binding affinity in B16/F1 murine
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melanoma cells (2.0 nM vs 0.3 nM, respectively) [127]. In this study, we
developed novel α-MSH peptides with further modifications to this same residue
in order to examine the influence of the amino acid on in-vivo melanoma
targeting of the α-MSH peptides. Initially the substitutions of the Gly residue with
Thr and Val amino acids were performed to examine the effects of the –
CH(CH3)OH and –CH(CH3)2 groups on the biodistribution properties of the

99m

Tc-

labeled RTD-Lys-(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH peptides. The
RTD-Lys-(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH peptides were
synthesized via fluorenylmethyloxycarbonyl (Fmoc) chemistry and purified
through RP-HPLC, with chemical purities >95%. Cellular binding studies on
B16/F1 murine melanoma cells demonstrated increased affinity for the MC1R as
compared to the original RGD-Lys-(Arg11)CCMSH peptide, but weaker affinity
than the RAD-Lys-(Arg11)CCMSH peptide with IC50 values of 0.70 ± 0.07 nM for
RTD-Lys-(Arg11)CCMSH and 1.00 ± 0.30 nM for RVD-Lys-(Arg11)CCMSH.
RTD-Lys-(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH peptides were
radiolabeled with 99mTc and purified via RP-HPLC with radiochemical purities
>95%. Both compounds demonstrated to be stable in mouse serum for 24 h at
37°C. In-vivo biodistribution studies in B16/F1 bearing female C57BL/6 mice
revealed high receptor-mediated melanoma uptake as compared with 99mTcRAD-Lys-(Arg11)CCMSH but with different uptake patterns.

99m

Tc-RTD-Lys-

(Arg11)CCMSH showed the highest tumor uptake of 18.77 ± 5.13% ID/g at 2 h
post-injection, whereas 99mTc-RVD-Lys-(Arg11)CCMSH showed the highest tumor
uptake of 19.63 ± 4.68% ID/g at 4 h post-injection. Both the 99mTc-RTD-Lys-
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(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH exhibited extremely high
renal uptake at 0.5, 2, and 4 h post-injection with values ranging from 105.54 ±
27.67- 144.56 ± 24.64% ID/g for 99mTc-RTD-Lys-(Arg11)CCMSH and 73.92 ±
3.73- 94.01 ± 18.31% ID/g for 99mTc-RVD-Lys-(Arg11)CCMSH. SPECT/CT
imaging studies utilizing 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys(Arg11)CCMSH as imaging probes demonstrated that B16/F1 lesions could be
clearly visualized by SPECT/CT imaging.
Further evaluation of the targeting and pharmacokinetic properties
associated with the substitution of the Gly residue in the RXD motif was
performed in the second study in which the Gly residue was substituted with Ser,
Nle, Phe, and DPhe amino acids. The substitutions were designed to evaluate the
effects of the long hydrocarbon chain (Nle), and the bulky benzene rings (Phe
and DPhe) on MC1R binding affinity and melanoma targeting properties of the
peptides. In addition, the –CH2OH group (Ser) was substituted in an attempt to
facilitate urinary clearance of the peptides compared to the hydrophobic Nle,
Phe, and DPhe compounds. The four peptides were synthesized utilizing a
similar Fmoc chemistry approach as the previously described RTD-Lys(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH peptides and purified to >95%
chemical purity via RP-HPLC. Cellular binding studies on B16/F1 murine
melanoma cells demonstrated varying impacts on the MC1R binding affinities of
the peptides. The long hydrocarbon chain from the Nle amino acid on RNleDLys-(Arg11)CCMSH peptide exhibited decreased MC1R binding affinity, whereas
the CH2OH group from the Ser amino acid and the bulky benzene rings from the
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Phe and DPhe amino acids increased MC1R binding affinity. IC50 values of RSDLys-(Arg11)CCMSH, RNleD-Lys-(Arg11)CCMSH, RFD-Lys-(Arg11)CCMSH, and
RfD-Lys-(Arg11)CCMSH were 1.30 ± 0.36, 2.99 ± 0.26, 0.82 ± 0.06, and 1.35 ±
0.08 nM respectively. The differences in receptor binding affinities of these
peptides indicate the Ser, Nle, Phe, and DPhe residues interact with the MC1R
binding moiety differently. The subtle differences may be explained by the
flexibility of the lactam bonds among the amino acid residues in the peptides.
In order to determine the in-vivo melanoma targeting, pharmacokinetic,
and imaging properties of the RSD-Lys-(Arg11)CCMSH, RFD-Lys-(Arg11)CCMSH,
and RfD-Lys-(Arg11)CCMSH peptides, all peptides were radiolabeled with

99m

Tc

and purified through RP-HPLC to a radiochemical purity >95%. Due to the poor
binding affinity of the RNleD-Lys-(Arg11)CCMSH peptide, further evaluation of the
in-vivo tumor targeting properties was not warranted nor determined. Despite the
similar pattern in B16/F1 cellular internalization and efflux,

99m

Tc-RSD-Lys-

(Arg11)CCMSH exhibited a contrast in tumor uptake as compared to the
RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH peptides.

99m

99m

Tc-

Tc-

RSD-Lys-(Arg11)CCMSH exhibited rapid and high receptor-specific melanoma
uptake of 18.01 ± 4.22% ID/g at 30 min post-injection, whereas 99mTc-RFD-Lys(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH exhibited their peak
melanoma uptake values of 13.11 ± 1.21 and 15.01 ± 4.40% ID/g at 4 h postinjection, respectively. In addition, 99mTc-RSD-Lys-(Arg11)CCMSH displayed 45%
and 32% lower renal uptake values at 24 h than

99m

Tc-RFD-Lys-(Arg11)CCMSH

and 99mTc-RfD-Lys-(Arg11)CCMSH respectively. Renal uptake values were still
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extremely high ranging from 69.23 ± 17.41% ID/g at 4 h post-injection to 80.01 ±
15.67% ID/g at 2 h post-injection. Not surprisingly, however, 99mTc-RSD-Lys(Arg11)CCMSH showed 12% and 23% lower liver uptake than 99mTc-RFD-Lys(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH, due to the absence of the
bulky benzene ring. Furthermore, 99mTc-RSD-Lys-(Arg11)CCMSH exhibited
faster urinary clearance over all time points as compared to both

99m

Tc-RFD-Lys-

(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH. SPECT/CT imaging studies
utilizing 99mTc-RSD-Lys-(Arg11)CCMSH as an imaging probe demonstrated that
B16/F1 lesions could be clearly visualized in B16/F1 bearing female C57BL/6
mice.
The extremely high renal uptake (67-135% ID/g at 2 h post-injection) has
become a common implication for all the reported

99m

Tc-RXD-Lys-(Arg11)CCMSH

peptides [128, 146, 150]. In order to facilitate further therapeutic applications of
these peptides, non-specific renal uptake must be reduced. In clinical cases
today, renal toxicity is the dose limiting factor in peptide-receptor radionuclide
therapy (PRRT), as acute nephrotoxicity and acute renal failure seen in patients
occurs due to accumulation of radiation dosage in the kidneys [154, 155].

It is

hypothesized that renal handling of these radiopharmaceuticals and peptides is
facilitated by the charge distribution throughout targeting molecule. In the
nephron, evidence has indicated that cationic and neutral molecules are filtered
through the glomerulus more efficiently than anionic molecules possibly due to
the negatively charged basement membrane of the glomerulus [154, 156]. In
addition, the proximal tubule contains negatively charged organic cation transfer
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(OCT) cell surface receptors that can interact with positively charged molecules
[154].
With the overall positive charge and strong positive charge of the Lys
linker in the 99mTc-RXD-Lys-(Arg11)CCMSH peptides, it stands to reason that high
renal uptake of these peptides is due to their potential electrostatic interactions
with multiple constituents of renal physiology. As a proof-of-concept study, coinjection of purified positively charged L-Lys amino acid with the 99mTc-RXD-Lys(Arg11)CCMSH peptides was performed. Co-injection of the L-Lys amino acid
dramatically decreased non-specific renal uptake of the 99mTc-RXD-Lys(Arg11)CCMSH peptides 37-50%, without affecting the tumor targeting properties
of those peptides. This reduction elucidated the necessity to mitigate the overall
positive charge of the 99mTc-RXD-Lys-(Arg11)CCMSH peptides in order to
facilitate reduced non-specific renal uptake. Clearly, the substitution of the
positively charged Lys linker in the 99mTc-RXD-Lys-(Arg11)CCMSH to a neutral or
negatively charged linker (i.e. Gly or Glu) can decrease the overall charge of the
99m

Tc-RXD-Lys-(Arg11)CCMSH peptides. In previous studies, reducing the

overall positive charge of

111

In-DOTA-GlyGlu-CycMSH via a negatively charged

glutamic acid linker coincided with a 44% reduction in renal uptake as compared
to 111In-DOTA-CycMSH [100]. According to the effect seen in the L-Lys coinjection studies and with the introduction of the glutamic acid linker in previous
studies, it was likely that such a substitution will provide a significant reduction in
non-specific renal uptake of the 99mTc-RXD-Lys-(Arg11)CCMSH peptides.

148

In the final study of this project we designed a multitude of novel α-MSH
peptides with reduced overall net charge. The positively charged Lys linker in
the RXD-Lys-(Arg11)CCMSH peptides was replaced with a neutral β-Ala linker to
yield the novel RAD-β-Ala-(Arg11)CCMSH, RSD-β-Ala-(Arg11)CCMSH, RTD-βAla-(Arg11)CCMSH, and RVD-β-Ala-(Arg11)CCMSH peptides. In addition, we
designed the novel XAD-β-Ala-(Arg11)CCMSH peptides containing substitutions
of the positively charged Arg residue in the RXD motif with a neutral Nle amino
acid and negatively charged Glu residue to create the NAD-β-Ala-(Arg11)CCMSH
EAD-β-Ala-(Arg11)CCMSH peptides, respectively. The substitutions of these
amino acids were performed to eliminate as many charge dipoles on the peptide
backbone as possible to facilitate reduction in the non-specific renal uptake seen
with the RXD-Lys-(Arg11)CCMSH peptides.
All peptides were synthesized utilizing a similar Fmoc chemistry approach
as described for the RXD-Lys-(Arg11)CCMSH peptides and purified via RP-HPLC
to a chemical purity >95%. Cellular binding studies performed in B16/F1 cells
demonstrated continued low nanomolar binding affinity for the RXD-β-Ala(Arg11)CCMSH and XAD-β-Ala-(Arg11)CCMSH peptides. IC50 values for the
RAD-β-Ala-(Arg11)CCMSH, RSD-β-Ala-(Arg11)CCMSH, RTD-β-Ala(Arg11)CCMSH, and RVD-β-Ala-(Arg11)CCMSH peptides were 0.35 ± 0.01, 2.76
± 0.51, 1.56 ± 0.63, and 1.99 ± 0.16 nM respectively. These values were
comparable to their Lys linker counterparts demonstrating no significant loss in
binding affinity for the MC1R. The binding affinity of the XAD-β-Ala(Arg11)CCMSH peptides for the MC1R was slightly lower with IC50 values of 3.84
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± 0.71 and 3.34 ± 0.28 nM for EAD-β-Ala-(Arg11)CCMSH and NAD-β-Ala(Arg11)CCMSH respectively.
In order to determine the in-vivo melanoma targeting, pharmacokinetic,
and imaging properties of the RXD-β-Ala-(Arg11)CCMSH and XAD-β-Ala(Arg11)CCMSH peptides, all peptides were radiolabeled with

99m

Tc and purified

through RP-HPLC to a radiochemical purity >95%. All RXD-β-Ala(Arg11)CCMSH peptides exhibited rapid and high receptor-specific melanoma
uptake similar to their Lys linker counterparts with the exception of RSD-β-Ala(Arg11)CCMSH. RAD-β-Ala-(Arg11)CCMSH exhibited peak melanoma uptake of
15.66 ± 6.19% ID/g at 2 h post-injection, not significantly different to RAD-Lys(Arg11)CCMSH with a peak melanoma uptake of 19.91 ± 4.02% ID/g. RTD-βAla-(Arg11)CCMSH exhibited peak melanoma uptake of 13.85 ± 1.43% ID/g at 2
h post-injection, not significantly different to RTD-Lys-(Arg11)CCMSH with a peak
melanoma uptake of 18.77 ± 5.13% ID/g. RVD-β-Ala-(Arg11)CCMSH exhibited
peak melanoma uptake of 13.11 ± 4.78% ID/g at 2 h post-injection, not
significantly different to RVD-Lys-(Arg11)CCMSH with a peak melanoma uptake
of 17.10 ± 3.82% ID/g. As previously stated, RSD-β-Ala-(Arg11)CCMSH
exhibited peak melanoma uptake of 12.15 ± 2.36% ID/g at 4 h post-injection,
which was significantly different to RSD-Lys-(Arg11)CCMSH with a peak
melanoma uptake of 17.42 ± 1.52% ID/g at 2 h post-injection. EAD-β-Ala(Arg11)CCMSH exhibited peak melanoma uptake of 13.36 ± 4.12% ID/g at 4 h
post-injection and NAD-β-Ala-(Arg11)CCMSH exhibited peak melanoma uptake of
11.38 ± 1.29% ID/g at 2 h post-injection.
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Importantly in this study, we wanted to determine the renal effects of the
charge substitutions made to the peptides. Non-specific renal uptake was
dramatically reduced in the RXD-β-Ala-(Arg11)CCMSH peptides. Non-specific
renal uptake of RAD-β-Ala-(Arg11)CCMSH, RSD-β-Ala-(Arg11)CCMSH, RTD-βAla-(Arg11)CCMSH, and RVD-β-Ala-(Arg11)CCMSH was reduced 79%, 65%,
79%, and 68% at 2 h post-injection as compared to their Lys linker counterparts.
All RXD-β-Ala-(Arg11)CCMSH exhibited non-specific renal uptake of less than
30% ID/g. The renal uptake of EAD-β-Ala-(Arg11)CCMSH and NAD-β-Ala(Arg11)CCMSH was not further reduced as compared to the RXD-β-Ala(Arg11)CCMSH with uptake values of 25.25 ± 9.26% and 37.23 ± 9.69% ID/g 2 h
post-injection.
The dramatic reduction in renal uptake with the substitution of the neutral
β-Ala linker demonstrates the importance of the electrostatic interactions of the
positive charges on the peptides in renal handling and non-specific uptake invivo. It is imperative to maintain high contrast of tumor uptake to normal organ
tissues for enhanced diagnostic imaging and potential therapeutic applications
utilizing radiolabeled peptide conjugates as targeting molecules.

99m

Tc-labeled

radiopharmaceuticals can be readily translated to therapeutic
radiopharmaceuticals through the replacement of

99m

Tc with 186Re/ 188Re [152,

153]. Both 99mTc and 186Re/ 188Re have similar coordination chemistry. The
same biomolecule can be labeled with 186Re/ 188Re without structural
modification. The combined use of

99m

Tc- and 186Re/ 188Re-labeled

radiopharmaceuticals for imaging and therapy will enhance the success of

151

targeted radionuclide treatment for individual patients. Imaging patients with
99m

Tc-labled radiopharmaceuticals can aid physicians in determining patient-

specific dosimetries for safe and efficacious treatment with the

186

Re/ 188Re

therapeutic radiopharmaceuticals. Furthermore, imaging during the treatment of
disease can monitor a patients response to treatment giving critical information to
the physician and allow for modification of treatment protocols, should they be
warranted, to further aid in therapeutic regimens [157].
Throughout this study, one α-MSH peptide conjugate has been elucidated
as a lead compound for further development of both imaging and therapeutic
applications. RAD-β-Ala-(Arg11)CCMSH has demonstrated high MC1R specific
melanoma uptake (15.66 ± 6.19% ID/g at 2 h post-injection) with limited nonspecific renal uptake (20.18 ± 3.86% ID/g at 2 h post-injection). This high
melanoma uptake and low kidney uptake correlates to a very favorable tumor to
kidney uptake ratio of 0.78 at 2 h post injection. The tumor (target) to kidney
uptake ratio is important in determining the total accumulation and potential dose
limiting exposure of a patient. The higher the ratio, the better the chance of
reducing or eliminating the deleterious effects of radiation within the nephron,
and allowing for stronger, more aggressive PRRT therapy to proceed [154, 155].

Future Directions
The use of α-MSH peptide analogs for diagnosis and treatment of
melanoma in clinical practice today is non-existent. The utilization of these
targeting molecules has been confined to the pre-clinical experimental phase.
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Further development and characterization on the use of these peptide conjugates
in human cell lines and human tissues should be extrapolated in order to
facilitate their potential use in patients seeking clinical aide for treatment of this
deadly disease. In order to begin the process of moving these novel α-MSH
peptides into a more clinical research venture, targeting and pharmacokinetic
properties of the lead compounds in human melanoma will need to be
established.
1) Defining the 3-D structure of the α-MSH peptides.
To date, it has been extremely difficult to determine the 3-D structure of the αMSH peptide derivatives. Characterizing the 3-D structure will further allow
investigators to understand the interactions of each part of the α-MSH peptide
conjugates with the melanocortin-1 receptor. Understanding the interactions will
allow for manipulation of the peptides to further enhance MC1R binding affinity
and ultimately increase in-vivo melanoma uptake. The increased melanoma
uptake will facilitate higher quality imaging characteristics and potential
therapeutic treatment with PRRT treatment.
2) Utilizing human melanoma cell lines such as TXM13
This entire study was developed around the utilization of the murine B16/F1
melanoma cell line which overexpresses the MC1R at densities around 7,000
receptor sites/cell [158]. Further experimentation into the use of these peptide
conjugates in human melanoma cells is imperative due to differences in behavior
of both tumors and peptide uptake previously seen. Human TXM13 melanoma
cell lines specifically overexpress the MC1R at densities slightly lower than
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B16/F1 around 5,500 receptor sites/cell [158]. In addition to lower MC1R
density, histopathological analysis of both B16/F1 murine and TXM13 human
melanoma tumors revealed striking differences. The B16/F1 murine tumors are
highly vascularized gelatinous masses, whereas TXM13 human tumors form
solid masses with viable tumor cells surrounding a necrotic core containing few
identifiable melanoma cells. Characterizing the targeting and pharmacokinetic
properties of our lead α-MSH compounds in human cell lines will enhance our
efforts for utilization in human patients.
3) Therapeutic treatment with 186Re/ 188Re.
In order to facilitate the potential of our lead α-MSH peptide conjugate as a
viable targeting therapeutic molecule, it is necessary to define the efficacy of
treatment of both B16/F1 and TXM13 tumors in-vivo, utilizing 186Re/ 188Re as the
radionuclide for radiation treatment. As stated before,

99m

Tc and 186Re/ 188Re

share similar coordination chemistry and our α-MSH peptides have been
successfully integrated with 186Re/ 188Re in previous studies [158]. A longitudinal
study to determine how well treatment with

186

Re/ 188Re -labeled α-MSH peptide

can decrease overall tumor volume and increase survival time of mice that have
been implanted with both B16/F1 and TXM13 melanoma cells is imperative for
moving this research into the clinical realm.
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